melatonin has been researched along with Breast Cancer in 371 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this double-blind, placebo-controlled, randomized study was to investigate whether topical melatonin administered during radiation therapy could increase the quality of life in patients with primary breast cancer." | 9.69 | Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial. ( Christophersen, C; Gülen, S; Hoffmeyer, B; Kamby, C; Mahmood, F; Paulsen, CB; Piga, E; Rosenberg, J; Zetner, D, 2023) |
| "This was a double-blind, placebo-controlled randomized study investigating whether melatonin can protect against radiation dermatitis in women receiving radiation therapy for primary breast cancer." | 9.69 | Effect of melatonin cream on acute radiation dermatitis in patients with primary breast cancer: A double-blind, randomized, placebo-controlled trial. ( Christophersen, C; Gülen, S; Hoffmeyer, B; Kamby, C; Mahmood, F; Paulsen, CB; Piga, E; Rosenberg, J; Zetner, D, 2023) |
| "This randomized, double-blinded, placebo-controlled trial tested the hypothesis that 20mg of melatonin before and during the first cycle of adjuvant chemotherapy for breast cancer (ACBC) reduced the side effects associated with cognitive impairment." | 9.34 | Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. ( Biazús, JV; Caumo, W; Fregni, F; Palmer, ACS; Santos, V; Souza, A; Torres, ILS; Zortea, M, 2020) |
| "This review proposes an overall vision of the protective and therapeutic role of melatonin in breast cancer: from the specific cases of blind women and their reduction of breast cancer incidence to all clinical uses of the sleep hormone in breast cancer." | 9.22 | Protective role of melatonin in breast cancer: what we can learn from women with blindness. ( Amé, S; Coliat, P; Mathelin, C; Minella, C; Neuberger, K; Reix, N; Stora, A, 2022) |
| " In this prospective phase II trial, we sought to assess the effect of melatonin on circadian biomarkers, sleep, and quality of life in breast cancer patients." | 9.22 | The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. ( Bjarnason, GA; Clemons, M; Eisen, A; Innominato, PF; Kiss, A; Lim, AS; Palesh, O; Pritchard, KI; Trudeau, M; Wang, C, 2016) |
| "To investigate whether administration of an oral dose of 6 mg melatonin before bedtime perioperatively in breast cancer surgery could change sleep outcomes measured by actigraphy." | 9.22 | Effect of Melatonin on Sleep in the Perioperative Period after Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Andersen, LT; Bokmand, S; Gögenur, I; Hageman, I; Hansen, MV; Madsen, MT; Rasmussen, LS; Rosenberg, J, 2016) |
| "The purpose is to examine the effects of melatonin supplementation on sleep, mood, and hot flashes in postmenopausal breast cancer survivors." | 9.19 | A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. ( Chen, WY; Gantman, K; Giobbie-Hurder, A; Parker, LM; Savoie, J; Scheib, R; Schernhammer, ES, 2014) |
| "We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the IGF-1/IGFBP-3 ratio) in postmenopausal breast cancer survivors." | 9.16 | A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. ( Chen, WY; Gantman, K; Giobbie-Hurder, A; Parker, LM; Savoie, J; Scheib, R; Schernhammer, ES, 2012) |
| "Exposure to higher levels of melatonin may be associated with lower breast cancer risk, but epidemiologic evidence has been limited." | 9.12 | Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies. ( Fensom, GK; Key, TJ; Onland-Moret, NC; Tong, TYN; Travis, RC; Wong, ATY, 2021) |
| "To review studies evaluating the circadian rhythm of melatonin in breast cancer patients." | 9.12 | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients. ( Ahabrach, H; Cauli, O; El Mlili, N; Errami, M, 2021) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 9.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| "Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth." | 9.08 | Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. ( Barni, S; Cazzaniga, M; Esposti, D; Fossati, V; Lissoni, P; Meregalli, S; Tancini, G, 1995) |
| "Melatonin has significant inhibitory effects in numerous cancers, especially breast cancer." | 9.05 | Melatonin: A Potential Therapeutic Option for Breast Cancer. ( Fang, Y; Gao, J; Gao, R; Kong, X; Reiter, RJ; Wang, J; Wang, X; Wang, Z, 2020) |
| "The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease." | 8.98 | Melatonin: A Molecule for Reducing Breast Cancer Risk. ( González-González, A; Mediavilla, MD; Sánchez-Barceló, EJ, 2018) |
| "Melatonin has a significant inhibitory effect on various cancers, especially on breast cancer." | 8.95 | [Inhibitory effects of melatonin on breast cancer]. ( Jiang, Z; Ma, F, 2017) |
| " To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death." | 8.95 | Melatonin, an inhibitory agent in breast cancer. ( Akbari, ME; Bashash, D; Nooshinfar, E; Safaroghli-Azar, A, 2017) |
| "The present review discusses recent work on melatonin-mediated circadian regulation, the metabolic and molecular signaling mechanisms that are involved in human breast cancer growth, and the associated consequences of circadian disruption by exposure to light at night (LEN)." | 8.91 | Melatonin: an inhibitor of breast cancer. ( Belancio, VP; Blask, DE; Brimer, S; Dauchy, RT; Frasch, T; Hauch, A; Hill, SM; Lundberg, PW; Mao, L; Summers, W; Xiang, S; Yuan, L, 2015) |
| "Melatonin inhibits human breast cancer cells stimulated with estrogen." | 8.91 | Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review. ( Reiter, RJ; Vriend, J, 2015) |
| "It has been hypothesized that suppressed nocturnal melatonin production is associated with an increased risk of breast cancer, but results from several small prospective studies of the association have been inconclusive." | 8.90 | First-morning urinary melatonin and breast cancer risk in the Guernsey Study. ( Allen, NE; Appleby, PN; Key, TJ; Tipper, S; Travis, RC; Wang, XS, 2014) |
| "Evidence from observational studies on light at night (LAN) exposure, sleep duration, endogenous melatonin levels, and risk for breast cancer in women is conflicting." | 8.90 | Light exposure at night, sleep duration, melatonin, and breast cancer: a dose-response analysis of observational studies. ( Deng, Q; Fan, WY; Wang, WY; Wang, X; Yang, WS, 2014) |
| "The usefulness of melatonin and melatoninergic drugs in breast cancer therapy is based on its Selective Estrogen Receptor Modulator (SERM) and Selective Estrogen Enzyme Modulator (SEEM) properties." | 8.88 | Breast cancer therapy based on melatonin. ( Alonso-Gonzalez, C; Mediavilla, MD; Rueda, N; Sanchez-Barcelo, EJ, 2012) |
| "This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo- or radiotherapy." | 8.88 | Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. ( Alonso-Gonzalez, C; Mediavilla, MD; Reiter, RJ; Sanchez-Barcelo, EJ, 2012) |
| "Exposure to electromagnetic radiation (EMR) may increase breast cancer risk by inducing oxidative stress and suppressing the production of melatonin." | 8.88 | Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+ signaling molecular pathways in breast cancer. ( Demirci, S; Naziroğlu, M; Tokat, S, 2012) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular, dietary, and metabolic signaling mechanisms involved in human breast cancer growth and the consequences of circadian disruption by exposure to light at night (LAN)." | 8.87 | Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. ( Blask, DE; Dauchy, E; Dauchy, RT; Duplessis, T; Hill, SM; Mao, L; Sauer, LA; Xiang, S; Yuan, L, 2011) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular and metabolic signaling mechanisms involved in human breast cancer growth and the associated consequences of circadian disruption by exposure to light-at-night (LAN)." | 8.87 | Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. ( Blask, DE; Dauchy, EM; Dauchy, RT; Duplesis, T; Frasch, T; Hill, SM; Mao, L; Xiang, S; Yuan, L, 2011) |
| "The oncostatic properties of melatonin as they directly or indirectly involve epigenetic mechanisms of cancer are reviewed with a special focus on breast cancer." | 8.85 | Role of melatonin in the epigenetic regulation of breast cancer. ( Korkmaz, A; Reiter, RJ; Sanchez-Barcelo, EJ; Tan, DX, 2009) |
| "Recent studies have suggested that the pineal hormone melatonin may protect against breast cancer, and the mechanisms underlying its actions are becoming clearer." | 8.85 | Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. ( Grant, SG; Latimer, JJ; Melan, MA; Witt-Enderby, PA, 2009) |
| "Although many factors have been suggested as causes for breast cancer, the increased incidence of the disease seen in women working in night shifts led to the hypothesis that the suppression of melatonin by light or melatonin deficiency plays a major role in cancer development." | 8.84 | Melatonin, environmental light, and breast cancer. ( Cardinali, DP; Esquifino, AI; Maestroni, GJ; Pandi-Perumal, SR; Spence, DW; Srinivasan, V; Trakht, I, 2008) |
| "Melatonin exerts oncostatic effects on different kinds of tumors, especially on endocrine-responsive breast cancer." | 8.83 | Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2006) |
| "The hypothesis is advanced that blindness from an early age may lead to a reduced risk of breast cancer through altered patterns of melatonin secretion by the pineal gland." | 8.78 | Breast cancer, blindness and melatonin. ( Coleman, MP; Reiter, RJ, 1992) |
| "Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer." | 8.12 | Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line. ( Akbarzadeh, M; Isazadeh, A; Jahanbazi, R; Kazemzadeh, H; Maroufi, NF; Mostafaei, S; Nejabati, HR; Nouri, M; Rashidi, M; Rashidi, MR; Vahedian, V, 2022) |
| " Additionally, melatonin has shown inhibitory effects on the growth of human breast cancer cells." | 8.12 | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines. ( Abdolmaleki, A; Asadi, A; Bahadori, MH; Ghorbani-Anarkooli, M; Hajizadeh Moghadam, A; Karimian, A; Mir Mohammadrezaei, F, 2022) |
| "Melatonin exerts oncostatic effects on breast cancer via immunomodulation and antioxidation." | 8.12 | Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model. ( Aytac, G; Dilmac, S; Farooqi, AA; Sindel, M; Tanriover, G, 2022) |
| "The goal of this work was to see how melatonin affected Bax and Bcl-2 expression, as well as apoptosis and autophagy, in MCF-7 and MDA-MB-231 breast cancer cell lines, which have distinct hormonal sensitivities." | 8.12 | Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis. ( Önder, GÖ; Özdamar, S; Sezer, G; Yay, A, 2022) |
| " In the current study, we find that Melatonin sensitizes HER2-positive breast cancer cells to the dual tyrosine kinase inhibitor Lapatinib in vitro." | 8.02 | Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. ( Cheng, H; Li, L; Liu, P; Liu, Y; Liu, Z; Rui, C; Sang, X; Tao, Z, 2021) |
| "This study aims to investigate the effects of zinc and melatonin supplementation on lipid peroxidation in the brain cortex in DMBA-induced breast cancer in female rats." | 7.96 | Zinc and melatonin supplementation ameliorates brain cortex tissue damage in DMBA-induced breast cancer in rats. ( Baltaci, SB; Mutlu, EG, 2020) |
| " Apoptosis assay was performed on breast cancer cells to evaluate melatonin effects." | 7.96 | Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells. ( Abdolahi, S; Akbarzadeh, M; Emami, A; Hosseinpourfeizi, MA; Khodaei, M; Khodavirdipour, A; Pourmahdi, M; Rajabi, A; Ravanbakhsh, R; Saber, A; Safaralizadeh, R, 2020) |
| "This prospective cohort study captured the patterns of sleep, sleep-wake activity rhythm, and first-morning urinary melatonin in breast cancer patients undergoing adjuvant chemotherapy." | 7.91 | Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study. ( Chan, DC; Ho, AW; Ho, CS; Kwok, CC; Li, W; Tse, LA; Wang, F; Wing, YK; Zhang, J, 2019) |
| "The aim of this study was to evaluate the role of melatonin and the tumor suppressor miR- 148a-3p on angiogenesis of breast cancer." | 7.91 | Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer. ( Aristizábal-Pachón, AF; Bajgelman, MC; Borin, TF; Ferreira, LC; Lacerda, JZ; Lopes, BC; Zuccari, DAPC, 2019) |
| "Disruption of circadian time structure and suppression of circadian nocturnal melatonin (MLT) production by exposure to dim light at night (dLAN), as occurs with night shift work and/or disturbed sleep-wake cycles, is associated with a significantly increased risk of breast cancer and resistance to tamoxifen and doxorubicin." | 7.91 | Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Hoffman, AE; Pointer, D; Xiang, S, 2019) |
| "Our purpose is to investigate the impact of circadian and melatonin pathway genes as well as their interactions with night-shift work (NSW) on breast cancer risk in Korean women." | 7.91 | Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women. ( Joo, J; Kim, J; Kim, SY; Kong, SY; Lee, ES; Park, B; Pham, TT; Yoon, KA, 2019) |
| "Melatonin exerts oncostatic activity in breast cancer through antiangiogenic actions." | 7.88 | Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in co‑cultures of human endothelial and breast cancer cells. ( Alonso-González, C; Cos, S; González, A; González-González, A; Martínez-Campa, C; Menéndez-Menéndez, J, 2018) |
| " As is reported in numerous studies, melatonin, an endogenous hormone secreted by the pineal gland, could markedly inhibit estrogen-induced proliferation of breast cancer (BC) cells." | 7.88 | Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways. ( Gong, M; Guan, Y; Liang, R; Liu, B; Liu, Y; Pan, J; Wang, T; Ye, L; Yuan, Y; Zhang, W, 2018) |
| "To test the anticancer potential of a combination of thymoquinone (TQ) and melatonin (MLT) against breast cancer implanted in mice." | 7.88 | Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice. ( Basheti, IA; Odeh, LH; Talib, WH, 2018) |
| " We have tested the affinity of oxyprenylated ferulic acid (1-4) and umbelliferone derivatives (5-11) to melatonin receptors as well as their antiproliferation and antimigratory properties against breast cancer (BC) cell lines." | 7.85 | Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration. ( Epifano, F; Fiorito, S; Genovese, S; Hasan, M; Witt-Enderby, PA, 2017) |
| "With the wide recognition of oncostatic effect of melatonin, the current study proposes a potential breast cancer target multimodality treatment based on melatonin-loaded magnetic nanocomposite particles (Melatonin-MNPs)." | 7.85 | Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles. ( Gao, Q; Guo, Z; Sun, X; Wang, D; Wang, W; Wang, X; Xie, W; Yan, H; Yuan, J; Zhao, L, 2017) |
| "Evaluate the viability and the expression of OCT4 in breast cancer stem cells, MCF-7 and MDA-MB- 231, after melatonin treatment." | 7.85 | Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres. ( da Silva Kavagutti, M; de Campos Zuccari, DAP; de Medeiros, FAF; Lopes, JR, 2017) |
| " In the present study, we investigated the combined effects of melatonin and arsenic trioxide (ATO) on cell death in human breast cancer cells." | 7.83 | Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. ( Choe, TB; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Lee, JK; Lee, YH; Noh, WC; Oh, ST; Park, IC; Seong, MK; Woo, SH; Ye, SK; Yun, SM, 2016) |
| " This study investigated potential application of nanostructured lipid carriers (NLCs) in increasing melatonin induced cytotoxicity and apoptosis in MCF-7 breast cancer cells." | 7.83 | Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. ( Akbarzadeh, M; Hamishehkar, H; Mohammadian, J; Molavi, O; Sabzichi, M; Samadi, N, 2016) |
| " Melatonin, a naturally occurring indoleamine synthesized in the pineal gland, has been considered as a biomarker for endocrine-dependent tumors, particularly breast cancer." | 7.83 | Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer. ( Akbari, ME; Bashash, D; Bayati, S; Ghaffari, SH; Nooshinfar, E; Rezaei-Tavirani, M; Safaroghli-Azar, A, 2016) |
| "Melatonin inhibition of Rsk2 represses the metastatic phenotype in breast cancer cells suppressing EMT or inhibiting other mechanisms that promote metastasis; disruption of the melatonin signal may promote metastatic progression in breast cancer." | 7.83 | Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Mao, L; Pointer, D; Reynolds, A; Summers, W; Wren-Dail, MA; Xiang, S; Yuan, L, 2016) |
| "Experimental and epidemiologic data support a protective role for melatonin in breast cancer etiology, yet studies in premenopausal women are scarce." | 7.81 | Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II. ( Arcaro, KF; Brown, SB; Eliassen, AH; Hankinson, SE; Qian, J; Reeves, KW; Schernhammer, ES; Wegrzyn, LR; Willett, WC, 2015) |
| "The aim of this study was to determine the effects of some polyunsaturated fatty acids plus phytomelatonin from walnuts in the development of mammary gland adenocarcinoma." | 7.81 | Synergistic anti-tumor effects of melatonin and PUFAs from walnuts in a murine mammary adenocarcinoma model. ( Berra, MA; Comba, A; Das, UN; Eynard, AR; Garcia, CP; Labuckas, DO; Lamarque, AL; Pasqualini, ME; Silva, RA, 2015) |
| "Results from prospective studies on the association between urinary levels of melatonin and risk of postmenopausal breast cancer have been mixed." | 7.80 | Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort. ( Bigelow, C; Doherty, A; Liu, S; Manson, JE; Neuhouser, ML; Ockene, JK; Reeves, KW; Stanczyk, FZ; Sturgeon, SR, 2014) |
| " Previously, we observed melatonin-induced differential expression of miRNA and miRNA-related genes in human breast cancer cell lines that indicated an anticancer effect of melatonin." | 7.79 | Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. ( Hwang, SY; Jeong, SI; Kim, SJ; Lee, SE; Park, CS; Park, YS; Yang, H; Yoon, HJ; Yu, SY, 2013) |
| "Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen-signaling pathways." | 7.79 | Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C, 2013) |
| "Previous studies suggest that melatonin may act on cancer growth through a variety of mechanisms, most notably by direct anti-proliferative effects on breast cancer cells and via interactions with the estrogen pathway." | 7.78 | Melatonin pathway genes and breast cancer risk among Chinese women. ( Beeghly-Fadiel, A; Cai, Q; Deming, SL; Gao, YT; Long, J; Lu, W; Shu, XO; Zheng, W; Zheng, Y, 2012) |
| "Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen signaling pathways." | 7.78 | Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C, 2012) |
| "The main biological active substance secreted by the pineal gland, melatonin (MLT), counteracts the effects of estrogens in breast cancer via exerting a number of its own oncostatic properties." | 7.78 | Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. ( Clyne, CD; Knower, KC; Miki, Y; Sasano, H; Simpson, ER; Takagi, K; To, SQ, 2012) |
| "Melatonin has been shown to inhibit breast cancer cell growth in numerous studies." | 7.78 | Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. ( Dama, A; Formigli, L; Francini, F; Margheri, M; Masala, E; Nosi, D; Pacini, N; Squecco, R; Tani, A; Zecchi-Orlandini, S, 2012) |
| "Melatonin suppresses breast cancer cell proliferation by inhibiting the upregulation of estrogen-induced cyclin D1 via its G-protein-coupled receptor MT1." | 7.77 | Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. ( Ekmekcioglu, C; Humpeler, S; Jäger, W; Klimpfinger, M; Königsberg, R; Rögelsperger, O; Svoboda, M; Thalhammer, T; Wlcek, K, 2011) |
| "The growth of estrogen-receptor positive breast cancer cells is inhibited by the pineal gland hormone, melatonin." | 7.76 | Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields. ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2010) |
| "Lower urinary melatonin levels are associated with a higher risk of breast cancer in postmenopausal women." | 7.76 | Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. ( Berrino, F; Cavalleri, A; Grioni, S; Krogh, V; Micheli, A; Muti, P; Schernhammer, ES; Schünemann, HJ; Secreto, G; Sempos, CT; Strano, S; Venturelli, E, 2010) |
| "The pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the proliferation of estrogen receptor α (ERα)-positive breast cancer cell lines." | 7.76 | Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. ( Burow, ME; Hill, SM; Jones, FE; Mao, L; Slakey, LM; Yuan, L, 2010) |
| "Melatonin seems to play a role in breast cancer etiology, but data addressing the association between melatonin levels and breast cancer risk in postmenopausal women is sparse." | 7.75 | Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. ( Hankinson, SE; Schernhammer, ES, 2009) |
| "Previous investigations demonstrated that melatonin exerts an oncostatic action on estrogen-responsive breast cancer, both in vitro and in vivo." | 7.75 | Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. ( Bizzarri, M; Coluccia, P; Cucina, A; D'Anselmi, F; Dinicola, S; Frati, L; Proietti, S, 2009) |
| "Melatonin possesses anti-estrogenic effects on estrogen receptor expressing (ER+) breast cancer cells in culture by reducing cell cycle progression and cell proliferation." | 7.75 | Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2009) |
| "Melatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits aromatase activity and expression." | 7.75 | Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2009) |
| "The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and - MCF-7 human breast cancer xenografts in female nude rats." | 7.75 | Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. ( Blask, DE; Brainard, GC; Dauchy, RT; Hanifin, JP, 2009) |
| "Low urinary melatonin levels have been associated with an increased risk of breast cancer in premenopausal women." | 7.74 | Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. ( Berrino, F; Cavalleri, A; Krogh, V; Micheli, A; Muti, P; Schernhammer, ES; Schünemann, HJ; Secreto, G; Sempos, CT; Sieri, S; Strano, S; Venturelli, E, 2008) |
| "Melatonin, via its MT1 receptor, but not the MT2 receptor, can modulate the transcriptional activity of various nuclear receptors - estrogen receptor alpha (ERalpha) and retinoic acid receptor alpha (RARalpha), but not ERbeta- in MCF-7, T47D, and ZR-75-1 human breast cancer cell lines." | 7.74 | The Galphai and Galphaq proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation. ( Chen, Q; Dong, C; Frasch, T; Hill, SM; Lai, L; Mao, L; Rowan, B; Yuan, L, 2008) |
| " The purpose of this exploratory study was to compare women with breast cancer to healthy control women on measures of salivary cortisol, urinary catecholamines, overnight urinary melatonin, and self-reported sleep quality, symptoms of stress, depression, anxiety and mood disturbance, to determine if discernable patterns of dysregulations across systems were apparent." | 7.74 | Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. ( Campbell, TS; Carlson, LE; Garland, SN; Grossman, P, 2007) |
| "A major mechanism through which melatonin reduces the development of breast cancer is based on its anti-estrogenic actions by interfering at different levels with the estrogen-signalling pathways." | 7.74 | Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Hill, SM; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ; Sánchez-Mateos, S, 2007) |
| "Sleep duration has been hypothesized to be inversely associated with breast cancer risk, possibly due to greater overall melatonin production in longer sleepers." | 7.74 | Sleep duration, melatonin and breast cancer among Chinese women in Singapore. ( Koh, WP; Lee, HP; Stanczyk, FZ; Wang, R; Wu, AH; Yu, MC, 2008) |
| "The goal was to evaluate whether melatonin (Mel) down-regulates hTERT expression induced by 17beta-estradiol (E(2)) or cadmium (Cd) in breast cancer cells." | 7.74 | Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, CM; Mediavilla, MD; Sanchez-Barcelo, EJ, 2008) |
| "Most of the current knowledge about the mechanisms by which melatonin inhibits the growth of breast cancer cells point to an interaction of melatonin with estrogen-responsive pathways, thus behaving as an antiestrogenic hormone." | 7.73 | Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. ( Cos, S; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| "Exposure to light at night suppresses melatonin production, and night-shift work (a surrogate for such exposure) has been associated with an increased risk of breast cancer." | 7.73 | Urinary melatonin levels and breast cancer risk. ( Hankinson, SE; Schernhammer, ES, 2005) |
| " The aim of this paper was to study if a melatonin pretreatment prior to aminoglutethimide increases the efficiency of the aromatase inhibitor used in treating breast cancer." | 7.73 | Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| "The increased breast cancer risk in female night shift workers has been postulated to result from the suppression of pineal melatonin production by exposure to light at night." | 7.73 | Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. ( Blask, DE; Brainard, GC; Dauchy, RT; Davidson, LK; Dubocovich, ML; Hanifin, JP; Jasser, SA; Krause, JA; Lynch, DT; Rivera-Bermudez, MA; Rollag, MD; Sauer, LA; Zalatan, F, 2005) |
| " The breast cancer cells were incubated for 2 days in the presence of melatonin, CGP 52608 (at concentrations of 10(-5)M, 10(-7)M, 10(-9)M, 10-(11)M ) and methotrexate (at concentrations of 0." | 7.73 | Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells. ( Karasek, M; Kunert-Radek, J; Lawnicka, H; Pawlikowski, M; Winczyk, K, 2006) |
| "Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells significantly enhances the response of these cells to the growth-inhibitory actions of melatonin." | 7.72 | Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. ( Cheng, Q; Collins, A; Hill, SM; Kiefer, TL; Lai, L; Yuan, L, 2003) |
| " The aim of this study was to assess the effect of combined treatment of 1,25-(OH)(2)D(3) at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4." | 7.72 | Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. ( Bizzarri, M; Borrelli, V; Cavallaro, A; Cucina, A; Stipa, F; Tagliaferri, F; Valente, MG, 2003) |
| "Experimental data from animals suggest a protective role for the pineal hormone melatonin in the etiology of breast cancer, but results from the few retrospective case-control studies that examined the association in humans have been inconsistent." | 7.72 | Melatonin and breast cancer: a prospective study. ( Allen, DS; Fentiman, IS; Key, TJ; Travis, RC, 2004) |
| "There are many subclones of human breast cancer MCF-7 cells that respond to different levels of estrogen and that have been used for evaluating the estrogenic potential of environmental chemicals such as bisphenol A." | 7.72 | Transient inhibition of synergistically insulin-like growth factor-1- and bisphenol A-induced poliferation of estrogen receptor alpha (ERalpha)-positive human breast cancer MCF-7 cells by melatonin. ( Ishido, M, 2004) |
| "Melatonin has repeatedly been shown to inhibit the proliferation of MCF-7 human breast cancer cells." | 7.71 | Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. ( Dai, J; Hill, SM; Ram, PT; Spriggs, LL; Yuan, L, 2001) |
| "To investigate the effect of chemotherapy on levels of melatonin in patients with breast cancer." | 7.71 | Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients. ( Kajdaniuk, D; Kos-Kudla, B; Marek, B, 2001) |
| "Circadian variations were studied in cortisol, melatonin, cytokines (basic fibroblast growth factor IbFGF], EGF, insulin-like growth factor-1 [IGF-1]), and a cytokine receptor (insulin-like growth factor binding protein-3 [IGFBP-3]) in the plasma of 28 patients with metastatic breast cancer." | 7.71 | Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. ( Bologa, S; Dumitriu, L; Haus, E; Nicolau, GY; Sackett-Lundeen, L, 2001) |
| "We have previously demonstrated that the pineal hormone, melatonin, can inhibit the growth of estrogen receptor-alpha (ERalpha)-positive breast cancer cells and suppress ERalpha gene transcription." | 7.71 | Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. ( Hill, SM; Kiefer, T; Ram, PT; Yuan, L, 2002) |
| "The negative correlation between the plasma melatonin and IGF-I concentrations in the breast cancer patients we studied could reach statistical significance in a larger population." | 7.71 | Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense? ( Buntner, B; Kajdaniuk, D; Kos-Kudła, B; Marek, B; Ostrowska, Z; Szymszal, J; Zwirska-Korczala, K, 2002) |
| "The pineal hormone, melatonin, has been shown to inhibit the proliferation of the estrogen receptor alpha (ERalpha)-positive macrophage chemotactic factor (MCF)-7 human breast cancer cells." | 7.71 | Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. ( Dai, J; Hill, SM; Inscho, EW; Yuan, L, 2002) |
| "Melatonin inhibits proliferation of the estrogen-responsive MCF-7 human breast cancer cells." | 7.71 | Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? ( Cos, S; Fernández, R; González-Lamuño, D; Mediavilla, MD; Sánchez-Barceló, EJ, 2002) |
| "Melatonin inhibits the proliferation of estrogen receptor alpha (ERalpha)-positive (MCF-7), but not ERalpha-negative (MDA-MB-231) breast cancer cells." | 7.71 | MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. ( Collins, AR; Dai, J; Dubocovich, ML; Hill, SM; Yuan, L, 2002) |
| "Melatonin was previously shown to inhibit proliferation of MCF-7 human breast cancer cells." | 7.70 | Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. ( Bianchi, P; Glencross, DK; Lottering, ML; Panzer, A; Seegers, JC; Stark, JH, 1998) |
| "The pineal hormone, melatonin, inhibits proliferation of estrogen receptor (ER)-positive MCF-7 human breast cancer cells, modulates both ER mRNA and protein expression, and appears to be serum dependent, indicating interaction between melatonin and serum components." | 7.70 | Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. ( Brown, GM; Hill, SM; Kiefer, T; Ram, PT; Silverman, M; Song, Y, 1998) |
| "Previous studies on human breast cancer patients showed a decline in circulating melatonin levels corresponding to primary tumor growth and an increase when relapse occurred." | 7.70 | Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion. ( Bartsch, C; Bartsch, H; Besenthal, I; Buchberger, A; Effenberger-Klein, A; Kruse-Jarres, JD; Mecke, D; Rokos, H; Stieglitz, A, 1999) |
| " In the current study, we examined the diurnal variations of peripheral blood cells (white blood cells, neutrophils, lymphocytes), granulocyte-macrophage-colony stimulating factor (GM-CSF), and melatonin levels, and considered the role of melatonin on these rhythms in healthy volunteers and in patients with early breast cancer." | 7.70 | The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. ( Akbulut, H; Akbulut, KG; Büyükcelik, A; Demirci, S; Icli, F, 1999) |
| "The aim of the present work was to study whether melatonin, at physiological concentrations, exerts its antiproliferative effects on MCF-7 human breast cancer cells by inducing the expression of some of the proteins involved in the control of the cell cycle." | 7.70 | Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. ( Cos, S; Mediavilla, MD; Sánchez-Barceló, EJ, 1999) |
| "Twenty-four breast cancer patients on adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were studied along with 16 healthy pre-menopausal women." | 7.70 | Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients. ( Kajdaniuk, D; Marek, B, 2000) |
| "It has been established that melatonin (Mlt) and retinoic acid, individually, inhibit the proliferation of the estrogen receptor-alpha (ER alpha)-positive MCF-7 breast cancer cell line." | 7.70 | Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. ( Eck-Enriquez, K; Hill, SM; Kiefer, TL; Spriggs, LL, 2000) |
| "Melatonin, the hormonal product of the pineal gland, has been shown to inhibit the development of mammary tumors in vivo and the proliferation of MCF-7 human breast cancer cells in vitro by mechanisms not yet identified." | 7.69 | Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. ( Hill, SM; Molis, TM; Spriggs, LL, 1994) |
| "Melatonin has been shown to have a direct inhibitory effect on the proliferation of estrogen-responsive MCF-7 human breast cancer cells, involving an interaction with estradiol." | 7.69 | Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. ( Cos, S; Crespo, D; Fernández-Viadero, C; Ovejero, V; Verduga, R, 1994) |
| "Melatonin has been shown to have direct oncostatic actions on estrogen-responsive, MCF-7 human breast cancer cells in culture." | 7.69 | Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. ( Blask, DE; Cos, S, 1994) |
| "The pineal hormone, melatonin, has been reported to have an inhibitory effect on the cell growth of human breast cancer." | 7.69 | 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7). ( Furuya, Y; Kohno, N; Ku, Y; Saitoh, Y; Yamamoto, K, 1994) |
| "It has been shown that melatonin has a direct inhibitory effect on the proliferation of MCF-7 human breast cancer cells in culture." | 7.69 | Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. ( Cos, S; Recio, J; Sánchez-Barceló, EJ, 1996) |
| "The aim of the present work was to study whether physiological doses of melatonin (1nM) modified DNA synthesis in MCF-7 human breast cancer cells." | 7.69 | Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. ( Cos, S; Fernández, F; Sánchez-Barceló, EJ, 1996) |
| "Melatonin, the chief hormone secreted by the pineal gland, has been previously shown to inhibit human breast cancer cell growth at the physiological concentration of 1 nM in vitro." | 7.69 | Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. ( Blask, DE; Wilson, ST; Zalatan, F, 1997) |
| "Between 1994 and 1995, 1 day nocturnal infusion of 5-fluorouracil (5-FU) was performed prior to surgery in 13 primary breast cancer patients; 300 mg/m2 of 5-FU was infused constantly from 2100 h to 0700 h via peripheral vein with a volumetric pump." | 7.69 | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1997) |
| "2 microT [12 milligauss], 60 Hz) block the growth inhibition of the hormone melatonin (10(-9) M) on MCF-7 human breast cancer cells in vitro." | 7.69 | Environmental magnetic fields inhibit the antiproliferative action of tamoxifen and melatonin in a human breast cancer cell line. ( Harland, JD; Liburdy, RP, 1997) |
| "In previous studies a tumor-size dependent decline of the circadian amplitude of serum melatonin was found in primary unoperated breast cancer patients, which was not due to changes of the hepatic metabolism of melatonin since its main peripheral metabolite, 6-sulphatoxymelatonin (aMT6s), showed similar serum levels." | 7.69 | Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. ( Bartsch, C; Bartsch, H; Franz, H; Karenovics, A; Mecke, D; Peiker, G, 1997) |
| "On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms." | 7.68 | Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993) |
| "The pineal hormone, melatonin, was examined for its capacity to modulate the proliferation of a panel of human breast cancer cell lines." | 7.68 | The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. ( Blask, DE; Hill, SM; Muraoka, H; Simon, MA; Spriggs, LL, 1992) |
| "Cultured MCF-7 human breast cancer cells were pre-exposed to either melatonin (232 ng/mL) or vehicle for 24 hrs prior to being washed and then re-exposed to either ethanol-vehicle or varying concentrations of tamoxifen (37." | 7.68 | Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. ( Blask, DE; Lemus-Wilson, AM; Wilson, ST, 1992) |
| "A seasonal variation in the month of initial detection of breast cancer has been previously observed in pre-menopausal women, and it has been proposed that this may be due to cyclic changes in tumour growth mediated by the effects of melatonin on ovarian function." | 7.68 | Seasonal changes in serum melatonin in women with previous breast cancer. ( Gibbs, EE; Holdaway, IM; Hopkins, KD; Mason, BH; Rajasoorya, C, 1991) |
| "Serum melatonin and its main metabolic product 6-sulfatoxymelatonin were determined in 17 patients with breast cancer (BC) with either a fresh primary tumor (nine) or a secondary tumor (eight) as well as in four patients with untreated benign breast disease (controls)." | 7.68 | Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. ( Bartsch, C; Bartsch, H; Bellmann, O; Lippert, TH, 1991) |
| "Daytime plasma melatonin values were measured by radioimmune assay in 86 patients with breast cancer; 280 assays were done and compared with the clinical status of the patients." | 7.68 | Plasma melatonin in patients with breast cancer. ( Falkson, G; Falkson, HC; Meyer, BJ; Rapoport, BL; Steyn, ME, 1990) |
| "Only physiological levels of melatonin exert an antiproliferative effect on MCF-7 breast cancer cells grown in an anchorage-dependent culture system." | 7.68 | Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system. ( Blask, DE; Cos, S, 1990) |
| "Serum melatonin was determined over 24 hours in 35 patients with breast cancer with either a fresh primary tumor (n = 23) or a secondary tumor (n = 12) and in 28 patients with untreated benign breast disease (controls) having a fibroadenoma (n = 10), fibrocystic mastopathy (n = 14), or other breast diseases (n = 4)." | 7.67 | Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. ( Bartsch, C; Bartsch, H; Bellmann, O; Fuchs, U; Gupta, D; Lippert, TH, 1989) |
| "Hypothyroidism and low iodine intake may be important aetiological factors in oestrogen dependent tumours of the breast, uterus and ovary." | 7.67 | Di-iodothyronine as part of the oestradiol and catechol oestrogen receptor--the role of iodine, thyroid hormones and melatonin in the aetiology of breast cancer. ( Clur, A, 1988) |
| "Since melatonin, the major hormone of the pineal gland, has been shown to inhibit the growth of mammary tumors in animal models of human breast cancer, we examined the hypothesis that this indoleamine has the potential to inhibit breast cancer growth by directly inhibiting cell proliferation as exemplified by the growth of the estrogen-responsive human breast cancer cell line MCF-7 in culture." | 7.67 | Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. ( Blask, DE; Hill, SM, 1988) |
| " More compelling evidence indicates that the pineal hormone melatonin, in addition to its well known antireproductive effects, may also exert oncostatic effects particularly in animal models of human breast cancer." | 7.67 | Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. ( Blask, DE; Hill, SM, 1986) |
| "We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women at high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy." | 7.67 | Plasma melatonin and the hormone-dependency of human breast cancer. ( Bagley, CS; Danforth, DN; Lippman, ME; Mulvihill, JJ; Tamarkin, L, 1985) |
| "Urinary melatonin levels were measured in 10 postmenopausal Indian women suffering from advanced stages of breast cancer and in 9 well-matched women with non-endocrine complaints, mostly uterovaginal prolapse." | 7.66 | Urinary melatonin levels in human breast cancer patients. ( Bartsch, C; Bartsch, H; Jain, AK; Laumas, KR; Wetterberg, L, 1981) |
| "Plasma melatonin concentrations were determined over a period of 24 hours in 20 women with clinical stage I or II breast cancer." | 7.66 | Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. ( Chabner, B; Cohen, M; Danforth, D; DeMoss, E; Lichter, A; Lippman, M; Tamarkin, L, 1982) |
| "Melatonin is a neurohormone involved in diverse physiological processes, including regulation of circadian rhythm, oncogenesis and immune function." | 7.30 | Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer. ( Gao, SC; Liu, YF; Wang, CL; Wu, MD; Zhang, XX, 2023) |
| "Melatonin is a multivalent compound which has a hand in several cellular and molecular processes and therefore, is an appropriate candidate for treatment of many diseases like cancer." | 6.82 | Molecular and cellular mechanisms of melatonin in breast cancer. ( Asemi, Z; Dana, PM; Heidar, Z; Mirzaei, H; Mirzamoradi, M; Mohammadi, S; Sadoughi, F; Shafabakhash, R; Targhazeh, N, 2022) |
| "In the developmental stages of breast cancer, estrogens are strongly involved." | 6.72 | Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer. ( Choi, YJ; Heo, K; Jin, Y; Park, SJ, 2021) |
| "Breast cancer is the prevalent type of tumor in women and is the leading cause of death among female cancers." | 6.72 | Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin. ( Gurer-Orhan, H; Panieri, E; Saso, L; Stepanić, V; Tascioglu Aliyev, A, 2021) |
| "The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology." | 6.69 | Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998) |
| "Breast cancer is the most common cancer among women and its metastasis which generally observed at the last stage is the major cause of breast cancer-related death." | 6.66 | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. ( Akbarzadeh, M; Amirzadeh-Iranaq, MT; Ashoori, Z; Ashouri, N; Bizzarri, M; Faridvand, Y; Fattahi, A; Kazemzadeh, H; Maroufi, NF; Mortezania, Z; Nejabati, HR; Nouri, M; Rashidi, MR; Vahedian, V, 2020) |
| " Breast cancer risk factors include smoking, alcohol consumption, personal and family history, hypertension, and hormone therapy, long-term use of nonsteroidal anti-inflammatory drugs and tobacco usage." | 6.61 | Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms. ( Amin, N; Asemi, Z; Reiter, RJ; Shafabakhsh, R, 2019) |
| "They analy onzed women with breast cancer and control patients, of which 10% and 90% were in the reproductive period and after menopause, respectively." | 6.61 | Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis. ( Abreu, LC; Baracat, EC; Baracat, MCP; Barros, EPM; Cipolla-Neto, J; Simões, R; Soares Junior, JM; Sorpreso, ICE; Valenti, VE; Veiga, ECA, 2019) |
| "As melatonin is toxic to breast cancer cells, its production within mitochondria poses a significant challenge to breast cancer cell survival." | 6.61 | Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology. ( Anderson, G, 2019) |
| "The breast cancer affects women with high mortality and morbidity worldwide." | 6.58 | Melatonin and breast cancer: Evidences from preclinical and human studies. ( Adamek, M; Busselberg, D; Caprnda, M; Danko, J; Gazdikova, K; Kruzliak, P; Kubatka, P; Kwon, TK; Opatrilova, R; Petrovic, D; Rodrigo, L; Zubor, P, 2018) |
| "Melatonin pre-treatment prior to ionizing radiation was associated with a decrease in cell proliferation and an increase in p53 mRNA expression, leading to an increase in the radiosensitivity of breast cancer cells." | 6.58 | Therapeutic potential of melatonin for breast cancer radiation therapy patients. ( Griffin, F; Marignol, L, 2018) |
| "Melatonin has been shown to reduce the incidence of experimentally induced cancers and can significantly inhibit the growth of some human tumors, namely hormone-dependent cancers." | 6.49 | Molecular mechanisms of melatonin's inhibitory actions on breast cancers. ( Bizzarri, M; Cucina, A; Proietti, S; Reiter, RJ, 2013) |
| "The global impact of breast cancer is large and growing." | 6.43 | Circadian disruption and breast cancer: from melatonin to clock genes. ( Stevens, RG, 2005) |
| "The impact of breast cancer on women across the world has been extensive and severe." | 6.41 | Ocular input for human melatonin regulation: relevance to breast cancer. ( Brainard, GC; Glickman, G; Levin, R, 2002) |
| "Worldwide, breast cancer is the most common malignancy accounting for 20-32% of all female cancers." | 6.40 | The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature. ( Brainard, GC; Kavet, R; Kheifets, LI, 1999) |
| "An effect of electric power on breast cancer would have profound implications, and this possibility deserves continued investigation." | 6.39 | The melatonin hypothesis: electric power and breast cancer. ( Davis, S; Stevens, RG, 1996) |
| "The aim of this double-blind, placebo-controlled, randomized study was to investigate whether topical melatonin administered during radiation therapy could increase the quality of life in patients with primary breast cancer." | 5.69 | Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial. ( Christophersen, C; Gülen, S; Hoffmeyer, B; Kamby, C; Mahmood, F; Paulsen, CB; Piga, E; Rosenberg, J; Zetner, D, 2023) |
| "This was a double-blind, placebo-controlled randomized study investigating whether melatonin can protect against radiation dermatitis in women receiving radiation therapy for primary breast cancer." | 5.69 | Effect of melatonin cream on acute radiation dermatitis in patients with primary breast cancer: A double-blind, randomized, placebo-controlled trial. ( Christophersen, C; Gülen, S; Hoffmeyer, B; Kamby, C; Mahmood, F; Paulsen, CB; Piga, E; Rosenberg, J; Zetner, D, 2023) |
| "Breast cancer is the most common neoplastic disorder diagnosed in women." | 5.51 | Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway. ( El-Sokkary, GH; Ismail, IA; Saber, SH, 2019) |
| "Melatonin treatment reduced tumor growth (p < 0." | 5.51 | RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model. ( Alexandre, PA; Chammas, R; Coutinho, LL; de Paula-Junior, R; Fukumasu, H; Jardim-Perassi, BV; Reis Júnior, O; Sonehara, NM; Zuccari, DAPC, 2019) |
| "Melatonin is a hormone synthesized by the pineal gland at night in the absence of light." | 5.48 | Evaluation of melatonin and AFMK levels in women with breast cancer. ( Bordin-Junior, NA; de Almeida, EA; de Campos Zuccari, DAP; de Castro, TB, 2018) |
| "Melatonin and Y27632 treatments reduced cell viability and invasion/migration of both cell lines and decreased ROCK-1 gene expression in metastatic cells and protein expression in nonmetastatic cell line." | 5.43 | Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. ( Arbab, AS; Borin, TF; Coimbra, VB; de Oliveira, JG; Fabri, VA; Ferreira, LC; Gelaleti, GB; Iskander, AS; Jardim-Perassi, BV; Moschetta, MG; Shankar, A; Varma, NR; Zuccari, DA, 2016) |
| "Melatonin pretreatment before radiation also decreased G2 -M phase arrest compared with irradiation alone, with a higher percentage of cells in the G0 -G1 phase and a lower percentage of cells in S phase." | 5.42 | Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. ( Alonso-González, C; Cos, S; Gómez-Arozamena, J; González, A; Martínez-Campa, C, 2015) |
| "Melatonin inhibits human breast cancer growth via mechanisms that include the suppression of tumor metabolism and inhibition of expression or phospho-activation of the receptor kinases AKT and ERK1/2 and various other kinases and transcription factors." | 5.42 | Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. ( Belancio, VP; Blask, DE; Dauchy, RT; Frasch, T; Hauch, A; Hill, SM; Mao, L; Mondal, D; Wren, MA; Xiang, S; Yuan, L, 2015) |
| "Melatonin in vitro treatment (1 mM) decreased cell viability (p<0." | 5.40 | Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. ( Ali, MM; Arbab, AS; Borin, TF; de Campos Zuccari, DA; Ferreira, LC; Iskander, AS; Jardim-Perassi, BV; Shankar, A; Varma, NR, 2014) |
| "Patients with breast cancer undergoing lumpectomy had significantly disturbed sleep architecture the night after surgery, and these changes were normalised after 2 weeks." | 5.39 | Sleep disturbances and changes in urinary 6-sulphatoxymelatonin levels in patients with breast cancer undergoing lumpectomy. ( Gögenur, I; Hansen, MV; Madsen, MT; Rosenberg, J; Wildschiødtz, G, 2013) |
| " Their combined use has made it possible to increase an overall survival but they are still penalized by adverse effects and toxicity." | 5.39 | Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report. ( Colori, B; Di Bella, G; Mascia, F; Ricchi, A, 2013) |
| "We updated the sleep duration-breast cancer association with 14 years of follow-up of 34,028 women in the SCHS." | 5.39 | Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. ( Koh, WP; Stanczyk, FZ; Wang, R; Wu, AH; Yu, MC; Yuan, JM, 2013) |
| "Melatonin has a variety of therapeutic effects, such as immunomodulatory actions, anti-inflammatory effects, and antioxidant actions." | 5.37 | MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. ( Hwang, SY; Kim, SJ; Lee, SE; Park, CS; Park, YS; Youn, JP, 2011) |
| "This randomized, double-blinded, placebo-controlled trial tested the hypothesis that 20mg of melatonin before and during the first cycle of adjuvant chemotherapy for breast cancer (ACBC) reduced the side effects associated with cognitive impairment." | 5.34 | Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. ( Biazús, JV; Caumo, W; Fregni, F; Palmer, ACS; Santos, V; Souza, A; Torres, ILS; Zortea, M, 2020) |
| "Increased breast cancer risks have been reported among women with gross cystic breast disease (GCBD), although the mechanism for this increase remains unexplained." | 5.34 | Melatonin and estrogen in breast cyst fluids. ( Anderson, BO; Burch, JB; Cosma, G; Craven, W; Finlayson, C; Hennesey, M; Rush, A; Walling, M; Wells, RL, 2007) |
| "0 or 5 mM), but melatonin (1 or 10 nM) was ineffective alone or in combination with valproic acid, in the first (MCF-7A) subline examined." | 5.34 | Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. ( Brown, GM; Jawed, S; Kim, B; Niles, LP; Ottenhof, T; Werstiuk, ES, 2007) |
| "Melatonin is a specific inhibitor of Cd-induced ER alpha-mediated transcription in both estrogen response elements (ERE)- and AP1-containing promoters, whereas ER beta-mediated transcription is not inhibited by the pineal indole." | 5.33 | Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Ramos, S; Sánchez-Barceló, EJ, 2006) |
| "Three types of human breast cancer cells were used in this study: MDA-MB-435, MDA-MB-231, and MCF-7." | 5.31 | Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells. ( Anderson, KW; Leman, ES; Sisken, BF; Zimmer, S, 2001) |
| " RORalpha receptors are also expressed in MCF-7 breast cancer cells and the putative RORalpha agonist CPG-52608 inhibits MCF-7 cell growth but with a very different dose-response than melatonin." | 5.31 | Involvement of the mt1 melatonin receptor in human breast cancer. ( Dai, J; Dong, C; Hill, SM; Kiefer, TL; Lai, L; Ram, PT; Yuan, L, 2002) |
| "Melatonin was also able to block 17beta-estradiol-induced invasion (P < 0." | 5.30 | Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. ( Cos, S; Fernández, R; Güézmes, A; Sánchez-Barceló, EJ, 1998) |
| "Melatonin (aMT) appears to be a potentially important oncostatic substance that can block the mitogenic effects of tumour-promoting hormones and growth factors such as oestradiol and epidermal growth factor, in vitro." | 5.29 | Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. ( Blask, DE; Kelly, PA; Lemus-Wilson, A, 1995) |
| "This review proposes an overall vision of the protective and therapeutic role of melatonin in breast cancer: from the specific cases of blind women and their reduction of breast cancer incidence to all clinical uses of the sleep hormone in breast cancer." | 5.22 | Protective role of melatonin in breast cancer: what we can learn from women with blindness. ( Amé, S; Coliat, P; Mathelin, C; Minella, C; Neuberger, K; Reix, N; Stora, A, 2022) |
| " In this prospective phase II trial, we sought to assess the effect of melatonin on circadian biomarkers, sleep, and quality of life in breast cancer patients." | 5.22 | The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. ( Bjarnason, GA; Clemons, M; Eisen, A; Innominato, PF; Kiss, A; Lim, AS; Palesh, O; Pritchard, KI; Trudeau, M; Wang, C, 2016) |
| "To investigate whether administration of an oral dose of 6 mg melatonin before bedtime perioperatively in breast cancer surgery could change sleep outcomes measured by actigraphy." | 5.22 | Effect of Melatonin on Sleep in the Perioperative Period after Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Andersen, LT; Bokmand, S; Gögenur, I; Hageman, I; Hansen, MV; Madsen, MT; Rasmussen, LS; Rosenberg, J, 2016) |
| "The purpose is to examine the effects of melatonin supplementation on sleep, mood, and hot flashes in postmenopausal breast cancer survivors." | 5.19 | A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. ( Chen, WY; Gantman, K; Giobbie-Hurder, A; Parker, LM; Savoie, J; Scheib, R; Schernhammer, ES, 2014) |
| "Women with breast cancer have decreased levels of melatonin or its metabolite in plasma and/or urine." | 5.17 | No effect of exercise on urinary 6-sulfatoxymelatonin and catecholamines in young women participating in a 16-week randomized controlled trial. ( Arikawa, AY; Kurzer, MS; Patel, SR; Thomas, W, 2013) |
| "We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the IGF-1/IGFBP-3 ratio) in postmenopausal breast cancer survivors." | 5.16 | A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. ( Chen, WY; Gantman, K; Giobbie-Hurder, A; Parker, LM; Savoie, J; Scheib, R; Schernhammer, ES, 2012) |
| "Exposure to higher levels of melatonin may be associated with lower breast cancer risk, but epidemiologic evidence has been limited." | 5.12 | Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies. ( Fensom, GK; Key, TJ; Onland-Moret, NC; Tong, TYN; Travis, RC; Wong, ATY, 2021) |
| "To review studies evaluating the circadian rhythm of melatonin in breast cancer patients." | 5.12 | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients. ( Ahabrach, H; Cauli, O; El Mlili, N; Errami, M, 2021) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 5.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| "Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth." | 5.08 | Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. ( Barni, S; Cazzaniga, M; Esposti, D; Fossati, V; Lissoni, P; Meregalli, S; Tancini, G, 1995) |
| "Melatonin has significant inhibitory effects in numerous cancers, especially breast cancer." | 5.05 | Melatonin: A Potential Therapeutic Option for Breast Cancer. ( Fang, Y; Gao, J; Gao, R; Kong, X; Reiter, RJ; Wang, J; Wang, X; Wang, Z, 2020) |
| "The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease." | 4.98 | Melatonin: A Molecule for Reducing Breast Cancer Risk. ( González-González, A; Mediavilla, MD; Sánchez-Barceló, EJ, 2018) |
| "Melatonin has a significant inhibitory effect on various cancers, especially on breast cancer." | 4.95 | [Inhibitory effects of melatonin on breast cancer]. ( Jiang, Z; Ma, F, 2017) |
| " To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death." | 4.95 | Melatonin, an inhibitory agent in breast cancer. ( Akbari, ME; Bashash, D; Nooshinfar, E; Safaroghli-Azar, A, 2017) |
| "The present review discusses recent work on melatonin-mediated circadian regulation, the metabolic and molecular signaling mechanisms that are involved in human breast cancer growth, and the associated consequences of circadian disruption by exposure to light at night (LEN)." | 4.91 | Melatonin: an inhibitor of breast cancer. ( Belancio, VP; Blask, DE; Brimer, S; Dauchy, RT; Frasch, T; Hauch, A; Hill, SM; Lundberg, PW; Mao, L; Summers, W; Xiang, S; Yuan, L, 2015) |
| "Melatonin inhibits human breast cancer cells stimulated with estrogen." | 4.91 | Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review. ( Reiter, RJ; Vriend, J, 2015) |
| "It has been hypothesized that suppressed nocturnal melatonin production is associated with an increased risk of breast cancer, but results from several small prospective studies of the association have been inconclusive." | 4.90 | First-morning urinary melatonin and breast cancer risk in the Guernsey Study. ( Allen, NE; Appleby, PN; Key, TJ; Tipper, S; Travis, RC; Wang, XS, 2014) |
| "Evidence from observational studies on light at night (LAN) exposure, sleep duration, endogenous melatonin levels, and risk for breast cancer in women is conflicting." | 4.90 | Light exposure at night, sleep duration, melatonin, and breast cancer: a dose-response analysis of observational studies. ( Deng, Q; Fan, WY; Wang, WY; Wang, X; Yang, WS, 2014) |
| "The pineal hormone melatonin (MLT) has potent anti-breast cancer activity, its actions are heavily mediated via the MT1 receptor and subsequent modulation of downstream signaling pathways including cAMP/PKA, Erk/MAPK, p38, and Ca2+/calmodulin." | 4.89 | Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. ( Blask, DE; Cheng, C; Dauchy, B; Hill, SM; Jockers, R; Mao, L; Yuan, L, 2013) |
| "The usefulness of melatonin and melatoninergic drugs in breast cancer therapy is based on its Selective Estrogen Receptor Modulator (SERM) and Selective Estrogen Enzyme Modulator (SEEM) properties." | 4.88 | Breast cancer therapy based on melatonin. ( Alonso-Gonzalez, C; Mediavilla, MD; Rueda, N; Sanchez-Barcelo, EJ, 2012) |
| "This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo- or radiotherapy." | 4.88 | Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. ( Alonso-Gonzalez, C; Mediavilla, MD; Reiter, RJ; Sanchez-Barcelo, EJ, 2012) |
| "The so-called 'Melatonin Hypothesis' proposed that decreased nocturnal production of melatonin (MLT) might explain the increased risk of breast cancer that has been formerly attributed to extremely low-frequency (ELF) magnetic fields (MF) of weak intensity." | 4.88 | Health effects of extremely low-frequency magnetic fields: reconsidering the melatonin hypothesis in the light of current data on magnetoreception. ( Bouland, C; Burda, H; de Brouwer, C; Vanderstraeten, J; Verschaeve, L, 2012) |
| "Exposure to electromagnetic radiation (EMR) may increase breast cancer risk by inducing oxidative stress and suppressing the production of melatonin." | 4.88 | Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+ signaling molecular pathways in breast cancer. ( Demirci, S; Naziroğlu, M; Tokat, S, 2012) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular, dietary, and metabolic signaling mechanisms involved in human breast cancer growth and the consequences of circadian disruption by exposure to light at night (LAN)." | 4.87 | Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. ( Blask, DE; Dauchy, E; Dauchy, RT; Duplessis, T; Hill, SM; Mao, L; Sauer, LA; Xiang, S; Yuan, L, 2011) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular and metabolic signaling mechanisms involved in human breast cancer growth and the associated consequences of circadian disruption by exposure to light-at-night (LAN)." | 4.87 | Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. ( Blask, DE; Dauchy, EM; Dauchy, RT; Duplesis, T; Frasch, T; Hill, SM; Mao, L; Xiang, S; Yuan, L, 2011) |
| "The oncostatic properties of melatonin as they directly or indirectly involve epigenetic mechanisms of cancer are reviewed with a special focus on breast cancer." | 4.85 | Role of melatonin in the epigenetic regulation of breast cancer. ( Korkmaz, A; Reiter, RJ; Sanchez-Barcelo, EJ; Tan, DX, 2009) |
| "Recent studies have suggested that the pineal hormone melatonin may protect against breast cancer, and the mechanisms underlying its actions are becoming clearer." | 4.85 | Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. ( Grant, SG; Latimer, JJ; Melan, MA; Witt-Enderby, PA, 2009) |
| "Melatonin exerts oncostatic effects on different kinds of tumors, especially on hormone-dependent breast cancer." | 4.84 | Melatonin as a selective estrogen enzyme modulator. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2008) |
| "Although many factors have been suggested as causes for breast cancer, the increased incidence of the disease seen in women working in night shifts led to the hypothesis that the suppression of melatonin by light or melatonin deficiency plays a major role in cancer development." | 4.84 | Melatonin, environmental light, and breast cancer. ( Cardinali, DP; Esquifino, AI; Maestroni, GJ; Pandi-Perumal, SR; Spence, DW; Srinivasan, V; Trakht, I, 2008) |
| " Persons who engage in nightshift work may exhibit altered nighttime melatonin levels and reproductive hormone profiles that could increase the risk of hormone-related diseases, including breast cancer." | 4.83 | Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. ( Davis, S; Mirick, DK, 2006) |
| "Melatonin exerts oncostatic effects on different kinds of tumors, especially on endocrine-responsive breast cancer." | 4.83 | Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2006) |
| "Melatonin might be implicated in menopause-associated processes such as insomnia, breast cancer, and general aging." | 4.80 | "Melatonin replacement therapy" for postmenopausal women: is it justified? ( Brzezinski, A, 1998) |
| "The disparity between the rates of breast cancer in industrialized and less-industrialized regions has led to many hypotheses, including the theory that exposure to light-at-night and/or electromagnetic fields (EMF) may suppress melatonin and that reduced melatonin may increase the risk of breast cancer." | 4.80 | Industrialization, electromagnetic fields, and breast cancer risk. ( Kheifets, LI; Matkin, CC, 1999) |
| "The hypothesis is advanced that blindness from an early age may lead to a reduced risk of breast cancer through altered patterns of melatonin secretion by the pineal gland." | 4.78 | Breast cancer, blindness and melatonin. ( Coleman, MP; Reiter, RJ, 1992) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer." | 4.12 | Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line. ( Akbarzadeh, M; Isazadeh, A; Jahanbazi, R; Kazemzadeh, H; Maroufi, NF; Mostafaei, S; Nejabati, HR; Nouri, M; Rashidi, M; Rashidi, MR; Vahedian, V, 2022) |
| " Additionally, melatonin has shown inhibitory effects on the growth of human breast cancer cells." | 4.12 | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines. ( Abdolmaleki, A; Asadi, A; Bahadori, MH; Ghorbani-Anarkooli, M; Hajizadeh Moghadam, A; Karimian, A; Mir Mohammadrezaei, F, 2022) |
| "Melatonin exerts oncostatic effects on breast cancer via immunomodulation and antioxidation." | 4.12 | Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model. ( Aytac, G; Dilmac, S; Farooqi, AA; Sindel, M; Tanriover, G, 2022) |
| "The goal of this work was to see how melatonin affected Bax and Bcl-2 expression, as well as apoptosis and autophagy, in MCF-7 and MDA-MB-231 breast cancer cell lines, which have distinct hormonal sensitivities." | 4.12 | Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis. ( Önder, GÖ; Özdamar, S; Sezer, G; Yay, A, 2022) |
| " In the current study, we find that Melatonin sensitizes HER2-positive breast cancer cells to the dual tyrosine kinase inhibitor Lapatinib in vitro." | 4.02 | Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. ( Cheng, H; Li, L; Liu, P; Liu, Y; Liu, Z; Rui, C; Sang, X; Tao, Z, 2021) |
| " The aim of this study was to evaluate a combination consisting of a ketogenic diet and melatonin to determine whether it would inhibit cisplatin- and vincristine-resistant breast cancer." | 3.96 | A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. ( Talib, WH, 2020) |
| "This study aims to investigate the effects of zinc and melatonin supplementation on lipid peroxidation in the brain cortex in DMBA-induced breast cancer in female rats." | 3.96 | Zinc and melatonin supplementation ameliorates brain cortex tissue damage in DMBA-induced breast cancer in rats. ( Baltaci, SB; Mutlu, EG, 2020) |
| " Apoptosis assay was performed on breast cancer cells to evaluate melatonin effects." | 3.96 | Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells. ( Abdolahi, S; Akbarzadeh, M; Emami, A; Hosseinpourfeizi, MA; Khodaei, M; Khodavirdipour, A; Pourmahdi, M; Rajabi, A; Ravanbakhsh, R; Saber, A; Safaralizadeh, R, 2020) |
| " Recent studies indicate that pineal hormone melatonin by its receptor melatonin 1 (MT1) also influences the development and growth of breast cancer cells." | 3.96 | Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors. ( Bal, A; Goyal, R; Gupta, T; Sahni, D; Singh, G, 2020) |
| "This prospective cohort study captured the patterns of sleep, sleep-wake activity rhythm, and first-morning urinary melatonin in breast cancer patients undergoing adjuvant chemotherapy." | 3.91 | Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study. ( Chan, DC; Ho, AW; Ho, CS; Kwok, CC; Li, W; Tse, LA; Wang, F; Wing, YK; Zhang, J, 2019) |
| "The aim of this study was to evaluate the role of melatonin and the tumor suppressor miR- 148a-3p on angiogenesis of breast cancer." | 3.91 | Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer. ( Aristizábal-Pachón, AF; Bajgelman, MC; Borin, TF; Ferreira, LC; Lacerda, JZ; Lopes, BC; Zuccari, DAPC, 2019) |
| "Disruption of circadian time structure and suppression of circadian nocturnal melatonin (MLT) production by exposure to dim light at night (dLAN), as occurs with night shift work and/or disturbed sleep-wake cycles, is associated with a significantly increased risk of breast cancer and resistance to tamoxifen and doxorubicin." | 3.91 | Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Hoffman, AE; Pointer, D; Xiang, S, 2019) |
| " Several mechanisms have been postulated to explain an association between night work and female breast cancer, but the most likely is suppression of the hormone melatonin by light exposure at night." | 3.91 | Shedding Light on the Association between Night Work and Breast Cancer. ( Cherrie, JW, 2019) |
| "Our purpose is to investigate the impact of circadian and melatonin pathway genes as well as their interactions with night-shift work (NSW) on breast cancer risk in Korean women." | 3.91 | Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women. ( Joo, J; Kim, J; Kim, SY; Kong, SY; Lee, ES; Park, B; Pham, TT; Yoon, KA, 2019) |
| "Melatonin exerts oncostatic activity in breast cancer through antiangiogenic actions." | 3.88 | Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in co‑cultures of human endothelial and breast cancer cells. ( Alonso-González, C; Cos, S; González, A; González-González, A; Martínez-Campa, C; Menéndez-Menéndez, J, 2018) |
| " As is reported in numerous studies, melatonin, an endogenous hormone secreted by the pineal gland, could markedly inhibit estrogen-induced proliferation of breast cancer (BC) cells." | 3.88 | Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways. ( Gong, M; Guan, Y; Liang, R; Liu, B; Liu, Y; Pan, J; Wang, T; Ye, L; Yuan, Y; Zhang, W, 2018) |
| "Through activation of the ERK pathway, nicotine, in both normal MCF-10A and low-malignant breast cancer cells (MCF7), promotes increased motility and invasiveness." | 3.88 | Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation. ( Bizzarri, M; Catizone, A; Cucina, A; Dinicola, S; Fabrizi, G; Masiello, MG; Minini, M; Proietti, S; Reiter, RJ; Ricci, G; Verna, R, 2018) |
| "The breast cancer xenografts nude mice treated with melatonin showed reduced tumor size (P=0." | 3.88 | Melatonin Differentially Modulates NF-кB Expression in Breast and Liver Cancer Cells. ( Braga, CZ; Colombo, J; Ferreira, JPS; Girol, AP; Jardim-Perassi, BV; Júnior, RP; Moschetta, MG; Sonehara, NM; Zuccari, DAPC, 2018) |
| "To test the anticancer potential of a combination of thymoquinone (TQ) and melatonin (MLT) against breast cancer implanted in mice." | 3.88 | Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice. ( Basheti, IA; Odeh, LH; Talib, WH, 2018) |
| " We have tested the affinity of oxyprenylated ferulic acid (1-4) and umbelliferone derivatives (5-11) to melatonin receptors as well as their antiproliferation and antimigratory properties against breast cancer (BC) cell lines." | 3.85 | Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration. ( Epifano, F; Fiorito, S; Genovese, S; Hasan, M; Witt-Enderby, PA, 2017) |
| "With the wide recognition of oncostatic effect of melatonin, the current study proposes a potential breast cancer target multimodality treatment based on melatonin-loaded magnetic nanocomposite particles (Melatonin-MNPs)." | 3.85 | Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles. ( Gao, Q; Guo, Z; Sun, X; Wang, D; Wang, W; Wang, X; Xie, W; Yan, H; Yuan, J; Zhao, L, 2017) |
| " Excessive exposure to hazardous ALAN containing short wavelength light may suppress pineal melatonin production and lead to an increased breast cancer (BC) risk." | 3.85 | Light and the City: Breast Cancer Risk Factors Differ Between Urban and Rural Women in Israel. ( Haim, A; Keshet-Sitton, A; Or-Chen, K; Tzabary, I; Yitzhak, S, 2017) |
| "Evaluate the viability and the expression of OCT4 in breast cancer stem cells, MCF-7 and MDA-MB- 231, after melatonin treatment." | 3.85 | Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres. ( da Silva Kavagutti, M; de Campos Zuccari, DAP; de Medeiros, FAF; Lopes, JR, 2017) |
| " In the present study, we investigated the combined effects of melatonin and arsenic trioxide (ATO) on cell death in human breast cancer cells." | 3.83 | Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. ( Choe, TB; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Lee, JK; Lee, YH; Noh, WC; Oh, ST; Park, IC; Seong, MK; Woo, SH; Ye, SK; Yun, SM, 2016) |
| "Excessive exposure to artificial light at night (ALAN) suppresses nocturnal melatonin (MLT) production in the pineal gland and is, therefore, associated with an increased risk of breast cancer (BC)." | 3.83 | Can Avoiding Light at Night Reduce the Risk of Breast Cancer? ( Haim, A; Keshet-Sitton, A; Or-Chen, K; Tzabary, I; Yitzhak, S, 2016) |
| " This study investigated potential application of nanostructured lipid carriers (NLCs) in increasing melatonin induced cytotoxicity and apoptosis in MCF-7 breast cancer cells." | 3.83 | Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. ( Akbarzadeh, M; Hamishehkar, H; Mohammadian, J; Molavi, O; Sabzichi, M; Samadi, N, 2016) |
| " Melatonin, a naturally occurring indoleamine synthesized in the pineal gland, has been considered as a biomarker for endocrine-dependent tumors, particularly breast cancer." | 3.83 | Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer. ( Akbari, ME; Bashash, D; Bayati, S; Ghaffari, SH; Nooshinfar, E; Rezaei-Tavirani, M; Safaroghli-Azar, A, 2016) |
| "Melatonin inhibition of Rsk2 represses the metastatic phenotype in breast cancer cells suppressing EMT or inhibiting other mechanisms that promote metastasis; disruption of the melatonin signal may promote metastatic progression in breast cancer." | 3.83 | Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Mao, L; Pointer, D; Reynolds, A; Summers, W; Wren-Dail, MA; Xiang, S; Yuan, L, 2016) |
| "Experimental and epidemiologic data support a protective role for melatonin in breast cancer etiology, yet studies in premenopausal women are scarce." | 3.81 | Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II. ( Arcaro, KF; Brown, SB; Eliassen, AH; Hankinson, SE; Qian, J; Reeves, KW; Schernhammer, ES; Wegrzyn, LR; Willett, WC, 2015) |
| "The aim of this study was to determine the effects of some polyunsaturated fatty acids plus phytomelatonin from walnuts in the development of mammary gland adenocarcinoma." | 3.81 | Synergistic anti-tumor effects of melatonin and PUFAs from walnuts in a murine mammary adenocarcinoma model. ( Berra, MA; Comba, A; Das, UN; Eynard, AR; Garcia, CP; Labuckas, DO; Lamarque, AL; Pasqualini, ME; Silva, RA, 2015) |
| "Results from prospective studies on the association between urinary levels of melatonin and risk of postmenopausal breast cancer have been mixed." | 3.80 | Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort. ( Bigelow, C; Doherty, A; Liu, S; Manson, JE; Neuhouser, ML; Ockene, JK; Reeves, KW; Stanczyk, FZ; Sturgeon, SR, 2014) |
| " Using tissue-isolated human breast cancer xenografts grown in nude rats, we determined that circulating systemic factors in the host and the Warburg effect, linoleic acid uptake/metabolism and growth signaling activities in the tumor are dynamically regulated, coordinated and integrated within circadian time structure over a 24-hour light/dark cycle by SCN-driven nocturnal pineal production of the anticancer hormone melatonin." | 3.80 | Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. ( Belancio, VP; Blask, DE; Dauchy, EM; Dauchy, RT; Davidson, L; Greene, MW; Hill, SM; Mao, L; Sauer, LA, 2014) |
| " Previously, we observed melatonin-induced differential expression of miRNA and miRNA-related genes in human breast cancer cell lines that indicated an anticancer effect of melatonin." | 3.79 | Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. ( Hwang, SY; Jeong, SI; Kim, SJ; Lee, SE; Park, CS; Park, YS; Yang, H; Yoon, HJ; Yu, SY, 2013) |
| "Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen-signaling pathways." | 3.79 | Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C, 2013) |
| "Previous studies suggest that melatonin may act on cancer growth through a variety of mechanisms, most notably by direct anti-proliferative effects on breast cancer cells and via interactions with the estrogen pathway." | 3.78 | Melatonin pathway genes and breast cancer risk among Chinese women. ( Beeghly-Fadiel, A; Cai, Q; Deming, SL; Gao, YT; Long, J; Lu, W; Shu, XO; Zheng, W; Zheng, Y, 2012) |
| "Melatonin exerts oncostatic effects on breast cancer by interfering with the estrogen signaling pathways." | 3.78 | Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C, 2012) |
| "The main biological active substance secreted by the pineal gland, melatonin (MLT), counteracts the effects of estrogens in breast cancer via exerting a number of its own oncostatic properties." | 3.78 | Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. ( Clyne, CD; Knower, KC; Miki, Y; Sasano, H; Simpson, ER; Takagi, K; To, SQ, 2012) |
| "Night shift work may disrupt the normal nocturnal rise in melatonin, resulting in increased breast cancer risk, possibly through increased reproductive hormone levels." | 3.78 | Night shift work and hormone levels in women. ( Chen, C; Davis, S; Mirick, DK; Stanczyk, FZ, 2012) |
| "Melatonin has been shown to inhibit breast cancer cell growth in numerous studies." | 3.78 | Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. ( Dama, A; Formigli, L; Francini, F; Margheri, M; Masala, E; Nosi, D; Pacini, N; Squecco, R; Tani, A; Zecchi-Orlandini, S, 2012) |
| "Melatonin suppresses breast cancer cell proliferation by inhibiting the upregulation of estrogen-induced cyclin D1 via its G-protein-coupled receptor MT1." | 3.77 | Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. ( Ekmekcioglu, C; Humpeler, S; Jäger, W; Klimpfinger, M; Königsberg, R; Rögelsperger, O; Svoboda, M; Thalhammer, T; Wlcek, K, 2011) |
| "The growth of estrogen-receptor positive breast cancer cells is inhibited by the pineal gland hormone, melatonin." | 3.76 | Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields. ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2010) |
| "Lower urinary melatonin levels are associated with a higher risk of breast cancer in postmenopausal women." | 3.76 | Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. ( Berrino, F; Cavalleri, A; Grioni, S; Krogh, V; Micheli, A; Muti, P; Schernhammer, ES; Schünemann, HJ; Secreto, G; Sempos, CT; Strano, S; Venturelli, E, 2010) |
| "The pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the proliferation of estrogen receptor α (ERα)-positive breast cancer cell lines." | 3.76 | Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. ( Burow, ME; Hill, SM; Jones, FE; Mao, L; Slakey, LM; Yuan, L, 2010) |
| "Melatonin seems to play a role in breast cancer etiology, but data addressing the association between melatonin levels and breast cancer risk in postmenopausal women is sparse." | 3.75 | Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. ( Hankinson, SE; Schernhammer, ES, 2009) |
| "Previous investigations demonstrated that melatonin exerts an oncostatic action on estrogen-responsive breast cancer, both in vitro and in vivo." | 3.75 | Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. ( Bizzarri, M; Coluccia, P; Cucina, A; D'Anselmi, F; Dinicola, S; Frati, L; Proietti, S, 2009) |
| "Melatonin possesses anti-estrogenic effects on estrogen receptor expressing (ER+) breast cancer cells in culture by reducing cell cycle progression and cell proliferation." | 3.75 | Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2009) |
| "Melatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits aromatase activity and expression." | 3.75 | Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. ( Alonso-González, C; Alvarez-García, V; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2009) |
| "The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and - MCF-7 human breast cancer xenografts in female nude rats." | 3.75 | Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. ( Blask, DE; Brainard, GC; Dauchy, RT; Hanifin, JP, 2009) |
| "The authors have shown that, via activation of its MT1 receptor, melatonin modulates the transcriptional activity of various nuclear receptors and the proliferation of both ER alpha+ and ER alpha- human breast cancer cells." | 3.75 | Molecular mechanisms of melatonin anticancer effects. ( Duplessis, T; Frasch, T; Hill, SM; Mao, L; Xiang, S; Yuan, L, 2009) |
| "Low urinary melatonin levels have been associated with an increased risk of breast cancer in premenopausal women." | 3.74 | Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. ( Berrino, F; Cavalleri, A; Krogh, V; Micheli, A; Muti, P; Schernhammer, ES; Schünemann, HJ; Secreto, G; Sempos, CT; Sieri, S; Strano, S; Venturelli, E, 2008) |
| "It has been hypothesized that exposure to light at night increases the risk of breast cancer by suppressing the normal nocturnal increase in melatonin production and release, thereby resulting in increased levels of circulating estrogen." | 3.74 | Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. ( Kashiki, Y; Nagao, Y; Nagata, C; Shibuya, C; Shimizu, H; Yamamoto, S, 2008) |
| "Melatonin, via its MT1 receptor, but not the MT2 receptor, can modulate the transcriptional activity of various nuclear receptors - estrogen receptor alpha (ERalpha) and retinoic acid receptor alpha (RARalpha), but not ERbeta- in MCF-7, T47D, and ZR-75-1 human breast cancer cell lines." | 3.74 | The Galphai and Galphaq proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation. ( Chen, Q; Dong, C; Frasch, T; Hill, SM; Lai, L; Mao, L; Rowan, B; Yuan, L, 2008) |
| "Exposure to 60-Hz magnetic fields may increase breast cancer risk by suppressing the nocturnal production of melatonin." | 3.74 | Residential magnetic fields, medication use, and the risk of breast cancer. ( Davis, S; Mirick, DK, 2007) |
| " The purpose of this exploratory study was to compare women with breast cancer to healthy control women on measures of salivary cortisol, urinary catecholamines, overnight urinary melatonin, and self-reported sleep quality, symptoms of stress, depression, anxiety and mood disturbance, to determine if discernable patterns of dysregulations across systems were apparent." | 3.74 | Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. ( Campbell, TS; Carlson, LE; Garland, SN; Grossman, P, 2007) |
| "A major mechanism through which melatonin reduces the development of breast cancer is based on its anti-estrogenic actions by interfering at different levels with the estrogen-signalling pathways." | 3.74 | Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Hill, SM; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ; Sánchez-Mateos, S, 2007) |
| "A protective role of melatonin in the etiology of breast cancer has been suggested." | 3.74 | Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women. ( Fujita, H; Hara, T; Kashiki, Y; Matsubara, T; Nagao, Y; Nagata, C; Shibuya, C; Shimizu, H; Yamamoto, S, 2007) |
| "Sleep duration has been hypothesized to be inversely associated with breast cancer risk, possibly due to greater overall melatonin production in longer sleepers." | 3.74 | Sleep duration, melatonin and breast cancer among Chinese women in Singapore. ( Koh, WP; Lee, HP; Stanczyk, FZ; Wang, R; Wu, AH; Yu, MC, 2008) |
| "The goal was to evaluate whether melatonin (Mel) down-regulates hTERT expression induced by 17beta-estradiol (E(2)) or cadmium (Cd) in breast cancer cells." | 3.74 | Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, CM; Mediavilla, MD; Sanchez-Barcelo, EJ, 2008) |
| "Most of the current knowledge about the mechanisms by which melatonin inhibits the growth of breast cancer cells point to an interaction of melatonin with estrogen-responsive pathways, thus behaving as an antiestrogenic hormone." | 3.73 | Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. ( Cos, S; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| "Exposure to light at night suppresses melatonin production, and night-shift work (a surrogate for such exposure) has been associated with an increased risk of breast cancer." | 3.73 | Urinary melatonin levels and breast cancer risk. ( Hankinson, SE; Schernhammer, ES, 2005) |
| "In this study, we investigated the effects of melatonin on adriamycin-induced cardiotoxicity both in vivo in rats and in vitro, and on the antitumor activities of adriamycin on MDA-231 and NCI breast cancer cells." | 3.73 | Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. ( Cuong, DV; Han, J; Joo, H; Kim, C; Kim, E; Kim, N; Min, CK; Park, WS; Park, YS; Youm, JB, 2005) |
| " The aim of this paper was to study if a melatonin pretreatment prior to aminoglutethimide increases the efficiency of the aromatase inhibitor used in treating breast cancer." | 3.73 | Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| "The increased breast cancer risk in female night shift workers has been postulated to result from the suppression of pineal melatonin production by exposure to light at night." | 3.73 | Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. ( Blask, DE; Brainard, GC; Dauchy, RT; Davidson, LK; Dubocovich, ML; Hanifin, JP; Jasser, SA; Krause, JA; Lynch, DT; Rivera-Bermudez, MA; Rollag, MD; Sauer, LA; Zalatan, F, 2005) |
| "An interaction between cellular estrogen response and melatonin signaling mediated by G-protein coupled receptors is present in breast cancer cells." | 3.73 | Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. ( Haldar, C; Ortmann, O; Treeck, O, 2006) |
| " The breast cancer cells were incubated for 2 days in the presence of melatonin, CGP 52608 (at concentrations of 10(-5)M, 10(-7)M, 10(-9)M, 10-(11)M ) and methotrexate (at concentrations of 0." | 3.73 | Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells. ( Karasek, M; Kunert-Radek, J; Lawnicka, H; Pawlikowski, M; Winczyk, K, 2006) |
| "Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells significantly enhances the response of these cells to the growth-inhibitory actions of melatonin." | 3.72 | Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. ( Cheng, Q; Collins, A; Hill, SM; Kiefer, TL; Lai, L; Yuan, L, 2003) |
| " The aim of this study was to assess the effect of combined treatment of 1,25-(OH)(2)D(3) at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4." | 3.72 | Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. ( Bizzarri, M; Borrelli, V; Cavallaro, A; Cucina, A; Stipa, F; Tagliaferri, F; Valente, MG, 2003) |
| "Experimental data from animals suggest a protective role for the pineal hormone melatonin in the etiology of breast cancer, but results from the few retrospective case-control studies that examined the association in humans have been inconsistent." | 3.72 | Melatonin and breast cancer: a prospective study. ( Allen, DS; Fentiman, IS; Key, TJ; Travis, RC, 2004) |
| "Detection of the antiestrogenic effect of melatonin on various breast cancer cell lines and its dependence of the differential expression of estrogen receptors (ERalpha and ERbeta) and melatonin receptors (mt1 and RZRalpha)." | 3.72 | Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. ( Bartsch, C; Girgert, R; Hanf, V; Hill, SM; Kreienberg, R, 2003) |
| "There are many subclones of human breast cancer MCF-7 cells that respond to different levels of estrogen and that have been used for evaluating the estrogenic potential of environmental chemicals such as bisphenol A." | 3.72 | Transient inhibition of synergistically insulin-like growth factor-1- and bisphenol A-induced poliferation of estrogen receptor alpha (ERalpha)-positive human breast cancer MCF-7 cells by melatonin. ( Ishido, M, 2004) |
| "2 microT(rms), 60 Hz magnetic fields could significantly reduce the inhibitory action of physiological levels of melatonin (10(-9) M) and of pharmacological levels of tamoxifen (10(-7) M) on the growth of MCF-7 human breast cancer cells in vitro." | 3.71 | The influence of 1.2 microT, 60 Hz magnetic fields on melatonin- and tamoxifen-induced inhibition of MCF-7 cell growth. ( Benane, SG; Blackman, CF; House, DE, 2001) |
| "Melatonin has repeatedly been shown to inhibit the proliferation of MCF-7 human breast cancer cells." | 3.71 | Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. ( Dai, J; Hill, SM; Ram, PT; Spriggs, LL; Yuan, L, 2001) |
| "To investigate the effect of chemotherapy on levels of melatonin in patients with breast cancer." | 3.71 | Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients. ( Kajdaniuk, D; Kos-Kudla, B; Marek, B, 2001) |
| "Exposure to 60-Hz magnetic fields may increase breast cancer risk by suppressing the normal nocturnal rise in melatonin." | 3.71 | Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. ( Chen, C; Davis, S; Kaune, WT; Mirick, DK; Stevens, RG, 2001) |
| "Circadian variations were studied in cortisol, melatonin, cytokines (basic fibroblast growth factor IbFGF], EGF, insulin-like growth factor-1 [IGF-1]), and a cytokine receptor (insulin-like growth factor binding protein-3 [IGFBP-3]) in the plasma of 28 patients with metastatic breast cancer." | 3.71 | Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. ( Bologa, S; Dumitriu, L; Haus, E; Nicolau, GY; Sackett-Lundeen, L, 2001) |
| "Exposure to light at night may increase the risk of breast cancer by suppressing the normal nocturnal production of melatonin by the pineal gland, which, in turn, could increase the release of estrogen by the ovaries." | 3.71 | Night shift work, light at night, and risk of breast cancer. ( Davis, S; Mirick, DK; Stevens, RG, 2001) |
| "We have previously demonstrated that the pineal hormone, melatonin, can inhibit the growth of estrogen receptor-alpha (ERalpha)-positive breast cancer cells and suppress ERalpha gene transcription." | 3.71 | Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. ( Hill, SM; Kiefer, T; Ram, PT; Yuan, L, 2002) |
| "Chronic exposure to 60-Hz magnetic fields may increase the risk of breast cancer by suppressing the normal nocturnal production of melatonin." | 3.71 | Residential magnetic fields and the risk of breast cancer. ( Davis, S; Mirick, DK; Stevens, RG, 2002) |
| "Our laboratory has demonstrated that treatment of MCF-7 breast cancer cells with melatonin (Mlt) followed 24h later with physiological concentrations of all-trans retinoic acid (atRA) results in apoptosis." | 3.71 | Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. ( Anderson, MB; Bischoff, ED; Cheng, Q; Dai, J; Dwived, PD; Hill, SM; Kiefer, TL; Lai, L; Melancon, K; Moro, K; Nowfar, S; Teplitzky, SR; Yuan, L, 2002) |
| "The negative correlation between the plasma melatonin and IGF-I concentrations in the breast cancer patients we studied could reach statistical significance in a larger population." | 3.71 | Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense? ( Buntner, B; Kajdaniuk, D; Kos-Kudła, B; Marek, B; Ostrowska, Z; Szymszal, J; Zwirska-Korczala, K, 2002) |
| "The pineal hormone, melatonin, has been shown to inhibit the proliferation of the estrogen receptor alpha (ERalpha)-positive macrophage chemotactic factor (MCF)-7 human breast cancer cells." | 3.71 | Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. ( Dai, J; Hill, SM; Inscho, EW; Yuan, L, 2002) |
| "Melatonin inhibits proliferation of the estrogen-responsive MCF-7 human breast cancer cells." | 3.71 | Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? ( Cos, S; Fernández, R; González-Lamuño, D; Mediavilla, MD; Sánchez-Barceló, EJ, 2002) |
| "Melatonin inhibits the proliferation of estrogen receptor alpha (ERalpha)-positive (MCF-7), but not ERalpha-negative (MDA-MB-231) breast cancer cells." | 3.71 | MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. ( Collins, AR; Dai, J; Dubocovich, ML; Hill, SM; Yuan, L, 2002) |
| "Melatonin was previously shown to inhibit proliferation of MCF-7 human breast cancer cells." | 3.70 | Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. ( Bianchi, P; Glencross, DK; Lottering, ML; Panzer, A; Seegers, JC; Stark, JH, 1998) |
| " Two such oncostatic agents, melatonin and retinoic acid, have been shown to suppress the growth of hormone-responsive breast cancer." | 3.70 | A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells. ( Ayettey, S; Chen, I; Cohn, CS; Duffy, L; Eck, KM; Hill, SM; Ram, PT; Reed, JC; Yuan, L, 1998) |
| "The pineal hormone, melatonin, inhibits proliferation of estrogen receptor (ER)-positive MCF-7 human breast cancer cells, modulates both ER mRNA and protein expression, and appears to be serum dependent, indicating interaction between melatonin and serum components." | 3.70 | Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. ( Brown, GM; Hill, SM; Kiefer, T; Ram, PT; Silverman, M; Song, Y, 1998) |
| "The pineal hormone melatonin has been reported to have in vitro antiproliferative effects on estrogen receptor-positive human breast cancer cell lines at concentrations near to plasma physiological concentrations (1 x 10(-11) to 1 x 10(-9) M)." | 3.70 | Effects of melatonin on proliferation of cancer cell lines. ( Dimitriadis, KA; Geromichalos, GD; Kortsaris, AH; Kouretas, D; Papazisis, KT; Sivridis, E; Tsekreli, OK, 1998) |
| "Previous studies on human breast cancer patients showed a decline in circulating melatonin levels corresponding to primary tumor growth and an increase when relapse occurred." | 3.70 | Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion. ( Bartsch, C; Bartsch, H; Besenthal, I; Buchberger, A; Effenberger-Klein, A; Kruse-Jarres, JD; Mecke, D; Rokos, H; Stieglitz, A, 1999) |
| " In the current study, we examined the diurnal variations of peripheral blood cells (white blood cells, neutrophils, lymphocytes), granulocyte-macrophage-colony stimulating factor (GM-CSF), and melatonin levels, and considered the role of melatonin on these rhythms in healthy volunteers and in patients with early breast cancer." | 3.70 | The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. ( Akbulut, H; Akbulut, KG; Büyükcelik, A; Demirci, S; Icli, F, 1999) |
| "The present study shows that melatonin prevents, within the first cell cycle, the estradiol-induced growth of synchronized MCF7 breast cancer cells." | 3.70 | Melatonin blocks the activation of estrogen receptor for DNA binding. ( del Rio, B; Lazo, PS; Martinez, MA; Pedrero, JG; Ramos, S; Rato, AG, 1999) |
| "The aim of the present work was to study whether melatonin, at physiological concentrations, exerts its antiproliferative effects on MCF-7 human breast cancer cells by inducing the expression of some of the proteins involved in the control of the cell cycle." | 3.70 | Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. ( Cos, S; Mediavilla, MD; Sánchez-Barceló, EJ, 1999) |
| "The melatonin hypothesis states that excess exposure to environmental light may contribute to breast cancer risks via impaired pineal secretion of melatonin." | 3.70 | Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited. ( Erren, TC; Piekarski, C, 1999) |
| "We evaluated the feasibility of using morning urine samples in epidemiological studies aimed at clarifying the relationship between nocturnal melatonin levels and breast cancer risk." | 3.70 | Morning urinary assessment of nocturnal melatonin secretion in older women. ( Cook, MR; Davis, S; Graham, C; Kavet, R; Kheifets, L; Stevens, RG, 2000) |
| "Twenty-four breast cancer patients on adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were studied along with 16 healthy pre-menopausal women." | 3.70 | Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients. ( Kajdaniuk, D; Marek, B, 2000) |
| "It has been established that melatonin (Mlt) and retinoic acid, individually, inhibit the proliferation of the estrogen receptor-alpha (ER alpha)-positive MCF-7 breast cancer cell line." | 3.70 | Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. ( Eck-Enriquez, K; Hill, SM; Kiefer, TL; Spriggs, LL, 2000) |
| "Melatonin, the hormonal product of the pineal gland, has been shown to inhibit the development of mammary tumors in vivo and the proliferation of MCF-7 human breast cancer cells in vitro by mechanisms not yet identified." | 3.69 | Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. ( Hill, SM; Molis, TM; Spriggs, LL, 1994) |
| "Melatonin has been shown to have a direct inhibitory effect on the proliferation of estrogen-responsive MCF-7 human breast cancer cells, involving an interaction with estradiol." | 3.69 | Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. ( Cos, S; Crespo, D; Fernández-Viadero, C; Ovejero, V; Verduga, R, 1994) |
| "Melatonin has been shown to have direct oncostatic actions on estrogen-responsive, MCF-7 human breast cancer cells in culture." | 3.69 | Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. ( Blask, DE; Cos, S, 1994) |
| "The pineal hormone, melatonin, has been reported to have an inhibitory effect on the cell growth of human breast cancer." | 3.69 | 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7). ( Furuya, Y; Kohno, N; Ku, Y; Saitoh, Y; Yamamoto, K, 1994) |
| "It has been shown that melatonin has a direct inhibitory effect on the proliferation of MCF-7 human breast cancer cells in culture." | 3.69 | Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. ( Cos, S; Recio, J; Sánchez-Barceló, EJ, 1996) |
| "The aim of the present work was to study whether physiological doses of melatonin (1nM) modified DNA synthesis in MCF-7 human breast cancer cells." | 3.69 | Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. ( Cos, S; Fernández, F; Sánchez-Barceló, EJ, 1996) |
| "Hormones such as melatonin whose serum concentrations vary seasonally have been previously implicated in the growth of breast cancer." | 3.69 | Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer. ( Evans, MC; Gibbs, EE; Holdaway, IM; Hopkins, KD; Lethaby, A; Lim, T; Mason, BH; Rajasoorya, C; Schooler, B, 1997) |
| "Melatonin, the chief hormone secreted by the pineal gland, has been previously shown to inhibit human breast cancer cell growth at the physiological concentration of 1 nM in vitro." | 3.69 | Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. ( Blask, DE; Wilson, ST; Zalatan, F, 1997) |
| "Between 1994 and 1995, 1 day nocturnal infusion of 5-fluorouracil (5-FU) was performed prior to surgery in 13 primary breast cancer patients; 300 mg/m2 of 5-FU was infused constantly from 2100 h to 0700 h via peripheral vein with a volumetric pump." | 3.69 | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1997) |
| "2 microT [12 milligauss], 60 Hz) block the growth inhibition of the hormone melatonin (10(-9) M) on MCF-7 human breast cancer cells in vitro." | 3.69 | Environmental magnetic fields inhibit the antiproliferative action of tamoxifen and melatonin in a human breast cancer cell line. ( Harland, JD; Liburdy, RP, 1997) |
| "In previous studies a tumor-size dependent decline of the circadian amplitude of serum melatonin was found in primary unoperated breast cancer patients, which was not due to changes of the hepatic metabolism of melatonin since its main peripheral metabolite, 6-sulphatoxymelatonin (aMT6s), showed similar serum levels." | 3.69 | Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. ( Bartsch, C; Bartsch, H; Franz, H; Karenovics, A; Mecke, D; Peiker, G, 1997) |
| "On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms." | 3.68 | Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993) |
| "The pineal hormone, melatonin, was examined for its capacity to modulate the proliferation of a panel of human breast cancer cell lines." | 3.68 | The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. ( Blask, DE; Hill, SM; Muraoka, H; Simon, MA; Spriggs, LL, 1992) |
| "Cultured MCF-7 human breast cancer cells were pre-exposed to either melatonin (232 ng/mL) or vehicle for 24 hrs prior to being washed and then re-exposed to either ethanol-vehicle or varying concentrations of tamoxifen (37." | 3.68 | Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. ( Blask, DE; Lemus-Wilson, AM; Wilson, ST, 1992) |
| "A seasonal variation in the month of initial detection of breast cancer has been previously observed in pre-menopausal women, and it has been proposed that this may be due to cyclic changes in tumour growth mediated by the effects of melatonin on ovarian function." | 3.68 | Seasonal changes in serum melatonin in women with previous breast cancer. ( Gibbs, EE; Holdaway, IM; Hopkins, KD; Mason, BH; Rajasoorya, C, 1991) |
| "Serum melatonin and its main metabolic product 6-sulfatoxymelatonin were determined in 17 patients with breast cancer (BC) with either a fresh primary tumor (nine) or a secondary tumor (eight) as well as in four patients with untreated benign breast disease (controls)." | 3.68 | Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. ( Bartsch, C; Bartsch, H; Bellmann, O; Lippert, TH, 1991) |
| "Daytime plasma melatonin values were measured by radioimmune assay in 86 patients with breast cancer; 280 assays were done and compared with the clinical status of the patients." | 3.68 | Plasma melatonin in patients with breast cancer. ( Falkson, G; Falkson, HC; Meyer, BJ; Rapoport, BL; Steyn, ME, 1990) |
| "Only physiological levels of melatonin exert an antiproliferative effect on MCF-7 breast cancer cells grown in an anchorage-dependent culture system." | 3.68 | Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system. ( Blask, DE; Cos, S, 1990) |
| "Serum melatonin was determined over 24 hours in 35 patients with breast cancer with either a fresh primary tumor (n = 23) or a secondary tumor (n = 12) and in 28 patients with untreated benign breast disease (controls) having a fibroadenoma (n = 10), fibrocystic mastopathy (n = 14), or other breast diseases (n = 4)." | 3.67 | Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. ( Bartsch, C; Bartsch, H; Bellmann, O; Fuchs, U; Gupta, D; Lippert, TH, 1989) |
| "Hypothyroidism and low iodine intake may be important aetiological factors in oestrogen dependent tumours of the breast, uterus and ovary." | 3.67 | Di-iodothyronine as part of the oestradiol and catechol oestrogen receptor--the role of iodine, thyroid hormones and melatonin in the aetiology of breast cancer. ( Clur, A, 1988) |
| "Since melatonin, the major hormone of the pineal gland, has been shown to inhibit the growth of mammary tumors in animal models of human breast cancer, we examined the hypothesis that this indoleamine has the potential to inhibit breast cancer growth by directly inhibiting cell proliferation as exemplified by the growth of the estrogen-responsive human breast cancer cell line MCF-7 in culture." | 3.67 | Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. ( Blask, DE; Hill, SM, 1988) |
| " More compelling evidence indicates that the pineal hormone melatonin, in addition to its well known antireproductive effects, may also exert oncostatic effects particularly in animal models of human breast cancer." | 3.67 | Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. ( Blask, DE; Hill, SM, 1986) |
| "Both prolactin (PRL) and melatonin (MLT) (the most important pineal hormone) have been shown to play a role in regulating breast cancer growth." | 3.67 | Correlation between changes in prolactin and melatonin serum levels after radical mastectomy. ( Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fraschini, F; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1987) |
| "In order to investigate the pineal function and its relation with the hypophysis in human neoplasms, melatonin and GH serum levels were determined in 63 patients, 42 affected by solid tumours and 21 by lymphoma or leukaemia." | 3.67 | The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. ( Bajetta, E; Bastone, A; di Bella, L; Esposti, D; Esposti, G; Lissoni, P; Mauri, R; Rovelli, F; Sala, R; Viviani, S, 1987) |
| "We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women at high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy." | 3.67 | Plasma melatonin and the hormone-dependency of human breast cancer. ( Bagley, CS; Danforth, DN; Lippman, ME; Mulvihill, JJ; Tamarkin, L, 1985) |
| "Urinary melatonin levels were measured in 10 postmenopausal Indian women suffering from advanced stages of breast cancer and in 9 well-matched women with non-endocrine complaints, mostly uterovaginal prolapse." | 3.66 | Urinary melatonin levels in human breast cancer patients. ( Bartsch, C; Bartsch, H; Jain, AK; Laumas, KR; Wetterberg, L, 1981) |
| "Plasma melatonin concentrations were determined over a period of 24 hours in 20 women with clinical stage I or II breast cancer." | 3.66 | Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. ( Chabner, B; Cohen, M; Danforth, D; DeMoss, E; Lichter, A; Lippman, M; Tamarkin, L, 1982) |
| "The hypothesis that diminished function of the pineal gland may promote the development of breast cancer in human beings is suggested by the relation between breast cancer and prolonged oestrogen excess, and by the observation that the pineal secretion, melatonin, inhibits ovarian oestrogen production, pituitary gonadotrophin production, and sexual development and maturation." | 3.66 | Role of pineal gland in aetiology and treatment of breast cancer. ( Chabner, B; Cohen, M; Lippman, M, 1978) |
| "Melatonin is a neurohormone involved in diverse physiological processes, including regulation of circadian rhythm, oncogenesis and immune function." | 3.30 | Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer. ( Gao, SC; Liu, YF; Wang, CL; Wu, MD; Zhang, XX, 2023) |
| "Melatonin is a serotonin-derived pineal gland hormone with many biological functions like regulating the sleep-wake cycle, circadian rhythm, menstrual cycle, aging, immunity, and antioxidants." | 3.01 | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. ( Almalki, WH; Chellappan, DK; Dua, K; Fuloria, NK; Fuloria, S; Gupta, G; Haniffa, SM; Jha, NK; Negi, P; Priya, S; Rohilla, S; Sekar, M; Singh, M; Singh, SK; Subramaniyan, V, 2023) |
| "Melatonin is a multivalent compound which has a hand in several cellular and molecular processes and therefore, is an appropriate candidate for treatment of many diseases like cancer." | 2.82 | Molecular and cellular mechanisms of melatonin in breast cancer. ( Asemi, Z; Dana, PM; Heidar, Z; Mirzaei, H; Mirzamoradi, M; Mohammadi, S; Sadoughi, F; Shafabakhash, R; Targhazeh, N, 2022) |
| "An increased risk of breast cancer has been observed in night shift workers." | 2.77 | Rotating night shift work and mammographic density. ( Bukowska, A; Gromadzinska, J; Kjuus, H; Lie, JA; Peplonska, B; Reszka, E; Sobala, W; Ursin, G; Wasowicz, W, 2012) |
| "In the developmental stages of breast cancer, estrogens are strongly involved." | 2.72 | Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer. ( Choi, YJ; Heo, K; Jin, Y; Park, SJ, 2021) |
| "Breast cancer is the prevalent type of tumor in women and is the leading cause of death among female cancers." | 2.72 | Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin. ( Gurer-Orhan, H; Panieri, E; Saso, L; Stepanić, V; Tascioglu Aliyev, A, 2021) |
| "Fifty-nine patients with breast cancer and 10 with prostate cancer enrolled in an eight-week Mindfulness-Based Stress Reduction (MBSR) program that incorporated relaxation, meditation, gentle yoga, and daily home practice." | 2.71 | Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. ( Carlson, LE; Goodey, E; Patel, KD; Speca, M, 2004) |
| "The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology." | 2.69 | Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998) |
| "Melatonin (MLT) has been proven to counteract chemotherapy toxicity, by acting as an anti-oxidant agent, and to promote apoptosis of cancer cells, so enhancing chemotherapy cytotoxicity." | 2.69 | Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. ( Ardizzoia, A; Barni, S; Lissoni, P; Longarini, R; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G; Vaghi, M, 1999) |
| "Breast cancer is the most common cancer among women and its metastasis which generally observed at the last stage is the major cause of breast cancer-related death." | 2.66 | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. ( Akbarzadeh, M; Amirzadeh-Iranaq, MT; Ashoori, Z; Ashouri, N; Bizzarri, M; Faridvand, Y; Fattahi, A; Kazemzadeh, H; Maroufi, NF; Mortezania, Z; Nejabati, HR; Nouri, M; Rashidi, MR; Vahedian, V, 2020) |
| "The incidence of breast cancer worldwide has increased in recent decades, accounting for 1 in 3 neoplasms in women." | 2.66 | Relationship between Night Shifts and Risk of Breast Cancer among Nurses: A Systematic Review. ( Camacho-Martín, S; Fagundo-Rivera, J; García-Iglesias, JJ; Gómez-Salgado, C; Gómez-Salgado, J; Ruiz-Frutos, C, 2020) |
| "The causal link between breast cancer and the sleep cycle or circadian disruption are yet to be established; however, disruption of the circadian cycles by light at night exposure or chronic exposure to stress-related mediators have all been linked to the increased risk of breast cancer." | 2.66 | Shift Work and Breast Cancer. ( Clanton, M; Gehlert, S, 2020) |
| " Breast cancer risk factors include smoking, alcohol consumption, personal and family history, hypertension, and hormone therapy, long-term use of nonsteroidal anti-inflammatory drugs and tobacco usage." | 2.61 | Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms. ( Amin, N; Asemi, Z; Reiter, RJ; Shafabakhsh, R, 2019) |
| "They analy onzed women with breast cancer and control patients, of which 10% and 90% were in the reproductive period and after menopause, respectively." | 2.61 | Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis. ( Abreu, LC; Baracat, EC; Baracat, MCP; Barros, EPM; Cipolla-Neto, J; Simões, R; Soares Junior, JM; Sorpreso, ICE; Valenti, VE; Veiga, ECA, 2019) |
| "As melatonin is toxic to breast cancer cells, its production within mitochondria poses a significant challenge to breast cancer cell survival." | 2.61 | Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology. ( Anderson, G, 2019) |
| "The breast cancer affects women with high mortality and morbidity worldwide." | 2.58 | Melatonin and breast cancer: Evidences from preclinical and human studies. ( Adamek, M; Busselberg, D; Caprnda, M; Danko, J; Gazdikova, K; Kruzliak, P; Kubatka, P; Kwon, TK; Opatrilova, R; Petrovic, D; Rodrigo, L; Zubor, P, 2018) |
| "Melatonin pre-treatment prior to ionizing radiation was associated with a decrease in cell proliferation and an increase in p53 mRNA expression, leading to an increase in the radiosensitivity of breast cancer cells." | 2.58 | Therapeutic potential of melatonin for breast cancer radiation therapy patients. ( Griffin, F; Marignol, L, 2018) |
| "The keywords used were "breast cancer risk", "night work" and "shift work"." | 2.52 | [Night work, shift work: Breast cancer risk factor?]. ( Benabu, JC; Gonzalez, M; Mathelin, C; Stoll, F, 2015) |
| "Melatonin has been shown to reduce the incidence of experimentally induced cancers and can significantly inhibit the growth of some human tumors, namely hormone-dependent cancers." | 2.49 | Molecular mechanisms of melatonin's inhibitory actions on breast cancers. ( Bizzarri, M; Cucina, A; Proietti, S; Reiter, RJ, 2013) |
| "Of particular relevance to breast cancer risk, melatonin may also block the estrogen receptor ERalpha and impact the enzyme aromatase, which produces estradiol." | 2.45 | Circulating melatonin and the risk of breast and endometrial cancer in women. ( Schernhammer, ES; Viswanathan, AN, 2009) |
| "The global impact of breast cancer is large and growing." | 2.43 | Circadian disruption and breast cancer: from melatonin to clock genes. ( Stevens, RG, 2005) |
| " However, exogenous administration of melatonin in an attempt to achieve this goal may have an untoward effect given that pharmacologic dosing with melatonin has been shown to phase shift humans depending on the time of day it's given." | 2.43 | Artificial lighting in the industrialized world: circadian disruption and breast cancer. ( Stevens, RG, 2006) |
| "Breast cancer is the most frequent cancer among women, and the number is increasing worldwide." | 2.43 | Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. ( Hansen, J, 2006) |
| "breast cancer in industrialized countries." | 2.43 | The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. ( Bartsch, C; Bartsch, H, 2006) |
| "Melatonin is an indolic hormone produced mainly by the pineal gland." | 2.42 | Melatonin and mammary cancer: a short review. ( Cos, S; Fernández, R; Mediavilla, MD; Sánchez-Barceló, EJ, 2003) |
| "The impact of breast cancer on women across the world has been extensive and severe." | 2.41 | Ocular input for human melatonin regulation: relevance to breast cancer. ( Brainard, GC; Glickman, G; Levin, R, 2002) |
| "Melatonin profiles are a diagnostic tool to distinguish between several forms of depression, like major depression, winter depression (SAD), unipolar depression, delayed sleep phase syndrome (DSPS)." | 2.41 | Melatonin deficiencies in women. ( Herold, J; Rohr, UD, 2002) |
| "The lifetime odds of developing breast cancer are apparently up to 1 in 8 women in North America and 1 in 12 in Western Europe." | 2.41 | Hormonal manipulations and breast cancer. ( Benshushan, A; Brzezinski, A, 2002) |
| "Worldwide, breast cancer is the most common malignancy accounting for 20-32% of all female cancers." | 2.40 | The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature. ( Brainard, GC; Kavet, R; Kheifets, LI, 1999) |
| "An effect of electric power on breast cancer would have profound implications, and this possibility deserves continued investigation." | 2.39 | The melatonin hypothesis: electric power and breast cancer. ( Davis, S; Stevens, RG, 1996) |
| "Melatonin, in turn, has a protective effect on breast cancer in experimental animals." | 2.38 | Breast cancer and electric power. ( Stevens, RG, 1993) |
| "Melatonin, in turn, has been shown to suppress mammary tumorigenesis in experimental animals." | 2.38 | Electric power, pineal function, and the risk of breast cancer. ( Anderson, LE; Davis, S; Stevens, RG; Thomas, DB; Wilson, BW, 1992) |
| "Melatonin is an important naturally occurring hormone in mammals." | 1.72 | Melatonin and cancer suppression: insights into its effects on DNA methylation. ( Asemi, Z; Davoodvandi, A; Nikfar, B; Reiter, RJ, 2022) |
| "Despite this, compared to female breast cancer patients, there are very few studies on biomarkers in male breast cancer patients." | 1.62 | A Case Control Study on Serum Levels of Potential Biomarkers in Male Breast Cancer Patients. ( Ahmed Abdelsalam, KE; Ahmed, MAI; Alghamdi, N; Alharbi, WA; Alrami, KN; Alrashed, A; Asad, M; Asdaq, SMB; Mohzari, Y, 2021) |
| "Remarkably, acidosis-mediated metastasis was significantly alleviated by BMAL1 overexpression in breast cancer cells." | 1.56 | Extracellular Acidosis Promotes Metastatic Potency via Decrease of the ( Kim, K; Kim, SK; Kwon, SH; Kwon, YJ; Lee, SH; Park, IC; Park, JW; Park, S; Park, SK; Seo, EB; Ye, SK, 2020) |
| "Breast cancer is the most common neoplastic disorder diagnosed in women." | 1.51 | Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway. ( El-Sokkary, GH; Ismail, IA; Saber, SH, 2019) |
| "Melatonin treatment reduced tumor growth (p < 0." | 1.51 | RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model. ( Alexandre, PA; Chammas, R; Coutinho, LL; de Paula-Junior, R; Fukumasu, H; Jardim-Perassi, BV; Reis Júnior, O; Sonehara, NM; Zuccari, DAPC, 2019) |
| "Melatonin is a hormone synthesized by the pineal gland at night in the absence of light." | 1.48 | Evaluation of melatonin and AFMK levels in women with breast cancer. ( Bordin-Junior, NA; de Almeida, EA; de Campos Zuccari, DAP; de Castro, TB, 2018) |
| "Shift work and sleep deprivation are thought to disrupt the normal light-dark cycle, although the disruption due to shiftwork may be dependent on sleep deprivation." | 1.46 | Sleep duration, nightshift work, and the timing of meals and urinary levels of 8-isoprostane and 6-sulfatoxymelatonin in Japanese women. ( Goto, Y; Ishihara, K; Konishi, K; Nagao, Y; Nagata, C; Tamura, T; Wada, K; Yamamoto, S, 2017) |
| "Melatonin and Y27632 treatments reduced cell viability and invasion/migration of both cell lines and decreased ROCK-1 gene expression in metastatic cells and protein expression in nonmetastatic cell line." | 1.43 | Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. ( Arbab, AS; Borin, TF; Coimbra, VB; de Oliveira, JG; Fabri, VA; Ferreira, LC; Gelaleti, GB; Iskander, AS; Jardim-Perassi, BV; Moschetta, MG; Shankar, A; Varma, NR; Zuccari, DA, 2016) |
| "Although melatonin exhibits oncostatic properties such as antiproliferative effects, the oral bioavailability of this hormone is less than 20%." | 1.43 | The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ( Fernandes, RT; França, EL; Honorio-França, AC; Marins, CM; Pereira, CC; Varotti, Fde P, 2016) |
| "Melatonin pretreatment before radiation also decreased G2 -M phase arrest compared with irradiation alone, with a higher percentage of cells in the G0 -G1 phase and a lower percentage of cells in S phase." | 1.42 | Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. ( Alonso-González, C; Cos, S; Gómez-Arozamena, J; González, A; Martínez-Campa, C, 2015) |
| "Melatonin inhibits human breast cancer growth via mechanisms that include the suppression of tumor metabolism and inhibition of expression or phospho-activation of the receptor kinases AKT and ERK1/2 and various other kinases and transcription factors." | 1.42 | Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. ( Belancio, VP; Blask, DE; Dauchy, RT; Frasch, T; Hauch, A; Hill, SM; Mao, L; Mondal, D; Wren, MA; Xiang, S; Yuan, L, 2015) |
| "Melatonin in vitro treatment (1 mM) decreased cell viability (p<0." | 1.40 | Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. ( Ali, MM; Arbab, AS; Borin, TF; de Campos Zuccari, DA; Ferreira, LC; Iskander, AS; Jardim-Perassi, BV; Shankar, A; Varma, NR, 2014) |
| "Melatonin is a hormone with well-known chronobiotic and hypnotic effects." | 1.40 | Chronobiology, cognitive function and depressive symptoms in surgical patients. ( Hansen, MV, 2014) |
| "Doxorubicin is effective against breast cancer, but its major side effect is cardiotoxicity." | 1.39 | Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. ( Arif, IS; Boateng, SY; Greco, F; Hooper, CL; Williams, AC, 2013) |
| "Patients with breast cancer undergoing lumpectomy had significantly disturbed sleep architecture the night after surgery, and these changes were normalised after 2 weeks." | 1.39 | Sleep disturbances and changes in urinary 6-sulphatoxymelatonin levels in patients with breast cancer undergoing lumpectomy. ( Gögenur, I; Hansen, MV; Madsen, MT; Rosenberg, J; Wildschiødtz, G, 2013) |
| " Their combined use has made it possible to increase an overall survival but they are still penalized by adverse effects and toxicity." | 1.39 | Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report. ( Colori, B; Di Bella, G; Mascia, F; Ricchi, A, 2013) |
| "We updated the sleep duration-breast cancer association with 14 years of follow-up of 34,028 women in the SCHS." | 1.39 | Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. ( Koh, WP; Stanczyk, FZ; Wang, R; Wu, AH; Yu, MC; Yuan, JM, 2013) |
| "Melatonin has a variety of therapeutic effects, such as immunomodulatory actions, anti-inflammatory effects, and antioxidant actions." | 1.37 | MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. ( Hwang, SY; Kim, SJ; Lee, SE; Park, CS; Park, YS; Youn, JP, 2011) |
| "The possibility that a portion of the breast cancer burden might be explained by the introduction and increasing use of electricity to light the night was suggested >20 years ago." | 1.35 | Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. ( Stevens, RG, 2009) |
| "Increased breast cancer risks have been reported among women with gross cystic breast disease (GCBD), although the mechanism for this increase remains unexplained." | 1.34 | Melatonin and estrogen in breast cyst fluids. ( Anderson, BO; Burch, JB; Cosma, G; Craven, W; Finlayson, C; Hennesey, M; Rush, A; Walling, M; Wells, RL, 2007) |
| "0 or 5 mM), but melatonin (1 or 10 nM) was ineffective alone or in combination with valproic acid, in the first (MCF-7A) subline examined." | 1.34 | Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. ( Brown, GM; Jawed, S; Kim, B; Niles, LP; Ottenhof, T; Werstiuk, ES, 2007) |
| "Melatonin is a specific inhibitor of Cd-induced ER alpha-mediated transcription in both estrogen response elements (ERE)- and AP1-containing promoters, whereas ER beta-mediated transcription is not inhibited by the pineal indole." | 1.33 | Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Ramos, S; Sánchez-Barceló, EJ, 2006) |
| "After surgical ablation of the breast tumors, serum's ability to increase MCF-7 cell proliferation decreased significantly." | 1.31 | Influence of serum from healthy or breast tumor-bearing women on the growth of MCF-7 human breast cancer cells. ( Alvarez, A; Bartsch, C; Bartsch, H; Cos, S; Mediavilla, MD; Sanchez-Barcelo, EJ, 2000) |
| "Three types of human breast cancer cells were used in this study: MDA-MB-435, MDA-MB-231, and MCF-7." | 1.31 | Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells. ( Anderson, KW; Leman, ES; Sisken, BF; Zimmer, S, 2001) |
| "We examined the relationship between breast cancer and working on rotating night shifts during 10 years of follow-up in 78 562 women from the Nurses' Health Study." | 1.31 | Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. ( Colditz, GA; Hunter, DJ; Kawachi, I; Laden, F; Schernhammer, ES; Speizer, FE; Willett, WC, 2001) |
| " There was no evidence of a dose-response relation with increasing number of months that electric blankets had been used." | 1.31 | Electric blanket or mattress cover use and breast cancer incidence in women 50-79 years of age. ( Baron, JA; Egan, KM; Hampton, JM; McElroy, JA; Newcomb, PA; Remington, PL; Stampfer, MJ; Titus-Ernstoff, L; Trentham-Dietz, A; Willett, WC, 2001) |
| " RORalpha receptors are also expressed in MCF-7 breast cancer cells and the putative RORalpha agonist CPG-52608 inhibits MCF-7 cell growth but with a very different dose-response than melatonin." | 1.31 | Involvement of the mt1 melatonin receptor in human breast cancer. ( Dai, J; Dong, C; Hill, SM; Kiefer, TL; Lai, L; Ram, PT; Yuan, L, 2002) |
| "Melatonin-treated T-47D cells observed in a transmission electronic microscope (TEM) showed an irregular nuclear shape and intermediate filaments disposed around the nucleus, which was not observed in control cells." | 1.30 | Alterations in F-actin distribution in cells treated with melatonin. ( Machado-Santelli, GM; Matsui, DH, 1997) |
| "Melatonin is a hormone primarily produced by the pineal gland at night and is suppressed by exposure to light." | 1.30 | Reduced cancer incidence among the blind. ( Ahlbom, A; Feychting, M; Osterlund, B, 1998) |
| "Melatonin was also able to block 17beta-estradiol-induced invasion (P < 0." | 1.30 | Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. ( Cos, S; Fernández, R; Güézmes, A; Sánchez-Barceló, EJ, 1998) |
| "Melatonin did not inhibit estradiol-stimulated proliferation under this protocol." | 1.30 | Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. ( Baldwin, WS; Barrett, JC; Risinger, JI; Travlos, GS, 1998) |
| "04) which suggests a dose-response relationship between visible light and breast cancer risk." | 1.30 | Inverse association between breast cancer incidence and degree of visual impairment in Finland. ( Ojamo, M; Pukkala, E; Rudanko, SL; Stevens, RG; Verkasalo, PK, 1999) |
| "Since colorectal cancer should not have any daylight-related hormone dependent risk determinants, a control cohort of 12,950 women with a diagnosis of colorectal cancer in the same calendar period was studied in a similar way." | 1.29 | Does the month of diagnosis affect survival of cancer patients? ( Joensuu, H; Pukkala, E; Sankila, R; Toikkanen, S, 1993) |
| "Melatonin (aMT) appears to be a potentially important oncostatic substance that can block the mitogenic effects of tumour-promoting hormones and growth factors such as oestradiol and epidermal growth factor, in vitro." | 1.29 | Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. ( Blask, DE; Kelly, PA; Lemus-Wilson, A, 1995) |
| "Breast cancer, lung carcinoma, and colorectum cancer were the three neoplasms detected in the patients investigated." | 1.27 | A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations. ( Barni, S; Cattaneo, G; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1988) |
| "Melatonin serum levels were measured by radioimmunoassay before and 28 days after each cycle of chemotherapy." | 1.27 | Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients. ( Barni, S; Cattaneo, G; Crispino, S; Fraschini, F; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1988) |
| "Each subject's risk of developing breast cancer, cardiovascular diseases resulting from an elevated blood pressure, and emotional conditions was numerically evaluated according to epidemiologic questionnaires." | 1.27 | Circadian characteristics of urinary melatonin from clinically healthy young women at different civilization disease risks. ( Cornelissen, G; Halberg, E; Halberg, F; Haus, E; Kawasaki, T; Matsuoka, M; Omae, T; Ueno, M; Uezono, K; Wetterberg, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (6.47) | 18.7374 |
| 1990's | 72 (19.41) | 18.2507 |
| 2000's | 120 (32.35) | 29.6817 |
| 2010's | 115 (31.00) | 24.3611 |
| 2020's | 40 (10.78) | 2.80 |
| Authors | Studies |
|---|---|
| Germain, AR | 1 |
| Carmody, LC | 1 |
| Nag, PP | 1 |
| Morgan, B | 1 |
| Verplank, L | 1 |
| Fernandez, C | 1 |
| Donckele, E | 1 |
| Feng, Y | 1 |
| Perez, JR | 1 |
| Dandapani, S | 1 |
| Palmer, M | 1 |
| Lander, ES | 1 |
| Gupta, PB | 1 |
| Schreiber, SL | 1 |
| Munoz, B | 1 |
| Hasan, M | 1 |
| Genovese, S | 1 |
| Fiorito, S | 1 |
| Epifano, F | 1 |
| Witt-Enderby, PA | 2 |
| Liu, Z | 2 |
| Sang, X | 2 |
| Wang, M | 2 |
| Liu, Y | 5 |
| Liu, J | 3 |
| Wang, X | 5 |
| Liu, P | 2 |
| Cheng, H | 2 |
| Wang, Q | 2 |
| Wang, Y | 4 |
| Du, L | 1 |
| Xu, C | 1 |
| Liu, Q | 1 |
| Fan, S | 1 |
| Maroufi, NF | 3 |
| Rashidi, M | 1 |
| Vahedian, V | 3 |
| Jahanbazi, R | 1 |
| Mostafaei, S | 1 |
| Akbarzadeh, M | 5 |
| Kazemzadeh, H | 2 |
| Nejabati, HR | 2 |
| Isazadeh, A | 1 |
| Rashidi, MR | 3 |
| Nouri, M | 3 |
| Minella, C | 1 |
| Coliat, P | 1 |
| Amé, S | 1 |
| Neuberger, K | 1 |
| Stora, A | 1 |
| Mathelin, C | 3 |
| Reix, N | 1 |
| Karimian, A | 1 |
| Mir Mohammadrezaei, F | 1 |
| Hajizadeh Moghadam, A | 1 |
| Bahadori, MH | 1 |
| Ghorbani-Anarkooli, M | 1 |
| Asadi, A | 1 |
| Abdolmaleki, A | 1 |
| Tanriover, G | 1 |
| Dilmac, S | 1 |
| Aytac, G | 1 |
| Farooqi, AA | 1 |
| Sindel, M | 1 |
| Sadoughi, F | 1 |
| Dana, PM | 1 |
| Asemi, Z | 3 |
| Shafabakhash, R | 1 |
| Mohammadi, S | 1 |
| Heidar, Z | 1 |
| Mirzamoradi, M | 1 |
| Targhazeh, N | 1 |
| Mirzaei, H | 1 |
| Wu, J | 1 |
| Tan, X | 1 |
| Diamantopoulou, Z | 1 |
| Castro-Giner, F | 1 |
| Schwab, FD | 1 |
| Foerster, C | 1 |
| Saini, M | 1 |
| Budinjas, S | 1 |
| Strittmatter, K | 1 |
| Krol, I | 1 |
| Seifert, B | 1 |
| Heinzelmann-Schwarz, V | 1 |
| Kurzeder, C | 1 |
| Rochlitz, C | 1 |
| Vetter, M | 1 |
| Weber, WP | 1 |
| Aceto, N | 1 |
| Önder, GÖ | 1 |
| Sezer, G | 1 |
| Özdamar, S | 1 |
| Yay, A | 1 |
| Davoodvandi, A | 1 |
| Nikfar, B | 1 |
| Reiter, RJ | 16 |
| Zetner, D | 4 |
| Kamby, C | 4 |
| Gülen, S | 4 |
| Christophersen, C | 4 |
| Paulsen, CB | 4 |
| Piga, E | 4 |
| Hoffmeyer, B | 4 |
| Mahmood, F | 4 |
| Rosenberg, J | 7 |
| Rohilla, S | 1 |
| Singh, M | 1 |
| Priya, S | 1 |
| Almalki, WH | 1 |
| Haniffa, SM | 1 |
| Subramaniyan, V | 1 |
| Fuloria, S | 1 |
| Fuloria, NK | 1 |
| Sekar, M | 1 |
| Singh, SK | 1 |
| Jha, NK | 1 |
| Chellappan, DK | 1 |
| Negi, P | 1 |
| Dua, K | 1 |
| Gupta, G | 1 |
| de Godoy, BLV | 1 |
| Moschetta-Pinheiro, MG | 1 |
| Chuffa, LGA | 1 |
| Pondé, NF | 1 |
| Colombo, J | 3 |
| Zuccari, DAPC | 4 |
| Gao, SC | 1 |
| Wu, MD | 1 |
| Zhang, XX | 1 |
| Liu, YF | 1 |
| Wang, CL | 1 |
| Silva, KMR | 1 |
| França, DCH | 1 |
| de Queiroz, AA | 1 |
| Fagundes-Triches, DLG | 1 |
| de Marchi, PGF | 1 |
| Morais, TC | 1 |
| Honorio-França, AC | 2 |
| França, EL | 2 |
| Wichert, K | 1 |
| Hoppe, R | 1 |
| Ickstadt, K | 1 |
| Behrens, T | 1 |
| Winter, S | 1 |
| Herold, R | 1 |
| Terschüren, C | 1 |
| Lo, WY | 1 |
| Guénel, P | 1 |
| Truong, T | 1 |
| Bolla, MK | 1 |
| Dennis, J | 1 |
| Michailidou, K | 1 |
| Lush, M | 1 |
| Andrulis, IL | 1 |
| Brenner, H | 1 |
| Chang-Claude, J | 1 |
| Cox, A | 1 |
| Cross, SS | 1 |
| Czene, K | 1 |
| Eriksson, M | 1 |
| Figueroa, JD | 1 |
| García-Closas, M | 1 |
| Goldberg, MS | 1 |
| Hamann, U | 1 |
| He, W | 1 |
| Holleczek, B | 1 |
| Hopper, JL | 1 |
| Jakubowska, A | 1 |
| Ko, YD | 1 |
| Lubiński, J | 1 |
| Mulligan, AM | 1 |
| Obi, N | 1 |
| Rhenius, V | 1 |
| Shah, M | 1 |
| Shu, XO | 2 |
| Simard, J | 1 |
| Southey, MC | 1 |
| Zheng, W | 2 |
| Dunning, AM | 1 |
| Pharoah, PDP | 1 |
| Hall, P | 1 |
| Easton, DF | 1 |
| Brüning, T | 1 |
| Brauch, H | 1 |
| Harth, V | 1 |
| Rabstein, S | 1 |
| Soares Júnior, JM | 3 |
| Mota, BS | 1 |
| Nobrega, GB | 1 |
| Filassi, JR | 1 |
| Sorpreso, ICE | 2 |
| Baracat, EC | 2 |
| Kesicioglu, T | 1 |
| Sengul, D | 1 |
| Sengul, I | 1 |
| González-González, A | 4 |
| García Nieto, E | 1 |
| González, A | 17 |
| Sánchez-Fernández, C | 1 |
| Alonso-González, C | 19 |
| Menéndez-Menéndez, J | 4 |
| Gómez-Arozamena, J | 3 |
| Cos, S | 33 |
| Martínez-Campa, C | 17 |
| Talib, WH | 2 |
| Palmer, ACS | 1 |
| Zortea, M | 1 |
| Souza, A | 1 |
| Santos, V | 1 |
| Biazús, JV | 1 |
| Torres, ILS | 1 |
| Fregni, F | 1 |
| Caumo, W | 1 |
| Kwon, YJ | 1 |
| Seo, EB | 1 |
| Kwon, SH | 1 |
| Lee, SH | 1 |
| Kim, SK | 1 |
| Park, SK | 1 |
| Kim, K | 1 |
| Park, S | 1 |
| Park, IC | 2 |
| Park, JW | 1 |
| Ye, SK | 2 |
| Amiri, M | 1 |
| Dizaji, BF | 1 |
| Roshanravan, N | 1 |
| Haiaty, S | 1 |
| Panchenko, AV | 1 |
| Tyndyk, ML | 1 |
| Maydin, MA | 1 |
| Baldueva, IA | 1 |
| Artemyeva, AS | 1 |
| Kruglov, SS | 1 |
| Kireeva, GS | 1 |
| Golubev, AG | 1 |
| Belyaev, AM | 1 |
| Anisimov, VN | 3 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 8 |
| Xue, L | 1 |
| Liu, L | 3 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 3 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 4 |
| Huang, W | 2 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 3 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 2 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 2 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 2 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 3 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 3 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 3 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 2 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 3 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 2 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 2 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 4 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 2 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Gao, R | 1 |
| Fang, Y | 1 |
| Gao, J | 1 |
| Mutlu, EG | 1 |
| Baltaci, SB | 1 |
| Ashouri, N | 1 |
| Mortezania, Z | 1 |
| Ashoori, Z | 1 |
| Amirzadeh-Iranaq, MT | 1 |
| Fattahi, A | 1 |
| Bizzarri, M | 5 |
| Faridvand, Y | 1 |
| Rajabi, A | 1 |
| Saber, A | 1 |
| Pourmahdi, M | 1 |
| Emami, A | 1 |
| Ravanbakhsh, R | 1 |
| Khodavirdipour, A | 1 |
| Khodaei, M | 1 |
| Abdolahi, S | 1 |
| Hosseinpourfeizi, MA | 1 |
| Safaralizadeh, R | 1 |
| Wong, ATY | 1 |
| Fensom, GK | 1 |
| Key, TJ | 3 |
| Onland-Moret, NC | 1 |
| Tong, TYN | 1 |
| Travis, RC | 3 |
| Ahabrach, H | 1 |
| El Mlili, N | 1 |
| Errami, M | 1 |
| Cauli, O | 1 |
| Fagundo-Rivera, J | 1 |
| Gómez-Salgado, J | 1 |
| García-Iglesias, JJ | 1 |
| Gómez-Salgado, C | 1 |
| Camacho-Martín, S | 1 |
| Ruiz-Frutos, C | 1 |
| Jin, Y | 1 |
| Choi, YJ | 1 |
| Heo, K | 1 |
| Park, SJ | 1 |
| Gehlert, S | 1 |
| Clanton, M | 1 |
| Vitti-Ruela, BV | 1 |
| Dokkedal-Silva, V | 1 |
| Hachul, H | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Tascioglu Aliyev, A | 1 |
| Panieri, E | 1 |
| Stepanić, V | 1 |
| Gurer-Orhan, H | 3 |
| Saso, L | 2 |
| Ahmed Abdelsalam, KE | 1 |
| Asad, M | 1 |
| Ahmed, MAI | 1 |
| Asdaq, SMB | 1 |
| Mohzari, Y | 1 |
| Alrashed, A | 1 |
| Alghamdi, N | 1 |
| Alrami, KN | 1 |
| Alharbi, WA | 1 |
| Rui, C | 1 |
| Tao, Z | 1 |
| Ma, F | 1 |
| Gelaleti, GB | 4 |
| Borin, TF | 5 |
| Maschio-Signorini, LB | 1 |
| Moschetta, MG | 5 |
| Jardim-Perassi, BV | 6 |
| Calvinho, GB | 1 |
| Facchini, MC | 1 |
| Viloria-Petit, AM | 1 |
| de Campos Zuccari, DAP | 3 |
| Ince, E | 2 |
| Konyar, D | 1 |
| Suzen, S | 2 |
| Xu, J | 1 |
| Sun, GP | 1 |
| Nagata, C | 4 |
| Tamura, T | 1 |
| Wada, K | 1 |
| Konishi, K | 1 |
| Goto, Y | 1 |
| Nagao, Y | 4 |
| Ishihara, K | 1 |
| Xie, W | 1 |
| Wang, D | 1 |
| Wang, W | 1 |
| Yuan, J | 1 |
| Guo, Z | 1 |
| Sun, X | 1 |
| Zhao, L | 1 |
| Wang, T | 1 |
| Liu, B | 1 |
| Guan, Y | 1 |
| Gong, M | 1 |
| Zhang, W | 1 |
| Pan, J | 1 |
| Liang, R | 1 |
| Yuan, Y | 1 |
| Ye, L | 1 |
| Proietti, S | 3 |
| Catizone, A | 1 |
| Masiello, MG | 1 |
| Dinicola, S | 2 |
| Fabrizi, G | 1 |
| Minini, M | 1 |
| Ricci, G | 1 |
| Verna, R | 1 |
| Cucina, A | 4 |
| Ferreira, JPS | 1 |
| Braga, CZ | 1 |
| Sonehara, NM | 3 |
| Júnior, RP | 1 |
| Girol, AP | 1 |
| Mediavilla, MD | 16 |
| Sánchez-Barceló, EJ | 25 |
| Kubatka, P | 2 |
| Zubor, P | 1 |
| Busselberg, D | 1 |
| Kwon, TK | 1 |
| Adamek, M | 1 |
| Petrovic, D | 1 |
| Opatrilova, R | 1 |
| Gazdikova, K | 1 |
| Caprnda, M | 1 |
| Rodrigo, L | 1 |
| Danko, J | 1 |
| Kruzliak, P | 2 |
| Griffin, F | 1 |
| Marignol, L | 1 |
| Chu, LW | 1 |
| John, EM | 1 |
| Yang, B | 1 |
| Kurian, AW | 1 |
| Zia, Y | 1 |
| Yu, K | 1 |
| Ingles, SA | 1 |
| Stanczyk, FZ | 5 |
| Hsing, AW | 1 |
| Rybnikova, N | 1 |
| Portnov, BA | 1 |
| de Castro, TB | 1 |
| Bordin-Junior, NA | 1 |
| de Almeida, EA | 1 |
| Ozcan-Sezer, S | 1 |
| Akdemir, A | 1 |
| Ceylan, ÖÖ | 1 |
| Odeh, LH | 1 |
| Basheti, IA | 1 |
| El-Sokkary, GH | 1 |
| Ismail, IA | 1 |
| Saber, SH | 1 |
| de Almeida Chuffa, LG | 1 |
| Seiva, FRF | 1 |
| Cucielo, MS | 1 |
| Silveira, HS | 1 |
| Lupi, LA | 1 |
| Alexandre, PA | 1 |
| de Paula-Junior, R | 1 |
| Reis Júnior, O | 1 |
| Fukumasu, H | 1 |
| Chammas, R | 1 |
| Coutinho, LL | 1 |
| Li, W | 1 |
| Kwok, CC | 1 |
| Chan, DC | 1 |
| Ho, AW | 1 |
| Ho, CS | 1 |
| Wing, YK | 1 |
| Wang, F | 1 |
| Tse, LA | 1 |
| Lacerda, JZ | 1 |
| Ferreira, LC | 4 |
| Lopes, BC | 1 |
| Aristizábal-Pachón, AF | 1 |
| Bajgelman, MC | 1 |
| Amin, N | 1 |
| Shafabakhsh, R | 1 |
| Xiang, S | 10 |
| Dauchy, RT | 14 |
| Hoffman, AE | 1 |
| Pointer, D | 2 |
| Frasch, T | 9 |
| Blask, DE | 27 |
| Hill, SM | 35 |
| Veiga, ECA | 1 |
| Simões, R | 1 |
| Valenti, VE | 1 |
| Cipolla-Neto, J | 1 |
| Abreu, LC | 1 |
| Barros, EPM | 1 |
| Baracat, MCP | 1 |
| Cherrie, JW | 1 |
| Goyal, R | 1 |
| Gupta, T | 1 |
| Bal, A | 1 |
| Sahni, D | 1 |
| Singh, G | 1 |
| Anderson, G | 1 |
| Santisteban, M | 1 |
| Pham, TT | 1 |
| Lee, ES | 1 |
| Kong, SY | 1 |
| Kim, SY | 1 |
| Joo, J | 1 |
| Yoon, KA | 1 |
| Park, B | 1 |
| Alvarez-García, V | 4 |
| Lehrer, S | 1 |
| Green, S | 1 |
| Ramanathan, L | 1 |
| Rosenzweig, KE | 1 |
| Figueiro, MG | 2 |
| White, RD | 1 |
| Arif, IS | 1 |
| Hooper, CL | 1 |
| Greco, F | 1 |
| Williams, AC | 1 |
| Boateng, SY | 1 |
| Wu, AH | 3 |
| Yu, MC | 3 |
| Erren, TC | 3 |
| Bukowska, A | 2 |
| Pepłońska, B | 1 |
| Hansen, MV | 4 |
| Madsen, MT | 3 |
| Wildschiødtz, G | 1 |
| Gögenur, I | 3 |
| Arikawa, AY | 1 |
| Thomas, W | 1 |
| Patel, SR | 1 |
| Kurzer, MS | 1 |
| Cheng, C | 1 |
| Yuan, L | 22 |
| Mao, L | 15 |
| Jockers, R | 1 |
| Dauchy, B | 1 |
| Arbab, AS | 2 |
| Varma, NR | 2 |
| Iskander, AS | 2 |
| Shankar, A | 2 |
| Ali, MM | 1 |
| de Campos Zuccari, DA | 1 |
| Wang, XS | 1 |
| Tipper, S | 1 |
| Appleby, PN | 1 |
| Allen, NE | 1 |
| Di Bella, G | 1 |
| Mascia, F | 1 |
| Ricchi, A | 1 |
| Colori, B | 1 |
| Sturgeon, SR | 1 |
| Doherty, A | 1 |
| Reeves, KW | 2 |
| Bigelow, C | 1 |
| Ockene, JK | 1 |
| Liu, S | 1 |
| Manson, JE | 1 |
| Neuhouser, ML | 1 |
| Chen, WY | 2 |
| Giobbie-Hurder, A | 2 |
| Gantman, K | 2 |
| Savoie, J | 2 |
| Scheib, R | 2 |
| Parker, LM | 2 |
| Schernhammer, ES | 12 |
| Andersen, LT | 2 |
| Hageman, I | 2 |
| Rasmussen, LS | 2 |
| Bokmand, S | 2 |
| Yang, WS | 1 |
| Fan, WY | 1 |
| Wang, WY | 1 |
| Chottanapund, S | 1 |
| Van Duursen, MB | 1 |
| Navasumrit, P | 1 |
| Hunsonti, P | 1 |
| Timtavorn, S | 1 |
| Ruchirawat, M | 1 |
| Van den Berg, M | 1 |
| Brimer, S | 2 |
| Wren, MA | 2 |
| Anbalagan, M | 1 |
| Hauch, A | 3 |
| Rowan, BG | 1 |
| Dauchy, EM | 5 |
| Greene, MW | 1 |
| Belancio, VP | 4 |
| Sauer, LA | 5 |
| Davidson, L | 1 |
| Killock, D | 1 |
| Bojková, B | 1 |
| Kassayová, M | 1 |
| Orendáš, P | 1 |
| Kajo, K | 1 |
| Výbohová, D | 1 |
| Adamicová, K | 1 |
| Péč, M | 1 |
| Stollárová, N | 1 |
| Adamkov, M | 1 |
| Brown, SB | 2 |
| Hankinson, SE | 5 |
| Eliassen, AH | 2 |
| Qian, J | 1 |
| Arcaro, KF | 1 |
| Wegrzyn, LR | 1 |
| Willett, WC | 4 |
| Papantoniou, K | 1 |
| Pozo, OJ | 1 |
| Espinosa, A | 1 |
| Marcos, J | 1 |
| Castaño-Vinyals, G | 1 |
| Basagaña, X | 1 |
| Juanola Pagès, E | 1 |
| Mirabent, J | 1 |
| Martín, J | 1 |
| Such Faro, P | 1 |
| Gascó Aparici, A | 1 |
| Middleton, B | 1 |
| Skene, DJ | 2 |
| Kogevinas, M | 1 |
| Garcia, CP | 1 |
| Lamarque, AL | 1 |
| Comba, A | 1 |
| Berra, MA | 1 |
| Silva, RA | 1 |
| Labuckas, DO | 1 |
| Das, UN | 1 |
| Eynard, AR | 1 |
| Pasqualini, ME | 1 |
| Mondal, D | 1 |
| Lundberg, PW | 1 |
| Summers, W | 2 |
| Lourenço, MR | 1 |
| Doho, GM | 1 |
| Grígolo, IH | 1 |
| Pires de Campos Zuccari, DA | 1 |
| Innominato, PF | 1 |
| Lim, AS | 1 |
| Palesh, O | 1 |
| Clemons, M | 1 |
| Trudeau, M | 1 |
| Eisen, A | 1 |
| Wang, C | 1 |
| Kiss, A | 1 |
| Pritchard, KI | 1 |
| Bjarnason, GA | 1 |
| Coimbra, VB | 1 |
| Fabri, VA | 1 |
| de Oliveira, JG | 1 |
| Zuccari, DA | 2 |
| Vriend, J | 1 |
| Smolensky, MH | 1 |
| Sackett-Lundeen, LL | 1 |
| Portaluppi, F | 1 |
| Cho, Y | 1 |
| Ryu, SH | 1 |
| Lee, BR | 1 |
| Kim, KH | 1 |
| Lee, E | 1 |
| Choi, J | 1 |
| Fernandes, RT | 1 |
| Marins, CM | 1 |
| Pereira, CC | 1 |
| Varotti, Fde P | 1 |
| García-Vidal, A | 1 |
| Koşar, PA | 1 |
| Nazıroğlu, M | 2 |
| Övey, İS | 1 |
| Çiğ, B | 1 |
| Benabu, JC | 1 |
| Stoll, F | 1 |
| Gonzalez, M | 1 |
| Yun, SM | 1 |
| Woo, SH | 1 |
| Oh, ST | 1 |
| Hong, SE | 1 |
| Choe, TB | 1 |
| Kim, EK | 1 |
| Seong, MK | 1 |
| Kim, HA | 1 |
| Noh, WC | 1 |
| Lee, JK | 1 |
| Jin, HO | 1 |
| Lee, YH | 1 |
| Keshet-Sitton, A | 2 |
| Or-Chen, K | 2 |
| Yitzhak, S | 2 |
| Tzabary, I | 2 |
| Haim, A | 2 |
| Gonçalves, Ndo N | 1 |
| Lopes, JR | 2 |
| Hellmén, E | 1 |
| Zanon, Cde F | 1 |
| Oliani, SM | 1 |
| Mori, F | 1 |
| Ferraiuolo, M | 1 |
| Santoro, R | 1 |
| Sacconi, A | 1 |
| Goeman, F | 1 |
| Pallocca, M | 1 |
| Pulito, C | 1 |
| Korita, E | 1 |
| Fanciulli, M | 1 |
| Muti, P | 3 |
| Blandino, G | 1 |
| Strano, S | 3 |
| Nooshinfar, E | 2 |
| Safaroghli-Azar, A | 2 |
| Bashash, D | 2 |
| Akbari, ME | 2 |
| Sabzichi, M | 1 |
| Samadi, N | 1 |
| Mohammadian, J | 1 |
| Hamishehkar, H | 1 |
| Molavi, O | 1 |
| Greenlee, H | 1 |
| Neugut, AI | 1 |
| Falci, L | 1 |
| Hillyer, GC | 1 |
| Buono, D | 1 |
| Mandelblatt, JS | 1 |
| Roh, JM | 1 |
| Ergas, IJ | 1 |
| Kwan, ML | 1 |
| Lee, M | 1 |
| Tsai, WY | 1 |
| Shi, Z | 1 |
| Lamerato, L | 1 |
| Kushi, LH | 1 |
| Hershman, DL | 1 |
| Bayati, S | 1 |
| Rezaei-Tavirani, M | 1 |
| Ghaffari, SH | 1 |
| Reynolds, A | 1 |
| Wren-Dail, MA | 1 |
| da Silva Kavagutti, M | 1 |
| de Medeiros, FAF | 1 |
| Devore, EE | 1 |
| Warner, ET | 1 |
| Beck, AH | 1 |
| Berrino, F | 2 |
| Krogh, V | 2 |
| Secreto, G | 2 |
| Micheli, A | 2 |
| Venturelli, E | 2 |
| Sieri, S | 1 |
| Sempos, CT | 2 |
| Cavalleri, A | 2 |
| Schünemann, HJ | 2 |
| Shibuya, C | 3 |
| Kashiki, Y | 3 |
| Shimizu, H | 3 |
| Korkmaz, A | 2 |
| Tan, DX | 2 |
| Lai, L | 6 |
| Dong, C | 4 |
| Rowan, B | 2 |
| Tamura, H | 1 |
| Manchester, LC | 1 |
| Ogden, GB | 1 |
| Kakizaki, M | 1 |
| Kuriyama, S | 1 |
| Sone, T | 1 |
| Ohmori-Matsuda, K | 1 |
| Hozawa, A | 1 |
| Nakaya, N | 1 |
| Fukudo, S | 1 |
| Tsuji, I | 1 |
| Cheng, Q | 3 |
| Viswanathan, AN | 1 |
| D'Anselmi, F | 1 |
| Coluccia, P | 1 |
| Frati, L | 1 |
| Grant, SG | 1 |
| Melan, MA | 1 |
| Latimer, JJ | 1 |
| Stevens, RG | 17 |
| Girgert, R | 3 |
| Hanf, V | 3 |
| Emons, G | 2 |
| Gründker, C | 2 |
| Brainard, GC | 6 |
| Hanifin, JP | 3 |
| Duplessis, T | 2 |
| Bilski, B | 1 |
| Costa, G | 1 |
| Haus, E | 3 |
| Stevens, R | 1 |
| Grioni, S | 1 |
| Dai, J | 7 |
| Slakey, LM | 3 |
| Jones, FE | 1 |
| Burow, ME | 1 |
| Rögelsperger, O | 1 |
| Wlcek, K | 1 |
| Ekmekcioglu, C | 2 |
| Humpeler, S | 1 |
| Svoboda, M | 1 |
| Königsberg, R | 1 |
| Klimpfinger, M | 2 |
| Jäger, W | 1 |
| Thalhammer, T | 2 |
| Stone, KL | 1 |
| Dauchy, E | 1 |
| Lee, SE | 2 |
| Kim, SJ | 2 |
| Youn, JP | 1 |
| Hwang, SY | 2 |
| Park, CS | 2 |
| Park, YS | 3 |
| Dupepe, LM | 1 |
| Ooms, TG | 1 |
| Hill, CR | 1 |
| Duplesis, T | 1 |
| Deming, SL | 1 |
| Lu, W | 1 |
| Beeghly-Fadiel, A | 1 |
| Zheng, Y | 1 |
| Cai, Q | 1 |
| Long, J | 1 |
| Gao, YT | 1 |
| Knower, KC | 1 |
| To, SQ | 1 |
| Takagi, K | 1 |
| Miki, Y | 1 |
| Sasano, H | 1 |
| Simpson, ER | 1 |
| Clyne, CD | 1 |
| Davis, S | 10 |
| Mirick, DK | 7 |
| Xiao, X | 1 |
| Shi, D | 1 |
| Chen, W | 1 |
| Fu, L | 1 |
| Xie, F | 1 |
| Kang, T | 1 |
| Deng, W | 1 |
| Rueda, N | 1 |
| Margheri, M | 1 |
| Pacini, N | 1 |
| Tani, A | 1 |
| Nosi, D | 1 |
| Squecco, R | 1 |
| Dama, A | 1 |
| Masala, E | 1 |
| Francini, F | 1 |
| Zecchi-Orlandini, S | 1 |
| Formigli, L | 1 |
| Peplonska, B | 1 |
| Sobala, W | 1 |
| Reszka, E | 1 |
| Gromadzinska, J | 1 |
| Wasowicz, W | 1 |
| Lie, JA | 1 |
| Kjuus, H | 1 |
| Ursin, G | 1 |
| Wang, R | 2 |
| Koh, WP | 2 |
| Yuan, JM | 1 |
| Vanderstraeten, J | 1 |
| Verschaeve, L | 1 |
| Burda, H | 1 |
| Bouland, C | 1 |
| de Brouwer, C | 1 |
| Yoon, HJ | 1 |
| Yu, SY | 1 |
| Jeong, SI | 1 |
| Shan, B | 1 |
| Duplessis, TT | 1 |
| Tokat, S | 1 |
| Demirci, S | 2 |
| Malina, C | 1 |
| Frigo, S | 1 |
| Czeczuga-Semeniuk, E | 1 |
| Wołczyński, S | 1 |
| Anchim, T | 1 |
| Dziecioł, J | 1 |
| Dabrowska, M | 1 |
| Pietruczuk, M | 1 |
| Glickman, G | 1 |
| Levin, R | 1 |
| Iizuka, N | 1 |
| Collins, A | 1 |
| Kiefer, TL | 4 |
| Valente, MG | 1 |
| Tagliaferri, F | 1 |
| Borrelli, V | 1 |
| Stipa, F | 1 |
| Cavallaro, A | 1 |
| Fernández, R | 4 |
| Krause, JA | 3 |
| Carlson, LE | 2 |
| Speca, M | 1 |
| Patel, KD | 1 |
| Goodey, E | 1 |
| Allen, DS | 1 |
| Fentiman, IS | 1 |
| Bartsch, C | 12 |
| Kreienberg, R | 1 |
| Hrushesky, WJ | 1 |
| Rosner, B | 1 |
| Laden, F | 2 |
| Colditz, GA | 2 |
| Leon-Blanco, MM | 1 |
| Guerrero, JM | 1 |
| Pozo, D | 1 |
| Schernhammer, E | 2 |
| Ishido, M | 1 |
| Mediavilla, D | 1 |
| Kim, C | 1 |
| Kim, N | 1 |
| Joo, H | 1 |
| Youm, JB | 1 |
| Park, WS | 1 |
| Cuong, DV | 1 |
| Kim, E | 1 |
| Min, CK | 1 |
| Han, J | 1 |
| Tarone, RE | 1 |
| Goto, K | 1 |
| Aust, S | 1 |
| Jaeger, W | 1 |
| Mayer, K | 1 |
| Baravalle, G | 1 |
| Davidson, LK | 2 |
| Rivera-Bermudez, MA | 1 |
| Dubocovich, ML | 2 |
| Jasser, SA | 1 |
| Lynch, DT | 2 |
| Rollag, MD | 1 |
| Zalatan, F | 2 |
| Treeck, O | 1 |
| Haldar, C | 1 |
| Ortmann, O | 1 |
| Lerchl, A | 2 |
| Bullough, JD | 1 |
| Rea, MS | 3 |
| Moser, M | 1 |
| Schaumberger, K | 1 |
| Hansen, J | 2 |
| Bartsch, H | 11 |
| Ramos, S | 2 |
| Blue, LM | 1 |
| Ross, K | 1 |
| Winczyk, K | 1 |
| Lawnicka, H | 1 |
| Pawlikowski, M | 1 |
| Kunert-Radek, J | 1 |
| Karasek, M | 1 |
| Patel, D | 1 |
| Borisenkov, MF | 1 |
| Bazhenov, SM | 1 |
| Burch, JB | 1 |
| Walling, M | 1 |
| Rush, A | 1 |
| Hennesey, M | 1 |
| Craven, W | 1 |
| Finlayson, C | 1 |
| Anderson, BO | 1 |
| Cosma, G | 1 |
| Wells, RL | 2 |
| Vinogradova, IA | 1 |
| Campbell, TS | 1 |
| Garland, SN | 1 |
| Grossman, P | 1 |
| Jawed, S | 1 |
| Kim, B | 1 |
| Ottenhof, T | 1 |
| Brown, GM | 2 |
| Werstiuk, ES | 1 |
| Niles, LP | 1 |
| Sánchez-Mateos, S | 2 |
| Sahar, S | 1 |
| Sassone-Corsi, P | 1 |
| Srinivasan, V | 1 |
| Spence, DW | 1 |
| Pandi-Perumal, SR | 1 |
| Trakht, I | 1 |
| Esquifino, AI | 1 |
| Cardinali, DP | 1 |
| Maestroni, GJ | 4 |
| Schwartzbaum, J | 1 |
| Ahlbom, A | 3 |
| Feychting, M | 3 |
| Matsubara, T | 1 |
| Hara, T | 1 |
| Fujita, H | 1 |
| Lee, HP | 1 |
| Martínez-Campa, CM | 1 |
| Ortíz-López, L | 1 |
| Morales-Mulia, S | 1 |
| Ramírez-Rodríguez, G | 1 |
| Benítez-King, G | 1 |
| Tharandt, L | 1 |
| Reinwein, D | 1 |
| Jain, AK | 1 |
| Laumas, KR | 1 |
| Wetterberg, L | 3 |
| Tamarkin, L | 3 |
| Danforth, D | 1 |
| Lichter, A | 1 |
| DeMoss, E | 1 |
| Chabner, B | 2 |
| Lippman, M | 2 |
| Molis, TM | 2 |
| Spriggs, LL | 7 |
| Jupiter, Y | 1 |
| Steinhilber, D | 1 |
| Brungs, M | 1 |
| Werz, O | 1 |
| Wiesenberg, I | 1 |
| Danielsson, C | 1 |
| Kahlen, JP | 1 |
| Nayeri, S | 1 |
| Schräder, M | 1 |
| Carlberg, C | 1 |
| Lissoni, P | 10 |
| Barni, S | 8 |
| Meregalli, S | 1 |
| Fossati, V | 1 |
| Cazzaniga, M | 1 |
| Esposti, D | 4 |
| Tancini, G | 8 |
| Zumoff, B | 1 |
| Small, RA | 1 |
| Brzezinski, A | 3 |
| Massion, AO | 1 |
| Teas, J | 1 |
| Hebert, JR | 1 |
| Wertheimer, MD | 1 |
| Kabat-Zinn, J | 1 |
| Crespo, D | 1 |
| Fernández-Viadero, C | 1 |
| Verduga, R | 1 |
| Ovejero, V | 1 |
| Flüchter, SH | 1 |
| Mecke, D | 4 |
| Lippert, TH | 4 |
| Furuya, Y | 2 |
| Yamamoto, K | 2 |
| Kohno, N | 2 |
| Ku, Y | 1 |
| Saitoh, Y | 2 |
| Taubes, G | 1 |
| Liburdy, RP | 2 |
| Sloma, TR | 1 |
| Sokolic, R | 1 |
| Yaswen, P | 1 |
| Rovelli, F | 6 |
| Brivio, F | 2 |
| Ardizzoia, A | 3 |
| Conti, A | 2 |
| Sankila, R | 1 |
| Joensuu, H | 1 |
| Pukkala, E | 2 |
| Toikkanen, S | 1 |
| Lemus-Wilson, A | 1 |
| Kelly, PA | 1 |
| Recio, J | 1 |
| Fernández, F | 1 |
| Bullough, J | 1 |
| Holdaway, IM | 2 |
| Mason, BH | 2 |
| Gibbs, EE | 2 |
| Rajasoorya, C | 2 |
| Lethaby, A | 1 |
| Hopkins, KD | 2 |
| Evans, MC | 1 |
| Lim, T | 1 |
| Schooler, B | 1 |
| Wilson, ST | 3 |
| Yamamoto, M | 1 |
| Harland, JD | 1 |
| Karenovics, A | 1 |
| Franz, H | 2 |
| Peiker, G | 1 |
| Matsui, DH | 1 |
| Machado-Santelli, GM | 1 |
| Panzer, A | 1 |
| Lottering, ML | 1 |
| Bianchi, P | 1 |
| Glencross, DK | 1 |
| Stark, JH | 1 |
| Seegers, JC | 1 |
| Baldwin, WS | 3 |
| Barrett, JC | 3 |
| Eck, KM | 2 |
| Duffy, L | 1 |
| Ram, PT | 7 |
| Ayettey, S | 1 |
| Chen, I | 1 |
| Cohn, CS | 1 |
| Reed, JC | 1 |
| Kiefer, T | 4 |
| Silverman, M | 1 |
| Song, Y | 1 |
| Osterlund, B | 1 |
| Mawson, AR | 1 |
| Moulder, JE | 1 |
| Güézmes, A | 1 |
| Giani, L | 2 |
| Zerbini, S | 1 |
| Trabattoni, P | 1 |
| Travlos, GS | 1 |
| Risinger, JI | 1 |
| Papazisis, KT | 1 |
| Kouretas, D | 1 |
| Geromichalos, GD | 1 |
| Sivridis, E | 1 |
| Tsekreli, OK | 1 |
| Dimitriadis, KA | 1 |
| Kortsaris, AH | 1 |
| Buchberger, A | 2 |
| Stieglitz, A | 1 |
| Effenberger-Klein, A | 1 |
| Kruse-Jarres, JD | 1 |
| Besenthal, I | 1 |
| Rokos, H | 1 |
| Kavet, R | 2 |
| Kheifets, LI | 2 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Büyükcelik, A | 1 |
| Akbulut, KG | 1 |
| Rato, AG | 1 |
| Pedrero, JG | 1 |
| Martinez, MA | 1 |
| del Rio, B | 1 |
| Lazo, PS | 1 |
| Matkin, CC | 1 |
| Paolorossi, F | 5 |
| Mandalà, M | 2 |
| Malugani, F | 2 |
| Coker, KH | 1 |
| Verkasalo, PK | 1 |
| Ojamo, M | 1 |
| Rudanko, SL | 1 |
| Piekarski, C | 1 |
| Cook, MR | 2 |
| Graham, C | 2 |
| Kheifets, L | 2 |
| Vaghi, M | 1 |
| Longarini, R | 1 |
| Kajdaniuk, D | 3 |
| Marek, B | 3 |
| Pillittere, D | 1 |
| Miller, M | 1 |
| Teplitzky, S | 1 |
| Alvarez, A | 1 |
| Klotz, DM | 1 |
| Eck-Enriquez, K | 1 |
| Kaune, W | 1 |
| Maidonis, I | 1 |
| Bayer, E | 1 |
| Blackman, CF | 1 |
| Benane, SG | 1 |
| House, DE | 1 |
| Scott, AE | 1 |
| Cosma, GN | 1 |
| Frank, AA | 1 |
| Gardner, HS | 1 |
| Leman, ES | 1 |
| Sisken, BF | 1 |
| Zimmer, S | 1 |
| Anderson, KW | 1 |
| Gerkovich, MM | 1 |
| Sastre, A | 1 |
| Kos-Kudla, B | 1 |
| Kaune, WT | 1 |
| Dumitriu, L | 1 |
| Nicolau, GY | 1 |
| Bologa, S | 1 |
| Sackett-Lundeen, L | 1 |
| Speizer, FE | 1 |
| Hunter, DJ | 1 |
| Kawachi, I | 1 |
| Bernstein, L | 1 |
| McElroy, JA | 1 |
| Newcomb, PA | 1 |
| Remington, PL | 1 |
| Egan, KM | 1 |
| Titus-Ernstoff, L | 1 |
| Trentham-Dietz, A | 1 |
| Hampton, JM | 1 |
| Baron, JA | 1 |
| Stampfer, MJ | 1 |
| Frentzel-Beyme, R | 1 |
| Porock, D | 1 |
| Gentry, J | 1 |
| Spiegel, D | 1 |
| Sephton, S | 1 |
| Kerenyi, N | 1 |
| Rohr, UD | 1 |
| Herold, J | 1 |
| Malone, RE | 1 |
| Coudert, B | 1 |
| Benshushan, A | 1 |
| Nowfar, S | 1 |
| Teplitzky, SR | 1 |
| Melancon, K | 1 |
| Dwived, PD | 1 |
| Bischoff, ED | 1 |
| Moro, K | 1 |
| Anderson, MB | 1 |
| Kos-Kudła, B | 1 |
| Zwirska-Korczala, K | 1 |
| Ostrowska, Z | 1 |
| Buntner, B | 1 |
| Szymszal, J | 1 |
| Inscho, EW | 1 |
| González-Lamuño, D | 1 |
| Collins, AR | 1 |
| Adami, HO | 1 |
| Rimsten, A | 1 |
| Wide, L | 1 |
| Lapin, V | 1 |
| Lemus-Wilson, AM | 2 |
| Coleman, MP | 1 |
| Simon, MA | 1 |
| Muraoka, H | 1 |
| Thomas, DB | 1 |
| Anderson, LE | 1 |
| Wilson, BW | 1 |
| Bellmann, O | 2 |
| Falkson, G | 1 |
| Falkson, HC | 1 |
| Steyn, ME | 1 |
| Rapoport, BL | 1 |
| Meyer, BJ | 1 |
| Hermida, RC | 1 |
| Fernandez, JR | 1 |
| Ayala, DE | 1 |
| Sanchez de la Pena, S | 1 |
| Halberg, F | 2 |
| Crispino, S | 4 |
| Sormani, A | 1 |
| Pelizzoni, F | 1 |
| Brenna, A | 1 |
| Bratina, G | 1 |
| Bojkowski, CJ | 1 |
| Currie, JE | 1 |
| Wright, J | 1 |
| Boulter, PS | 1 |
| Arendt, J | 1 |
| Sheĭnina, LI | 1 |
| Kutivadze, DA | 1 |
| Sulava, TA | 1 |
| Gabuniia, UA | 1 |
| Kvetnoĭ, IM | 1 |
| Fuchs, U | 1 |
| Gupta, D | 1 |
| Arbesman, H | 1 |
| Byers, T | 1 |
| Ferri, L | 2 |
| Cattaneo, G | 2 |
| Esposti, G | 3 |
| Clur, A | 1 |
| Miles, A | 1 |
| Philbrick, D | 1 |
| Fraschini, F | 2 |
| Bastone, A | 1 |
| Sala, R | 1 |
| Mauri, R | 1 |
| Viviani, S | 1 |
| Bajetta, E | 1 |
| di Bella, L | 1 |
| Halberg, E | 1 |
| Kawasaki, T | 1 |
| Ueno, M | 1 |
| Uezono, K | 1 |
| Cornelissen, G | 1 |
| Matsuoka, M | 1 |
| Omae, T | 1 |
| Prasad, GC | 1 |
| Singh, AK | 1 |
| Raj, R | 1 |
| Almeida, OF | 1 |
| Danforth, DN | 2 |
| Mulvihill, JJ | 1 |
| Bagley, CS | 1 |
| Lippman, ME | 1 |
| Burns, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints[NCT02886832] | 30 participants (Anticipated) | Interventional | 2016-09-21 | Completed | |||
| Role of Endogenous Melatonin Level in Preoperative and Postoperative Anxiety in Bariatric Surgery Patients[NCT03109054] | 50 participants (Anticipated) | Observational | 2017-03-15 | Enrolling by invitation | |||
| The Influence of Postoperative Analgesia on Systemic Inflammatory Response and Postoperative Cognitive Disfunction in Elderly Patients After Surgical Repair of Femoral Fractures[NCT02848599] | Phase 2 | 86 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Relationship Between Melatonin Level and Postoperative Analgesia Consumption in Bariatric Surgery Patients.[NCT03107702] | 35 participants (Anticipated) | Observational | 2017-03-29 | Enrolling by invitation | |||
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Diet and Chronotype: a Randomized Controlled Trial to Evaluate the Effects of a Chronotype-adapted Diet on Weight Loss in Overweight/Obese Subjects[NCT05941871] | 150 participants (Anticipated) | Interventional | 2023-03-06 | Recruiting | |||
| Circadian Health in Patients Admitted to Intensive Care Units and Hospitalization (CHRONOHOSPI)[NCT04113876] | 975 participants (Actual) | Observational [Patient Registry] | 2019-01-01 | Completed | |||
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients[NCT00390169] | Phase 3 | 300 participants (Anticipated) | Interventional | 2006-10-31 | Active, not recruiting | ||
| Mind-Body Health in Uro-Oncology: A Randomized Controlled Trial[NCT03852030] | 120 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education[NCT02871752] | 225 participants (Actual) | Interventional | 2016-08-10 | Completed | |||
| Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes[NCT04417153] | 1,000 participants (Anticipated) | Observational | 2019-09-20 | Recruiting | |||
| REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology[NCT02495376] | 151 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Randomised Double-blind Placebo-controlled Trial on Encapsulated Lemon Balm Efficacy and Tolerance on Sleep Quality Changes, and Mood and Wellbeing Effects Using Objective and Subjective Measures[NCT05422599] | 99 participants (Actual) | Interventional | 2022-05-05 | Completed | |||
| Effects of Shift Work on Health: Assessment of Sleep Quality, Motor Control and Cardiovascular Risk.[NCT03453398] | 71 participants (Actual) | Interventional | 2018-01-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of postoperative hospital stay in days (NCT02848599)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Morphine | 7 |
| Levobupivacaine | 7 |
Measurement will be done before and 24,72 and 120 hours after the surgery. (NCT02848599)
Timeframe: Before, 24,72 and 120 hours after the surgery
| Intervention | mg/L (Median) | |||
|---|---|---|---|---|
| Before surgery | 24 h after surgery | 72 h after surgery | 120 h after surgery | |
| Levobupivacaine | 57.8 | 98.1 | 95 | 54.6 |
| Morphine | 57.2 | 106.2 | 118.5 | 66.9 |
"Assessment of cognitive function will be done using the Mini-mental state examination (MMSE) rating scales before and 24,48,72,96 and 120 hours after the surgery at the same time every morning.~Mini-Mental State Examination Scale: minimum score is 0 and maximum score is 30; the severity of cognitive impairment: no cognitive impairment=25-30; mild cognitive impairment=19-24; moderate cognitive impairment=10-18; and severe cognitive impairment<9. Higher scores mean a better and lower scores mean a worse outcome." (NCT02848599)
Timeframe: Before, 24,48,72,96 and 120 hours after the surgery
| Intervention | score on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Before surgery | 24 h after surgery | 48 h after surgery | 72 h after surgery | 96 h after surgery | 120 h after surgery | |
| Levobupivacaine | 22 | 22 | 21 | 21 | 21 | 22 |
| Morphine | 21 | 20 | 20 | 20 | 20 | 20 |
Measurement will be done before and 24,72 and 120 hours after the surgery. (NCT02848599)
Timeframe: Before, 24,72 and 120 hours after the surgery
| Intervention | g/L (Median) | |||
|---|---|---|---|---|
| Before surgery | 24 h after surgery | 72 h after surgery | 120 h after surgery | |
| Levobupivacaine | 4.5 | 4.7 | 5.2 | 5 |
| Morphine | 5.5 | 5.3 | 5.7 | 5.4 |
"Assessment will be done using Numeric Rating Scale (NRS). During the first 72 hours after the surgery assessment will be done every 3 hours, after that assessment will be done 3 times daily. Median of 8 time points measurements during the first 24, 48 and 72 hours after the surgery will be reported. After that, median of 3 time points will be reported from the 4. to 6. postoperative day and on the day of discharge.~Minimum score 0 and maximum score 10 ( 0-No Pain; 1-3 Mild Pain; 4-6 Moderate Pain; 7-10 Severe Pain ). Higher scores mean a worse and lower scores mean a better outcome." (NCT02848599)
Timeframe: During the first 72 hours after the surgery assessment will be done every 3 hours, after that assessment will be done 3 times daily until discharge
| Intervention | score on a scale (Median) | ||||||
|---|---|---|---|---|---|---|---|
| 3,6,9,12,15,18,21 and 24h after surgery | 27,30,33,36,39,42,45 and 48h after surgery | 51,54,57,60,63,66,69 and 72h after surgery | 4. postoperative day (every 8 hours) | 5. postoperative day (every 8 hours) | 6. postoperative day (every 8 hours) | Day of discharge | |
| Levobupivacaine | 0.6 | 0.5 | 0.5 | 0.3 | 0 | 0 | 0 |
| Morphine | 1.4 | 1.5 | 1.4 | 1.4 | 1.4 | 1.3 | 1 |
Measurement will be done before and 24 and 72 hours after the surgery. (NCT02848599)
Timeframe: Before, 24 and 72 hours after the surgery
| Intervention | pg/ml (Median) | ||
|---|---|---|---|
| Before surgery | 24h after surgery | 72h after surgery | |
| Levobupivacaine | 26.6 | 97.7 | 30.5 |
| Morphine | 27.2 | 104 | 50 |
87 reviews available for melatonin and Breast Cancer
| Article | Year |
|---|---|
Protective role of melatonin in breast cancer: what we can learn from women with blindness.
Topics: Animals; Blindness; Breast Neoplasms; Female; Humans; Incidence; Melatonin; Prospective Studies | 2022 |
Molecular and cellular mechanisms of melatonin in breast cancer.
Topics: Antioxidants; Breast Neoplasms; Female; Humans; Melatonin | 2022 |
Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kidney Neoplasms; Lung Neoplasms; | 2023 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Melatonin: A Potential Therapeutic Option for Breast Cancer.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Receptors, Estrogen; Signal | 2020 |
The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Humans; Melatonin; Neoplastic Processes | 2020 |
Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies.
Topics: Breast Neoplasms; Case-Control Studies; Female; Humans; Logistic Models; Melatonin; Middle Aged; Pos | 2021 |
Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients.
Topics: Antioxidants; Breast Neoplasms; Circadian Rhythm; Female; History, 21st Century; Humans; Melatonin; | 2021 |
Relationship between Night Shifts and Risk of Breast Cancer among Nurses: A Systematic Review.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Female; Humans; Incidence; Melatonin; Nurses; Risk Factor | 2020 |
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.
Topics: Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Central Nervous System Depressants; Fema | 2021 |
Shift Work and Breast Cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Shift Work Schedule; Work Schedule To | 2020 |
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Melatonin; Neoplasm Proteins; NF-E2-Rel | 2021 |
[Inhibitory effects of melatonin on breast cancer].
Topics: Animals; Breast Neoplasms; Cell Proliferation; Circadian Rhythm; Drug Resistance, Neoplasm; Female; | 2017 |
The Role of Oxidative Stress Modulators in Breast Cancer.
Topics: Animals; Ascorbic Acid; Breast Neoplasms; Carotenoids; Female; Humans; Melatonin; Oxidative Stress; | 2018 |
Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis.
Topics: Breast Neoplasms; Humans; Incidence; Melatonin; Prospective Studies; Risk Assessment | 2017 |
Melatonin: A Molecule for Reducing Breast Cancer Risk.
Topics: Animals; Breast Neoplasms; Environment; Estrogen Receptor Modulators; Female; Humans; Melatonin; Obe | 2018 |
Melatonin and breast cancer: Evidences from preclinical and human studies.
Topics: Animals; Breast Neoplasms; Female; Humans; Melatonin; Prospective Studies; Signal Transduction | 2018 |
Therapeutic potential of melatonin for breast cancer radiation therapy patients.
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Estrogen Receptor alpha; Female; H | 2018 |
Mitochondrial functions and melatonin: a tour of the reproductive cancers.
Topics: Animals; Breast Neoplasms; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Male; M | 2019 |
Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms.
Topics: Breast Neoplasms; Female; Humans; Inflammation; Melatonin; Oxidative Stress; Signal Transduction | 2019 |
Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Melatonin; Reference Values; Risk Factors | 2019 |
Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology.
Topics: Animals; Breast Neoplasms; Female; Humans; Melatonin; Mitochondria; Oxidative Stress; Serotonin | 2019 |
Health consequences of shift work and implications for structural design.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Hospital Design and Construction; Humans; Intensive Car | 2013 |
[Night shift work and prolactin as a breast cancer risk factor].
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Prolactin; Prospective Studies; Risk; | 2013 |
Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth.
Topics: Aging; Animals; Breast Neoplasms; Female; Humans; Mammary Neoplasms, Experimental; Melatonin; Mice; | 2013 |
First-morning urinary melatonin and breast cancer risk in the Guernsey Study.
Topics: Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Female; Guernsey; Humans; Logistic Models; | 2014 |
Light exposure at night, sleep duration, melatonin, and breast cancer: a dose-response analysis of observational studies.
Topics: Breast Neoplasms; Environmental Exposure; Female; Humans; Light; Melatonin; Risk Factors; Sleep; Sle | 2014 |
Melatonin: an inhibitor of breast cancer.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Signal Transduction | 2015 |
Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Topics: Adenomatous Polyposis Coli Protein; BRCA1 Protein; Breast Neoplasms; Cell Proliferation; Estrogen Re | 2015 |
Effects of artificial light at night on human health: A literature review of observational and experimental studies applied to exposure assessment.
Topics: Breast Neoplasms; Circadian Clocks; Circadian Rhythm; Female; Humans; Lighting; Male; Melatonin; Neo | 2015 |
[Night work, shift work: Breast cancer risk factor?].
Topics: Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Cohort Studies; Female; Humans; Melatonin; | 2015 |
Melatonin, an inhibitory agent in breast cancer.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Estrogens; Female; Humans; Melatonin; Metabolic Net | 2017 |
Role of melatonin in the epigenetic regulation of breast cancer.
Topics: Aromatase; Breast Neoplasms; Cell Nucleus; DNA Methylation; Environment; Estrogens; Female; Gene Exp | 2009 |
Circulating melatonin and the risk of breast and endometrial cancer in women.
Topics: Aromatase; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Transformation, Neoplastic; Circa | 2009 |
Melatonin as a selective estrogen enzyme modulator.
Topics: 17-Hydroxysteroid Dehydrogenases; Aromatase; Breast Neoplasms; Estrogens; Humans; Melatonin; Neoplas | 2008 |
Melatonin, sleep disturbance and cancer risk.
Topics: Animals; Breast Neoplasms; Cell Transformation, Neoplastic; Circadian Rhythm; Dietary Fats; Female; | 2009 |
Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.
Topics: Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Controlled Clinical Trials as Topic; | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
Defining chronodisruption.
Topics: Biological Clocks; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Male | 2009 |
[Shift and night work--is it a cancer risk factor?].
Topics: Breast Neoplasms; Causality; Chronobiology Disorders; Circadian Rhythm; Colorectal Neoplasms; Female | 2005 |
Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.
Topics: Breast Neoplasms; Cell Proliferation; Circadian Rhythm; Diet; Female; Gene Expression Regulation, Ne | 2011 |
Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer.
Topics: Animals; Breast; Breast Neoplasms; Circadian Clocks; Female; Humans; Mammary Glands, Animal; Mammary | 2011 |
Breast cancer therapy based on melatonin.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Estrogens; Female; | 2012 |
Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Estrogen Antagonists; Female; Humans | 2012 |
Health effects of extremely low-frequency magnetic fields: reconsidering the melatonin hypothesis in the light of current data on magnetoreception.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Environmental Exposure; Female; Humans; Leukemia; Magne | 2012 |
Molecular mechanisms of melatonin's inhibitory actions on breast cancers.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Epigenesi | 2013 |
Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+ signaling molecular pathways in breast cancer.
Topics: Breast Neoplasms; Calcium; Electromagnetic Radiation; Environmental Exposure; Female; Humans; Melato | 2012 |
[Sleep and breast cancer: is there a link?].
Topics: Breast Neoplasms; Female; Humans; Melatonin; Risk Factors; Sleep; Sleep Wake Disorders | 2013 |
Ocular input for human melatonin regulation: relevance to breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Light; Melatonin; Photoreceptor Cells, Vertebrat | 2002 |
Melatonin and mammary cancer: a short review.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Melatonin; Mice; Neoplasms, Hormon | 2003 |
Mechanisms of cancer inhibition by melatonin.
Topics: Animals; Breast Neoplasms; Endothelin-1; Humans; Linoleic Acid; Melatonin; Neoplasms; Telomerase | 2004 |
Circadian disruption and breast cancer: from melatonin to clock genes.
Topics: Breast Neoplasms; Cell Cycle; Circadian Rhythm; Epidemiologic Studies; Female; Gene Expression Regul | 2005 |
Melatonin-estrogen interactions in breast cancer.
Topics: Breast Neoplasms; Estrogens; Female; Humans; Melatonin; Selective Estrogen Receptor Modulators | 2005 |
[Melatonin].
Topics: Aging; Biomarkers; Breast Neoplasms; Chromatography, High Pressure Liquid; Circadian Rhythm; Depress | 2005 |
Of mice and women: light as a circadian stimulus in breast cancer research.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Disease Models, Animal; Female; Humans; Light; Light Si | 2006 |
Artificial lighting in the industrialized world: circadian disruption and breast cancer.
Topics: Alcohol Drinking; Animals; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Developing C | 2006 |
Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark.
Topics: Breast Neoplasms; Female; Humans; Melatonin; Photoperiod; Risk Factors; Work Schedule Tolerance | 2006 |
Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle.
Topics: Animals; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Electromagnetic Fields; Humans | 2006 |
The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Proliferation; Chronobiology Disorders; Cir | 2006 |
Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Estrog | 2006 |
[Light-dark conditions, melatonin and risk of cancer].
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Colonic Neoplasms; Darkness; Female; Humans; Life Style | 2006 |
Circadian clock and breast cancer: a molecular link.
Topics: Acetylation; Animals; ARNTL Transcription Factors; Basic Helix-Loop-Helix Transcription Factors; Bre | 2007 |
Melatonin, environmental light, and breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Light; Lighting; Melatonin; Occupational Exposur | 2008 |
[Melatonin, a clinically important hormone?].
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Central Nervous System; Circadian Rhythm; Female; Humans | 1983 |
Hormonal profiles in women with breast cancer.
Topics: Adolescent; Adult; Aged; Androgens; Animals; Anovulation; Breast Neoplasms; Child; Estradiol; Estrio | 1994 |
Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth?
Topics: Aging; Animals; Breast Neoplasms; Circadian Rhythm; Endocrine Glands; Female; Humans; Male; Melatoni | 1994 |
Breast cancer and electric power.
Topics: Animals; Breast Neoplasms; Electricity; Electromagnetic Fields; Female; Humans; Male; Melatonin; Rat | 1993 |
The melatonin hypothesis: electric power and breast cancer.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Electromagnetic Fields; Humans; Light; Melatonin | 1996 |
Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers.
Topics: Breast Neoplasms; Electromagnetic Fields; Humans; Melatonin; Neoplasms, Hormone-Dependent; Receptors | 1998 |
"Melatonin replacement therapy" for postmenopausal women: is it justified?
Topics: Aging; Animals; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Postmenopause; Sleep | 1998 |
Power-frequency fields and cancer.
Topics: Animals; Breast Neoplasms; Cell Division; Chromosome Aberrations; Electromagnetic Fields; Environmen | 1998 |
The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature.
Topics: Animals; Breast Neoplasms; Breast Neoplasms, Male; Electromagnetic Fields; Environmental Exposure; F | 1999 |
Industrialization, electromagnetic fields, and breast cancer risk.
Topics: Breast Neoplasms; Dose-Response Relationship, Radiation; Electromagnetic Fields; Female; Humans; Mal | 1999 |
Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies.
Topics: Antioxidants; Breast Neoplasms; Breathing Exercises; Female; Humans; Life Change Events; Male; Medit | 1999 |
Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer.
Topics: Animals; Breast Neoplasms; Female; Humans; Immunologic Deficiency Syndromes; Melatonin; Mice; Neopla | 1999 |
Melatonin and mammary pathological growth.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Mammary Neoplasms, Experimental; Melatonin | 2000 |
Melatonin, experimental basis for a possible application in breast cancer prevention and treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Susceptibility; Female; Humans; Mammary Gl | 2000 |
Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Syner | 1999 |
Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Developed Countries; Endocrine Glands; Environmental Expo | 2001 |
Melatonin deficiencies in women.
Topics: Breast Neoplasms; Circadian Rhythm; Depression; Female; Humans; Jet Lag Syndrome; Melatonin; Menopau | 2002 |
Circadian concepts in normal and neoplastic breast.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Chronotherapy; Circadian Rh | 2002 |
Hormonal manipulations and breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Contraceptives, Oral, Hormonal; Estrogens; Estrogens, Non-S | 2002 |
Pineal gland and malignancy.
Topics: Age Factors; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Female; Gonadotropins; Humans; Lymph | 1976 |
Breast cancer: a model system for studying the neuroendocrine role of pineal melatonin in oncology.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Line; Female; Humans; Mammary Neoplasms, | 1992 |
Breast cancer, blindness and melatonin.
Topics: Blindness; Breast Neoplasms; Female; Humans; Male; Melatonin | 1992 |
Electric power, pineal function, and the risk of breast cancer.
Topics: Animals; Breast Neoplasms; Dietary Fats; Electricity; Electromagnetic Fields; Ethanol; Female; Ferti | 1992 |
[Role of the pineal body in reproduction and in gynecologic tumors].
Topics: Animals; Breast Neoplasms; Female; Genital Neoplasms, Female; Humans; Melatonin; Menstrual Cycle; Pi | 1991 |
Melatonin: perspectives in laboratory medicine and clinical research.
Topics: Brain Neoplasms; Breast Neoplasms; Humans; Male; Melanoma; Melatonin; Mood Disorders; Prostatic Neop | 1987 |
18 trials available for melatonin and Breast Cancer
267 other studies available for melatonin and Breast Cancer
| Article | Year |
|---|---|
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neopla | 2013 |
Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coumaric Acids; Coum | 2017 |
Melatonin potentiates the cytotoxic effect of Neratinib in HER2
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endo | 2021 |
The Effects of Melatonin Administration on Intestinal Injury Caused by Abdominal Irradiation from Mice.
Topics: Abdomen; Animals; Breast Neoplasms; Calgranulin B; Carrier Proteins; Cell Survival; Cytokine TWEAK; | 2021 |
Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Melatonin; Neoplastic Stem Cells; N | 2022 |
Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Damage; Female; Humans; Melatonin; X | 2022 |
Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Melatonin | 2022 |
The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
Topics: Breast Neoplasms; Circadian Rhythm; Cohort Studies; Databases, Factual; Female; Humans; Male; Melato | 2022 |
The metastatic spread of breast cancer accelerates during sleep.
Topics: Animals; Breast Neoplasms; Cell Count; Cell Proliferation; Disease Models, Animal; Female; Glucocort | 2022 |
Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis.
Topics: Apoptosis; Autophagy; bcl-2-Associated X Protein; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Cell | 2022 |
Melatonin and cancer suppression: insights into its effects on DNA methylation.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; DNA Methylation; Epigenesis, Genetic; Female; Humans; M | 2022 |
Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
Topics: Breast Neoplasms; Caspase 3; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Human | 2023 |
Polarization of Melatonin-Modulated Colostrum Macrophages in the Presence of Breast Tumor Cell Lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Colostrum; Female; Humans; Macrophages; Melatonin; Pregnancy; Re | 2023 |
Polymorphisms in genes of melatonin biosynthesis and signaling support the light-at-night hypothesis for breast cancer.
Topics: Bayes Theorem; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Hu | 2023 |
Breast cancer survivals and hormone therapy: estrogen and melatonin.
Topics: Breast; Breast Neoplasms; Estrogens; Female; Humans; Melatonin | 2023 |
Of sight, and insight into melatonin's role in breast cancer?
Topics: Breast Neoplasms; Female; Humans; Melatonin | 2023 |
Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts.
Topics: Adipocytes; Antineoplastic Agents; Aromatase; Breast Neoplasms; Cancer-Associated Fibroblasts; CCAAT | 2019 |
A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cisplatin; | 2020 |
Extracellular Acidosis Promotes Metastatic Potency via Decrease of the
Topics: Acidosis; ARNTL Transcription Factors; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Surviv | 2020 |
Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Topics: Angiogenic Proteins; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Dru | 2020 |
Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.
Topics: Anemia; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diseas | 2020 |
Zinc and melatonin supplementation ameliorates brain cortex tissue damage in DMBA-induced breast cancer in rats.
Topics: Animals; Anthracenes; Antioxidants; Breast Neoplasms; Cerebral Cortex; Dietary Supplements; Female; | 2020 |
Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antioxidants; Apoptosis; Biomarkers, Tu | 2020 |
Melatonin and vitamin D: complementary therapeutic strategies for breast cancer.
Topics: Breast Neoplasms; Female; Humans; Melatonin; Sleep; Vitamin D; Vitamins | 2021 |
A Case Control Study on Serum Levels of Potential Biomarkers in Male Breast Cancer Patients.
Topics: Biomarkers; Breast Neoplasms; Breast Neoplasms, Male; Case-Control Studies; Cross-Sectional Studies; | 2021 |
Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Endoplasmic Reticulu | 2021 |
Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Fluorescent Antibody Technique | 2017 |
Sleep duration, nightshift work, and the timing of meals and urinary levels of 8-isoprostane and 6-sulfatoxymelatonin in Japanese women.
Topics: Adult; Biomarkers; Breakfast; Breast Neoplasms; Circadian Rhythm; Dinoprost; Eating; Feeding Behavio | 2017 |
Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles.
Topics: Breast Neoplasms; Cell Survival; Combined Modality Therapy; Drug Liberation; Female; Ferric Compound | 2017 |
Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in co‑cultures of human endothelial and breast cancer cells.
Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cocultu | 2018 |
Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF‑7 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Doc | 2018 |
Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Environmental Pollutan | 2018 |
Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Movement; Humans; MAP Kinase Signaling System; MCF-7 Cells; M | 2018 |
Melatonin Differentially Modulates NF-кB Expression in Breast and Liver Cancer Cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening A | 2018 |
Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies.
Topics: Aged; Aged, 80 and over; Blood Chemical Analysis; Breast Neoplasms; Epidemiologic Studies; Female; H | 2018 |
Population-level study links short-wavelength nighttime illumination with breast cancer incidence in a major metropolitan area.
Topics: Breast Neoplasms; Circadian Rhythm; Humans; Incidence; Israel; Melatonin; Risk Factors; Sleep; Urban | 2018 |
Evaluation of melatonin and AFMK levels in women with breast cancer.
Topics: Biomarkers; Breast Neoplasms; Circadian Rhythm; Female; Humans; Kynuramine; Lymphatic Metastasis; Me | 2018 |
Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Humans; Hydrazones; Indoles; | 2019 |
Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice.
Topics: Animals; Antioxidants; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Proliferation; Drug Synergis | 2018 |
Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cadherins | 2019 |
RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model.
Topics: Animals; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression | 2019 |
Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study.
Topics: Actigraphy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasm | 2019 |
Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Screening | 2019 |
Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; | 2019 |
Shedding Light on the Association between Night Work and Breast Cancer.
Topics: Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Female; Humans; Melatonin; Occupational | 2019 |
Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
Topics: Adult; Blood Vessels; Breast Neoplasms; Correlation of Data; Cross-Sectional Studies; Epithelial Cel | 2020 |
[Restful sleep, melatonin and breast cancer].
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Risk Factors; Sleep | 2019 |
Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Circadian Clocks; CLOCK Proteins; Epistasis, Ge | 2019 |
Antiangiogenic effects of melatonin in endothelial cell cultures.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Movement; Cell Proliferation; Culture Media, Conditi | 2013 |
Insufficient sleep associated with increased breast cancer mortality.
Topics: Adult; Breast Neoplasms; Female; Humans; Melatonin; Prevalence; Risk Factors; Sleep Deprivation | 2013 |
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cells, Culture | 2013 |
Author's reply to: Sleep duration, melatonin and breast cancer in the Singapore Chinese Health Study: on null results and their interpretation.
Topics: Breast Neoplasms; Female; Humans; Melatonin; Sleep | 2013 |
Sleep duration, melatonin and breast cancer in the Singapore Chinese Health Study: on null results and their interpretation.
Topics: Breast Neoplasms; Female; Humans; Melatonin; Sleep | 2013 |
Sleep disturbances and changes in urinary 6-sulphatoxymelatonin levels in patients with breast cancer undergoing lumpectomy.
Topics: Adult; Aged; Anesthesia, General; Breast Neoplasms; Fatigue; Female; Humans; Mastectomy, Segmental; | 2013 |
Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.
Topics: Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; ErbB Receptors; Female; Gene Express | 2014 |
Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholecalciferol; Cycl | 2013 |
Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Cohort Studies; Female; Humans; Melatonin; Middle Aged | 2014 |
Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Topics: Adipose Tissue; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured | 2014 |
Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Circadian Rhythm; Disease Models, Animal | 2014 |
Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Circadian Rhythm; Female; Glycolysi | 2014 |
Drug therapy: keeping rats in the dark sheds light on tamoxifen resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Circadian Rhythm; Female; Humans; Light; | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Chronobiology, cognitive function and depressive symptoms in surgical patients.
Topics: Adult; Aged; Anxiety; Biomarkers; Breast Neoplasms; Case-Control Studies; Central Nervous System Dep | 2014 |
Combination of Pitavastatin and melatonin shows partial antineoplastic effects in a rat breast carcinoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe | 2014 |
Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Female; Humans; Melatonin; Middle Aged; Prospective S | 2015 |
Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair.
Topics: Breast Neoplasms; Cell Cycle; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; Female; H | 2015 |
Increased and mistimed sex hormone production in night shift workers.
Topics: Adult; Androgens; Breast Neoplasms; Circadian Rhythm; Estrogens; Female; Humans; Male; Melatonin; Mi | 2015 |
Synergistic anti-tumor effects of melatonin and PUFAs from walnuts in a murine mammary adenocarcinoma model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cyclooxygen | 2015 |
Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal.
Topics: Animals; Blotting, Western; Breast Neoplasms; Circadian Rhythm; Doxorubicin; Drug Resistance, Neopla | 2015 |
Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines.
Topics: Angiogenesis Inhibitors; Antioxidants; Breast Neoplasms; Cell Hypoxia; Cell Survival; Cytokines; Erb | 2016 |
Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.
Topics: Amides; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melatonin; Mice; Mice, Nude; Ne | 2016 |
Nocturnal light pollution and underexposure to daytime sunlight: Complementary mechanisms of circadian disruption and related diseases.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Female; Humans; Lighting; Male; Melatonin; Prostatic Ne | 2015 |
The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells.
Topics: Analysis of Variance; Annexin A5; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Survi | 2016 |
Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis.
Topics: 17-Hydroxysteroid Dehydrogenases; Aromatase; Breast Neoplasms; Cell Proliferation; Estrogens; Female | 2016 |
Synergic Effects of Doxorubicin and Melatonin on Apoptosis and Mitochondrial Oxidative Stress in MCF-7 Breast Cancer Cells: Involvement of TRPV1 Channels.
Topics: Apoptosis; Breast Neoplasms; Calcium; Caspase 3; Caspase 9; Cell Survival; Doxorubicin; Female; Huma | 2016 |
Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Death; Cell Line, Tumor; | 2016 |
Can Avoiding Light at Night Reduce the Risk of Breast Cancer?
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Circadian Rhythm; Female; Habits; Humans; Incidenc | 2016 |
Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines.
Topics: Animals; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dogs; Epithelial- | 2016 |
Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Cell Pr | 2016 |
Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Carriers; Female; Human | 2016 |
Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study.
Topics: Acupuncture Therapy; Adult; Aged; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Chemotherap | 2016 |
Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Cycle; Cell Proliferation; Drug Syne | 2016 |
Light and the City: Breast Cancer Risk Factors Differ Between Urban and Rural Women in Israel.
Topics: Breast Neoplasms; Circadian Rhythm; Female; Habits; Humans; Incidence; Israel; Light; Logistic Model | 2017 |
Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Express | 2016 |
Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; MC | 2017 |
Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Creatine; Female; Humans; Incidence | 2017 |
Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Creatinine; Female; Humans; Logisti | 2008 |
Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women.
Topics: Androgens; Biomarkers; Breast Neoplasms; Circadian Rhythm; Estrogens; Female; Humans; Japan; Light; | 2008 |
The Galphai and Galphaq proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cy | 2008 |
Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chrom | 2009 |
Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study.
Topics: Adult; Aged; Breast Neoplasms; Cohort Studies; Female; Humans; Melatonin; Middle Aged; Proportional | 2008 |
Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines.
Topics: Blotting, Southern; Breast Neoplasms; Caveolae; Estrogen Receptor alpha; Estrogens; Female; Fluoresc | 2009 |
Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Female; Humans; Logistic Models; M | 2009 |
Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cel | 2009 |
Light-at-night, circadian disruption and breast cancer: assessment of existing evidence.
Topics: Animals; Blindness; Breast Neoplasms; Chronobiology Disorders; Circadian Rhythm; Disease Models, Ani | 2009 |
Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
Topics: BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Depende | 2009 |
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Topics: Aromatase; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP; Dinoprostone; Female; Gene Expression Reg | 2009 |
Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields.
Topics: BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Cycl | 2010 |
Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Growth Processes; Cell Proliferation; Circa | 2009 |
Molecular mechanisms of melatonin anticancer effects.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Circadian Rhythm; Estrogen Receptor alpha; Female; Gene | 2009 |
Shift work and cancer - considerations on rationale, mechanisms, and epidemiology.
Topics: Breast Neoplasms; Chronobiology Disorders; Female; Humans; Male; Melatonin; Middle Aged; Occupationa | 2010 |
Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Female; Humans; Melatonin; Middle | 2010 |
Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Estradiol; Estrogen Receptor alph | 2010 |
Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Female; Gene Expression; Hu | 2010 |
Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer.
Topics: Biotransformation; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Huma | 2011 |
Light pollution ≠ light pollution?
Topics: Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Female; Humans; Light; Lighting; Melatonin | 2011 |
MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Female; Gene Expression Profiling; G | 2011 |
Eliminating animal facility light-at-night contamination and its effect on circadian regulation of rodent physiology, tumor growth, and metabolism: a challenge in the relocation of a cancer research laboratory.
Topics: Academies and Institutes; Animals; Animals, Laboratory; Blood Glucose; Breast Neoplasms; Carcinoma, | 2011 |
Melatonin pathway genes and breast cancer risk among Chinese women.
Topics: Adult; Age Factors; Arylalkylamine N-Acetyltransferase; Asian People; Breast Neoplasms; Case-Control | 2012 |
Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production.
Topics: 3T3-L1 Cells; Animals; Aromatase; Base Sequence; Breast Neoplasms; Cell Differentiation; Cell Line, | 2012 |
Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Topics: Adipose Tissue; Aromatase; Breast Neoplasms; Carcinoma, Ductal, Breast; Cells, Cultured; Dinoproston | 2012 |
Night shift work and hormone levels in women.
Topics: Adult; Biomarkers; Breast Neoplasms; Circadian Rhythm; Female; Follicle Stimulating Hormone; Humans; | 2012 |
Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells.
Topics: Antioxidants; Apoptosis; Apoptotic Protease-Activating Factor 1; Breast Neoplasms; Caspases; Cell Li | 2012 |
Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Ne | 2012 |
Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore.
Topics: Breast Neoplasms; Case-Control Studies; China; Female; Humans; Melatonin; Middle Aged; Risk Factors; | 2013 |
Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Down-Regulation; Early G | 2013 |
Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3β.
Topics: Animals; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Circadian Rhythm; Enzyme Activation; Epit | 2012 |
Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Culture Media, Conditioned; | 2013 |
Effect of melatonin and all-trans retinoic acid on the proliferation and induction of the apoptotic pathway in the culture of human breast cancer cell line MCF-7.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Count; Cell Division; Dose-Response Relatio | 2002 |
Regarding the article 'Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-1 concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defe
Topics: Breast Neoplasms; Data Interpretation, Statistical; Female; Humans; Insulin-Like Growth Factor I; Me | 2002 |
Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice.
Topics: Animals; Breast Neoplasms; Female; Humans; Melatonin; Mice; Mice, Nude; Neoplasm Transplantation; Re | 2003 |
Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures.
Topics: Adjuvants, Immunologic; Animals; Breast Neoplasms; Cell Division; Cholecalciferol; Female; Growth In | 2003 |
The role of pineal gland in breast cancer development.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogens; Female; Humans; Light; Melatonin; M | 2003 |
Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression.
Topics: Animals; Antioxidants; Antithrombins; Breast Neoplasms; Cell Transformation, Neoplastic; Circadian R | 2003 |
Melatonin and breast cancer: a prospective study.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Female; Humans; Matched-Pair Analysis; Melatoni | 2004 |
Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Interactions; Estrad | 2003 |
Re: Melatonin and breast cancer: a prospective study.
Topics: Animals; Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Female; Humans; Light; Liver Neop | 2004 |
Epidemiology of urinary melatonin in women and its relation to other hormones and night work.
Topics: Adult; Androstenedione; Androstenols; Biological Availability; Biomarkers; Body Mass Index; Breast N | 2004 |
RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line.
Topics: Acetamides; Breast Neoplasms; Catalytic Domain; Female; Humans; Hypnotics and Sedatives; Melatonin; | 2004 |
Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
Topics: Androgens; Androstenedione; Antineoplastic Agents; Aromatase; Breast Neoplasms; Cell Proliferation; | 2005 |
Epidemiology of urinary melatonin in women and its relation to other hormones and night work.
Topics: Breast Neoplasms; Female; Hormones; Humans; Light; Melatonin; Work Schedule Tolerance | 2005 |
Transient inhibition of synergistically insulin-like growth factor-1- and bisphenol A-induced poliferation of estrogen receptor alpha (ERalpha)-positive human breast cancer MCF-7 cells by melatonin.
Topics: Antioxidants; Benzhydryl Compounds; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship | 2004 |
Association of vegetable intake with urinary 6-sulfatoxymelatonin level.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Japan; Melatonin; Middle Aged; Neoplasms; Nutrition A | 2005 |
Urinary melatonin levels and breast cancer risk.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Confidence Intervals; Female; Humans; Incidence | 2005 |
Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Breast Neoplasms; Cell Line, Tumor; Comet Assay; | 2005 |
Circadian disruption and breast cancer.
Topics: Breast Neoplasms; Cell Cycle; Circadian Rhythm; Epidemiologic Studies; Female; Gene Expression Regul | 2005 |
Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1.
Topics: Antineoplastic Agents, Hormonal; Arylsulfotransferase; Biotransformation; Breast Neoplasms; Cell Lin | 2005 |
Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Antioxidants; Aromatase; Breast Neoplasms; Femal | 2005 |
Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Circadian Rhythm; Female; Humans; Light; Liver Neo | 2005 |
Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Hu | 2006 |
It's Erren's brainchild, folks!
Topics: Breast Neoplasms; Female; Humans; Melatonin; Sleep; Sleep Wake Disorders | 2006 |
Cancer and rhythm.
Topics: Animals; Breast Neoplasms; Chronobiology Phenomena; Chronotherapy; Circadian Rhythm; Humans; Life St | 2006 |
Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium.
Topics: Breast Neoplasms; Cadmium; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor alpha; Estrogen R | 2006 |
Human cancer xenograft perfusion in situ in rats: a new perfusion system that minimizes delivery time and maintains normal tissue physiology and responsiveness to growth-inhibitory agents.
Topics: Analgesics; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Eicosapentaenoic Acid; | 2006 |
Circadian rhythms play role in cancer research.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cell Cycle Proteins; Chron | 2006 |
Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineopl | 2006 |
Shift work, light at night and risk of breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Employment; Environmental Exposure; Estrogens; Female; Humans; M | 2006 |
[Seasonal patterns of breast tumor growth in Far North residents].
Topics: Adult; Aged; Breast Neoplasms; Electromagnetic Fields; Female; Humans; Melatonin; Middle Aged; Russi | 2005 |
Melatonin and estrogen in breast cyst fluids.
Topics: Adult; Breast Cyst; Breast Neoplasms; Cell Line, Tumor; Cyst Fluid; Dehydroepiandrosterone Sulfate; | 2007 |
Residential magnetic fields, medication use, and the risk of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Drug-Related Side Effects and | 2007 |
Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls.
Topics: Adult; Anxiety; Breast Neoplasms; Catecholamines; Depression; Female; Health Status; Humans; Hydroco | 2007 |
Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
Topics: Animals; Anticonvulsants; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Pro | 2007 |
Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2007 |
Cohort study of cancer risk among male and female shift workers.
Topics: Adolescent; Adult; Breast Neoplasms; Cohort Studies; Female; Humans; Male; Melatonin; Middle Aged; N | 2007 |
Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women.
Topics: Adult; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Japan; Mammography; Melatonin; Men | 2007 |
Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Estrogens; Humans; Melatonin; | 2008 |
Sleep duration, melatonin and breast cancer among Chinese women in Singapore.
Topics: Aged; Asian People; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Incidence; | 2008 |
Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cadmium; Cell Line, Tumor; Down-Regulation; Estradiol; Estrogen Receptor alpha; Es | 2008 |
ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration.
Topics: Amides; Analysis of Variance; Animals; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movem | 2009 |
Urinary melatonin levels in human breast cancer patients.
Topics: Aged; Breast Neoplasms; Circadian Rhythm; Female; Follicle Stimulating Hormone; Humans; Luteinizing | 1981 |
Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Circadian Rhythm; Humans; Melatonin; Middle Aged; Pineal Gland; Recep | 1982 |
Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate.
Topics: Breast Neoplasms; Cell Count; Cell Division; Humans; Melatonin; Tumor Cells, Cultured | 1995 |
Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer.
Topics: Blotting, Northern; Breast Neoplasms; Down-Regulation; Estrogens; Female; Genes, fos; Genes, myc; Hu | 1995 |
The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes.
Topics: Arachidonate 5-Lipoxygenase; B-Lymphocytes; Base Sequence; Binding Sites; Breast Neoplasms; Cell Lin | 1995 |
Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells.
Topics: Blotting, Northern; Breast Neoplasms; Cycloheximide; Feedback; Gene Expression Regulation; Humans; K | 1994 |
Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer.
Topics: Breast Neoplasms; Contraceptives, Oral, Combined; Endometrial Neoplasms; Female; Humans; Melatonin; | 1995 |
Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data.
Topics: Adult; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Male; Melatonin; Middle Aged; Phil | 1995 |
Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Count; Cell Cycle; Cell Differentiation; Cell Division; Cell Size; Drug Combi | 1994 |
Melatonin modulates growth factor activity in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Culture Media, Conditioned; Epidermal Growth Factor; Estradiol; Fem | 1994 |
Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation.
Topics: Breast Neoplasms; Cell Division; Circadian Rhythm; Drug Administration Schedule; Humans; Kinetics; M | 1994 |
5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7).
Topics: Breast Neoplasms; Cell Division; Drug Interactions; Estrogens; Female; Fluorouracil; Humans; Melaton | 1994 |
Electromagnetic fields. Breast cancer link claimed, criticized.
Topics: Breast Neoplasms; Electromagnetic Fields; Female; Humans; Male; Melatonin; Neoplasms, Radiation-Indu | 1994 |
ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin's oncostatic action on ER+ breast cancer cell proliferation.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Electromagnetic Fields; Humans; Melatonin; Radiatio | 1993 |
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Topics: Adult; Aged; Biopterins; Breast Neoplasms; Colonic Neoplasms; Drug Therapy, Combination; Eosinophils | 1993 |
Does the month of diagnosis affect survival of cancer patients?
Topics: Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Incidence; Melatonin; Pineal Gland; Prognosi | 1993 |
Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Cattle; Cell Division; Dru | 1995 |
Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; DNA, Neoplasm; Female; Humans; Melatonin; Mitosis; Thym | 1996 |
Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro.
Topics: Breast Neoplasms; Cell Division; DNA; Female; Humans; Melatonin; Thymidine; Tumor Cells, Cultured | 1996 |
"The enzymatic basis for the rat liver 6-hydroxymelatonin sulfotransferase activity".
Topics: Breast Neoplasms; Humans; Male; Melatonin; Prostatic Neoplasms; Sulfotransferases | 1996 |
Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cell Nucleus; Female; Humans; Mela | 1996 |
Light and magnetic fields in a neonatal intensive care unit.
Topics: Breast Neoplasms; Circadian Rhythm; Depression; Electromagnetic Fields; Equipment and Supplies, Hosp | 1996 |
Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer.
Topics: Breast Neoplasms; Female; Hormones; Human Growth Hormone; Humans; Hydrocortisone; Insulin-Like Growt | 1997 |
Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Buthionine Sulfo | 1997 |
Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA).
Topics: Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1997 |
Environmental magnetic fields inhibit the antiproliferative action of tamoxifen and melatonin in a human breast cancer cell line.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Radiation; Elect | 1997 |
Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size.
Topics: Breast Neoplasms; Female; Fibroadenoma; Fibrocystic Breast Disease; Humans; Leiomyoma; Melatonin; Mi | 1997 |
Alterations in F-actin distribution in cells treated with melatonin.
Topics: Actins; Animals; Breast Neoplasms; Cytoskeleton; Dogs; Drug Combinations; Estradiol; Female; Fluores | 1997 |
Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Rel | 1998 |
A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Nor | 1998 |
Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
Topics: Blotting, Western; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Epidermal Growth | 1998 |
Reduced cancer incidence among the blind.
Topics: Aged; Blindness; Breast Neoplasms; Cohort Studies; Female; Humans; Incidence; Male; Melatonin; Middl | 1998 |
Breast cancer in female flight attendants.
Topics: Aerospace Medicine; Breast Neoplasms; Circadian Rhythm; Female; Finland; Humans; Melatonin; Occupati | 1998 |
Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Basement Membrane; Breast Neoplasms; Cadherins; Cell | 1998 |
Melatonin attenuates hydrogen peroxide toxicity in MCF7 cells only at pharmacological concentrations.
Topics: Antioxidants; Breast Neoplasms; Cell Survival; Drug Interactions; Female; Free Radical Scavengers; H | 1998 |
Flight attendants, breast cancer, and melatonin.
Topics: Aerospace Medicine; Breast Neoplasms; Confounding Factors, Epidemiologic; Cosmic Radiation; Female; | 1998 |
Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Division; Estradiol; Female; Humans; Melatonin; Mice; Mi | 1998 |
Effects of melatonin on proliferation of cancer cell lines.
Topics: Breast Neoplasms; Buthionine Sulfoximine; Cell Division; Cell Survival; Colonic Neoplasms; DNA Repli | 1998 |
Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Biopterins; Breast Neoplasms; Catecholami | 1999 |
Complementary treatments highlighted at recent meeting.
Topics: Breast Neoplasms; Coenzymes; Drug Therapy, Combination; Female; Humans; Melatonin; Receptors, Estrog | 1999 |
The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte-Ma | 1999 |
Melatonin blocks the activation of estrogen receptor for DNA binding.
Topics: Base Sequence; Binding Sites; Biological Transport, Active; Breast Neoplasms; Cell Division; Cell Nu | 1999 |
Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Female; | 1999 |
Inverse association between breast cancer incidence and degree of visual impairment in Finland.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Female; Finland; Humans; Incidence; Melatonin; Middle Age | 1999 |
Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited.
Topics: Alaska; Arctic Regions; Breast Neoplasms; Canada; Darkness; Female; Greenland; Humans; Male; Melaton | 1999 |
Morning urinary assessment of nocturnal melatonin secretion in older women.
Topics: Adult; Aged; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Middle Aged; Pineal Glan | 2000 |
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cis | 2000 |
Researchers search for link between circadian rhythms, breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin | 2000 |
Influence of serum from healthy or breast tumor-bearing women on the growth of MCF-7 human breast cancer cells.
Topics: Adenocarcinoma, Papillary; Breast Neoplasms; Cell Division; Culture Media; Endometrial Neoplasms; Es | 2000 |
Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin.
Topics: Blotting, Northern; Breast Neoplasms; Estradiol; Female; Humans; Melatonin; Protein Biosynthesis; Pr | 2000 |
Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western | 2000 |
Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Communication; Dextrans; Female; Fluorescent Dyes; Gap Junctions; Humans; Iso | 2000 |
Alcohol consumption and urinary concentration of 6-sulfatoxymelatonin in healthy women.
Topics: Adult; Aged; Alcohol Drinking; Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Electromagn | 2000 |
Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cycloph | 2000 |
The influence of 1.2 microT, 60 Hz magnetic fields on melatonin- and tamoxifen-induced inhibition of MCF-7 cell growth.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Humans; Magnetics; Melaton | 2001 |
Disruption of mitochondrial respiration by melatonin in MCF-7 cells.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antioxidants; Breast Neoplasms; Cell Respiration; Electron T | 2001 |
Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Electromagnetic Fields; Female; Humans; Melatonin; Neoplasm Invasiv | 2001 |
Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin.
Topics: Antioxidants; Blotting, Western; Breast Neoplasms; Calcium Signaling; Calcium-Calmodulin-Dependent P | 2001 |
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Breast Neoplasms; Chemotherapy, | 2001 |
Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Alcohol Drinking; Body Mass Index; Breast Neo | 2001 |
Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer.
Topics: Analysis of Variance; Breast Neoplasms; Circadian Rhythm; Epidermal Growth Factor; Female; Fibroblas | 2001 |
Light at night, shiftwork, and breast cancer risk.
Topics: Adult; Animals; Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Cohort Studies; Estrogens; | 2001 |
Night shift work, light at night, and risk of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Circadian Rhythm; Electromagnetic Fields; Environmental Exposure; Fem | 2001 |
Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Cohort Studies; Female; Follow-Up Studies; Humans; Incide | 2001 |
The roles of physical activity and electric blankets in breast cancer occurrence.
Topics: Aged; Bedding and Linens; Breast Neoplasms; Electric Wiring; Electromagnetic Fields; Exercise; Femal | 2001 |
Electric blanket or mattress cover use and breast cancer incidence in women 50-79 years of age.
Topics: Aged; Bedding and Linens; Breast Neoplasms; Case-Control Studies; Electric Wiring; Electromagnetic F | 2001 |
[Can light exposure affect the risk of breast cancer? Female flight attendants and shift-workers probably the most vulnerable groups].
Topics: Aerospace Medicine; Breast Neoplasms; Chronobiology Disorders; Environmental Exposure; Female; Human | 2001 |
Light at night and breast cancer: an editorial correction.
Topics: Breast Neoplasms; Darkness; Electricity; Estrogens; Female; Humans; Light; Melatonin; Pineal Gland | 2002 |
Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Cyclic AMP; Estradiol; Estrogen Receptor alpha; Female; Ge | 2002 |
Residential magnetic fields and the risk of breast cancer.
Topics: Adult; Aged; Antioxidants; Breast Neoplasms; Case-Control Studies; Circadian Rhythm; Electromagnetic | 2002 |
The melatonin hypothesis: a matter of method.
Topics: Antioxidants; Breast Neoplasms; Circadian Rhythm; Confounding Factors, Epidemiologic; Down-Regulatio | 2002 |
Involvement of the mt1 melatonin receptor in human breast cancer.
Topics: Breast Neoplasms; Carbazoles; Cell Division; Dose-Response Relationship, Drug; Humans; Immunoblottin | 2002 |
Re: Night shift work, light at night, and risk of breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Electromagnetic Fields; Environmental Exposure; Female; Habits; | 2002 |
Re: Night shift work, light at night, and risk of breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Electromagnetic Fields; Environmental Exposure; Female; Humans; | 2002 |
Re: Night shift work, light at night, and risk of breast cancer.
Topics: Breast Neoplasms; Circadian Rhythm; Electromagnetic Fields; Environmental Exposure; Female; Humans; | 2002 |
Night shifts and breast cancer risk: policy implications.
Topics: Breast Neoplasms; Humans; Light; Melatonin; Night Care; Nursing Staff, Hospital; Occupational Diseas | 2002 |
Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin.
Topics: Administration, Oral; Alitretinoin; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Dis | 2002 |
Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense?
Topics: Adult; Breast Neoplasms; Case-Control Studies; Female; Humans; Insulin-Like Growth Factor I; Melaton | 2002 |
Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells.
Topics: Adenosine Triphosphate; Breast Neoplasms; Calcium; Calmodulin; Cell Division; Drug Synergism; Female | 2002 |
Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cell Cycle; Cell Division; C | 2002 |
MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Estrogen Receptor alpha; Estrogens; Female; Gene Ex | 2002 |
Role of pineal gland in aetiology and treatment of breast cancer.
Topics: Breast Neoplasms; Calcinosis; Estrogens; Female; Hormones; Humans; Melatonin; Ovary; Pineal Gland | 1978 |
Role of pineal gland in aetiology and treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Mammary Neopl | 1978 |
Pineal gland, F.S.H., and breast-cancer aetiology.
Topics: Aged; Breast Neoplasms; Estrone; Female; Follicle Stimulating Hormone; Humans; Melatonin; Menopause; | 1978 |
Clinical importance of melatonin.
Topics: Adolescent; Adult; Aged; Amniotic Fluid; Breast Neoplasms; Child; Circadian Rhythm; Female; Humans; | 1979 |
The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Interactions; Estrogen Antagonists; Est | 1992 |
Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro.
Topics: Breast Neoplasms; Cell Division; Drug Synergism; Humans; Melatonin; Tamoxifen; Tumor Cells, Cultured | 1992 |
Seasonal changes in serum melatonin in women with previous breast cancer.
Topics: Adult; Breast Neoplasms; Female; Humans; Lymphatic Metastasis; Melatonin; Menstruation; Periodicity; | 1991 |
Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism.
Topics: Adult; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Middle Aged | 1991 |
Plasma melatonin in patients with breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Melatonin; Menopause; Middle Aged; Neoplasm Met | 1990 |
Nonparametric testing of melatonin characteristics as potential markers of breast cancer risk.
Topics: Biomarkers; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Periodicity; Risk Factors | 1990 |
Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Division; Culture Media; Depression, Ch | 1990 |
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Surface; Breast Neoplasms; Female; Humans; Ki-67 Antigen; | 1990 |
6-sulphatoxymelatonin production in breast cancer patients.
Topics: Adult; Aged; Aging; Analysis of Variance; Biopsy; Breast Neoplasms; Circadian Rhythm; Female; Humans | 1990 |
[Functional morphology of breast APUD cells in dysplasia and neoplastic processes].
Topics: Adenofibroma; Adrenocorticotropic Hormone; APUD Cells; beta-Endorphin; Breast Neoplasms; Carcinoma; | 1989 |
Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Melatonin; Middle Aged; Neoplasm Staging; Prolactin; | 1989 |
Possible association between breast cancer and malignant melanoma.
Topics: Adrenergic beta-Antagonists; Breast Neoplasms; Female; Humans; Melanoma; Melatonin; Pineal Gland; Ri | 1988 |
A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Topics: Adult; beta-Endorphin; Breast Neoplasms; Colonic Neoplasms; Endorphins; Female; Growth Hormone; Huma | 1988 |
Di-iodothyronine as part of the oestradiol and catechol oestrogen receptor--the role of iodine, thyroid hormones and melatonin in the aetiology of breast cancer.
Topics: Breast Neoplasms; Diiodothyronines; Dopamine; Female; Humans; Hypothyroidism; Iodine; Melatonin; Mod | 1988 |
Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture.
Topics: Breast Neoplasms; Cell Division; DNA, Neoplasm; Female; Humans; Melatonin; Tumor Cells, Cultured; Va | 1988 |
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Humans; | 1988 |
Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture.
Topics: 5-Methoxytryptamine; Breast Neoplasms; Cell Division; Cell Line; Estradiol; Female; Humans; Kinetics | 1986 |
Correlation between changes in prolactin and melatonin serum levels after radical mastectomy.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Mastectomy; Melatonin; Middle Aged; Prolactin; Radioi | 1987 |
The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Growth Hormone; Humans; Ma | 1987 |
Circadian characteristics of urinary melatonin from clinically healthy young women at different civilization disease risks.
Topics: Adolescent; Adult; Breast Neoplasms; Cardiovascular Diseases; Circadian Rhythm; Depression; Female; | 1986 |
Pineal-thyroid relationship in breast cancer.
Topics: Adult; Breast Neoplasms; Female; Humans; Melatonin; Middle Aged; Thyroid Hormones | 1985 |
Melatonin and malignant disease.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Breast Neoplasms; Cell Line; Female; Hormones; Humans; Ma | 1985 |
Plasma melatonin and the hormone-dependency of human breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Circadian Rhythm; Female; Humans; Melatonin; Menopause; M | 1985 |
Administration of melatonin to non-human primates and to women with breast carcinoma.
Topics: Animals; Blood Cell Count; Blood Glucose; Breast Neoplasms; Calcium; Cholesterol; Estrogens; Female; | 1973 |